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ISummary
The polymeric antibodies secretory IgA (slgA) and IgM are 
important in immunity to influenza virus and this work was 
undertaken primarily to investigate the mechanisms by which they 
neutralized type A influenza virus (A/fowl plague 
virus/Rostock/34; H7N1) (FPV/R). Secondly, this thesis presents 
data on the quantitative aspects of neutralization by monoclonal 
and polyclonal IgG, focusing particularly on the number of 
antibody molecules binding to virus particles at minimum and 
maximum levels of neutralization.
The attachment of FFV/R neutralized by slgA and IgM was 
completely blocked at 4°C. The large molecular structure of 
these antibodies suggests that steric hindrance may be the 
mechanism by which attachment is impaired. However at 25 and 
37°C neutralizing slgA and IgM inhibited attachment of only 50% 
of the neutralized virus and none of this attached virus was 
internalized. It is inferred that IgM and slgA interfere with 
the endocytotic event responsible for internalization of virus.
In contrast when neutralized by either IgG or monomeric IgA 
(obtained from the partial reduction of the above slgA), FPV/R 
attached to and penetrated into BHK-21 cells, with the genome 
accumulating in the nucleus, at a rate indistinguishable from 
that of non-neutralized virus. This behaviour was independent of 
temperature from 4 to 37°C. Thus IgG and monomeric IgA 
neutralized infactivity at a stage subsequent to penetration. 
Virus was neutralized by F(ab')2 and Fa'b/ fragments of 
monoclonal anti-HA IgG. Neither prevented the attachment, 
penetration, or the accumulation of viral genomes in the 
nucleus.
Radiochemical data obtained on the binding of 
immunoglobulins (IgG, slgA) to the haemagglutinin (HA) of FFV/R 
in suspension suggests that the virus is saturated at 
approximately one four-chain immunoglobulin unit per HA spike. 
Two-step competition assays show that the binding of one 
molecule of monoclonal IgG to a HA spike prevents the binding of 
monoclonal antibodies to two different epitopes on that spike 
and also the binding of polyclonal antibody to the HA. These 
observations argue against direct epitope-epitope competition 
and for a steric or allosteric block on the binding of further 
IgG to the HA spike by prebound IgG.
The kinetics of neutralization of FPV/R at 4°C with minimal 
concentrations of monoclonal IgG suggested that 3 IgG molecules 
were required to neutralize an infectious virus particle. The 
discrepancy between this and radiochemical data indicating that 
least 50 antibodies per virus particle are required for 
neutralization i3 reconciled by a theory that neutralization 
only occurs when antibody binds to certain "neutralization 
relevant" HA spikes, which are in the minority, and differ from 
"neutralization irrelevant" spikes only in their interaction 
with the viral core.
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1INFLUENZA VIRUS
1. An overview
1.1. Classification of strains
Three antigenically distinct types of human influenza virus 
A, B and C have been identified according to the cross reactivity 
of their major internal protein, the nucleoprotein (Smith et al., 
1933; Francis, 1940; Taylor, 1949). Type A is the most most 
extensively studied influenza virus strain and is the most 
important epidemiologically and pathologically. Influenza A 
viruses cause epidemics in birds, swine, horses and seals as well 
as man. Whereas influenza B is thought only to infect humans, 
studies have recently shown that influenza C can infect pigs as 
well as humans (Guo et al., 1983). The three types share many 
common molecular and structural features (Webster et al., 1982; 
Scholtissek, 1983), however influenza C can be distinguished from 
types A and B in that it does not possess the surface 
glycoprotein neuraminidase. The influenza C virus is able to free 
itself from receptors (section 2.4) by the action of 
neuraminate-O-acetylesterase (Herrler et al., 1985)
While many distinct subtypes of type A have been recognized, 
none are known for types B and C. Within the type A viruses, a 
further classification is based on the immunological
2
cross-reactivity of the haemagglutinin (HA) and neuraminidase 
(NA) surface antigens. Among type A viruses 13 HA subtypes 
(designated HI to H13) and 9 NA subtypes (N1-N9) have been 
distinguished so far (WHO memorandum, 1980) Three influenza A 
combinations, with the antigenic compositions of: H1N1 
(1918-1957, 1977-present), H2N2 (1957-1968) and H3N2 
(1968-present) have been responsible for influenza epidemics in 
man this century. The generation of completely new subtype 
antigens is called antigenic shift and the initial appearance of 
a new subtype has resulted in major pandemics since the 
population has no immunity to the new antigens. In the interim 
periods between antigenic shifts influenza A undergoes minor 
antigenic variation or drift causing epidemics. This means that 
included among influenza A viruses of a common subtype 
designation there will be strains showing considerable antigenic 
variation. Thus the human influenza virus A/Bangkok/1/79 (H3N2) 
contains HA and NA antigens demonstratably related to those of 
influenza virus A/Hong Kong/68 (H3N2) but show degrees of 
differences from them.
The nomenclature system can be understood as follows: A/fowl 
plague/Rostock/34 (H7N1) refers to an influenza A virus isolated 
from domestic poultry in Rostock (Germany, now the German 
Democratic Republic) in 1934 with an HA of subtype H7 and a NA of 
the subtype N1. This avian influenza virus was used in the 
majority of studies described in this thesis and the following 
review of the features of influenza and immunity to influenza
3
will concentrate on the studies of type A influenza viruses.
1.2. Structure of the influenza virus particle
Influenza viruses are best described as being highly 
pleiomorphic enveloped viruses. Examination of particles of 
influenza virus by electron microscopy has shown that there is 
considerable variation in particle shape and size which is 
dependent on strain and isolation (Horne et al.,1960; Bachi et 
al., 1969; Tiffany and Blough, 1970 a,b; Wrigley, 1979). 
Influenza particles are spherical or filamentous. Particles 
cultured in the chlorioallantoic membrane of chick embroyos have 
a spherical or roughly spherical shape typically 80-120 nm in 
diameter (Tiffany and Blough, 1970a; Nermut and Frank, 1971; 
Wrigley, 1979). The percentage exhibiting spherical morphology 
increases with passage (Choppin et al., 1960). Fresh isolates 
from man and other species show a much greater shape variation 
including elongated filamentous particles of over lu in length 
(Wrigley, 1979). These probably represent the true state of 
influenza particles in nature.
The virus particle has a lipid envelope that is derived from 
the host cell (Kates et al., 1961; Klenk and Choppin, 1969; 1970) 
and this is studded with two types of morphologically 
distinguishable glycoprotein spikes which project radially 
outwards from all over the virus surface. The phospholipid,
4
glycolipid and chlolesterol composition of the virus membrane is 
a reflection qualitatively and quantitatively of that of the host 
membrane from which the virus was formed during budding (Patzer 
et al., 1979). The HA spike is roughly triangular in cross 
section and extends approximately 12 nm from the lipid membrane 
(Laver and Valentine, 1969) whereas the NA takes on the form of a 
mushroom but with a narrow stalk (Wrigley et al., 1973). The HA 
protein is the influenza virus attachment protein (VAP) 
interacting with terminal neuraminic acid cellular receptor units 
(CRUs) that are contained on plasma membrane glycoproteins or 
glycolipids. The HA is also involved in the penetration of the 
virus into the cell. The NA protein cleaves neuraminic acid from 
receptors on the cell surface as well as from other 
sialoglycoproteins and glycolipids. Both HA and NA have now been 
crystallized and their three-dimensional structures established 
by X-ray crystallography (Wilson et al., 1981; Wiley et al., 
1981; Varghese et al., 1983; Colman et al., 1983). The 
conspicuous spikes are quoted as numbering between 700 and 1000 
per virion (Tiffany and Blough, 1970b; Wrigley, 1979) in a 
proportion of roughly 5 HA spikes to 1 NA, but again these 
statistics are dependent on the strain of virus. The spikes are 
closely packed in an even manner, each spike having six 
neighbouring spikes on average according to the principal of the 
honeycomb (Wrigley, 1979). It is now thought that the NA spikes 
are clustered in discrete areas on the virion while the HA spikes 
are distributed uniformly over the virus surface (Murti and 
Webster, 1986). Both spikes are thought to penetrate through the
lipid bilayer via hydrophobic amino acids and may make contact
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with the underlying electro-dense layer of matrix (Ml) protein.
Encompassed by the lipid bilayer is a 6nm thick shell or 
matrix protein which is composed of the Ml protein. Within this 
are the ribonucleoprotein (RNP) structures consisting of 4 
protein components and the virus genome of 8 molecular species of 
single stranded RNAs of differing coding potential (Inglis et 
al., 1976). The predominant protein is the nucleoprotein (NP) and 
in smaller quantities are the polymerase proteins PB1, PB2 and 
PA. The 3 polymerase proteins constitute an RNA transcriptase 
enzyme (Kawakami and Ishihama, 1983). In the RNP complex the 
subunits of NP are arranged like beads on a string coiled doubled 
back on itself and then twisted into a helix (Compans et al., 
1972). It has been calculated that approximately 20 nucleotides 
of RNA interact with a single NP subunit (Winter and Fields, 
1981). The RNA is partially exposed since it is susceptible to 
RNase activity. Since RNase activity also destroys the RNP, RNA 
must be an integral part of the total structure.
1.3. Genome structure
The genetic information of influenza A viruses resides in 
eight segments of single stranded RNA. These code for 7 virion 
structural proteins (PB1, PB2, PA, HA, NA, NP and Ml) and three 
nonstructural proteins found only in infected cells (NSi ,NS2 and
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Mz). The virus RNA is negatively stranded, i.e. viral mRNAs are 
complementary to genome RNAs. Naked virion RNA is not infectious 
because it must be transcribed by a virion associated 
RNA-dependent RNA transcriptase.
The segmented genome also allows a high degree of genetic 
recombination between influenza A strains. This reassortment 
plays an important part in the initiation of influenza epidemics 
throughout the world since it can result in expression on the 
virion surface of new HA and NA antigens (antigenic shift) 
against which the population has no immunity.
The demonstration that the eight RNAs are distinct was shown 
by two dimensional oligonucleotide fingerprinting (McGeoch et 
al., 1976). The assignments of viral polypeptides to RNA segments 
have been made (Review: Lamb and Choppin, 1983). The gene 
assignments are indicated in the discussion of the influenza 
virus proteins in section 2.
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2. Influenza protein structure and function
The biological characteristics of the influenza virus are 
intrinsic to the nature, composition and function of its viral 
proteins. Reviewed below are more detailed descriptions of the 
structure and function of the proteins of influenza.
2.1. Transcriptase associated proteins; PB1, PB2, and PA 
(encoded by RNA segments 1,2 and 3 respectively).
The three largest RNA segments direct the synthesis of
single proteins MW 82,000 to 95,000. PB1 , PB2 and PA
(Horisberger, 1980) are components of the transcriptase complex 
in viruses and infected cells (Bishop et al., 1972; Bean and 
Simpson, 1973). These proteins are present in very small amounts 
in the virion (less than 3%). It is known that PB1 and PB2 are 
required for mRNA synthesis and PA possibly for vRNA synthesis 
(Scholtissek and Bowles, 1975; Palese et al., 1977). In 
investigating in vitro transcriptase reactions it has been found 
that PB2 is involved in binding to the cap structure of host cell 
mRNA (Ulmanen et al., 1981; Penn et al., 1982) and that PB1 
initiates transcription (Ulmanen et al., 1983). Braam et al 
(1983) showed that a complex of PB1, PB2, and PA proteins move 
down the elongating viral mRNA chains constituting a 
transcriptase catalyzing mRNA synthesis.
82.2. Haemagglutinin (HA) (encoded by RNA segment 4).
The HA glycoproteins of influenza virus membranes are 
responsible for the attachment of influenza to cells by 
interacting with the sialic acid residues on cellular receptor 
molecules (section 3.1). In fact, HA is a multifunctional protein 
since as well as mediating attachment (Lazarowitz and Choppin, 
1975) and the agglutination of erythrocytes (Hirst, 1941), it is 
a major determinant of virulence of influenza (Bosch et al., 
1979; Rott, 1979), the most important viral antigen to which 
neutralizing antibodies are directed (Laver and Kilbourne, 1966; 
Virelizier, 1975) and has been strongly implicated in mediating 
fusion events (White et al., 1982; Wharton et al., 1986) which
result in the initiation of the replication of influenza in the 
cell (section 3.3). Amino acid sequence variation resulting in 
altered antigenic properties of the HA accompany the recurrent 
epidemics of influenza respiratory disease in man. This variation 
can occur in two ways. Small changes in antigenicity (antigenic 
drift) are the result of a gradual accumulation of point 
mutations, while the complete change in antigenic properties 
(antigenic shift) involves the replacement of the gene coding for 
one HA with that for another (section 5.2).
In 1981 Wilson and his colleagues using X-ray 
crystallography described the three dimensional structure of the 
HA of a H3N2 influenza virus. This together with data on its 
functions means that the HA is now one of the most extensively
characterized
1979; Gething et al., 1980; Palese and Young, 1982), that the HA 
has a trimeric structure (Wiley et al., 1981; Wilson et al.,
1981) , its orientation with respect to the membrane (Skehel and
Waterfield, 1975), the location of the neutralizing antigenic 
sites (Wiley et al., 1931; Caton et al., 1982), the glycosylation 
sites (Gething et al., 1980; Ward and Dolpheide, 1981; Wilson et 
al., 1981), the probable location of the cell binding site
(Wilson et al., 1981; Rogers et al., 1983) and fusion sequences
(Richardson et al., 1980; Wilson et al., 1981; White et al.,
1982) .
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of all protein molecules. F o r  i n s t a n c e  we k n o w  the
c o m p l e t e  amino acid sequences of several HAs (Porter et al.,
The determination to 0.3nm resolution of the 
three-dimensional structure of the A/Hong Kong/1968 HA (H3) has 
revealed that the HA spike is a non-convalently linked trimer 
(Wiley et al., 1981). The structure of the H3 is a good model for 
other HAs since sequence comparisons of other influenza HAs show 
that many structurally important residues are conserved.
The HA monomer is synthesized as a single polypeptide which 
undergoes post-translational cleavage in 3 places. The synthetic 
pathway follows the route typical of membrane glycoproteins. 
After translation of the HA monomer the N-terminal signal 
sequence is removed by proteolysis (Air, 1979; Waterfield et al., 
1979) and the monomer is moved from the endoplasmic reticulum to 
the Golgi apparatus. Whilst in the endoplasmic reticulum the
elongating chain is glycosylated, oligosaccharides are added to 
the polypeptide (Klenk et al., 1974), these are then further 
modified in the Golgi apparatus where the addition of N-acetyl 
glycosamine, galactose, terminal sugars and sialic acid occurs 
(Compans, 1973b; Rothman and Lodish, 1977; Elder et al., 1979). 
Also in the Golgi the glycoprotein becomes acylated (Schmidt, 
1982) .
Depending on the host cell and virus strain, the HA molecule 
is cleaved with the removal of one or more intervening residues 
to give two polypeptide chains; HA1 (36,000 daltons MW) and HA2 
(27,000 daltons MW). This proteolytic cleavage is required for 
activating infectivity but does not affect antigenic or receptor 
binding properties. The HA1 and HA2 remain joined by a single 
disulphide bond. In addition to this inter-peptide bond there are 
four disulphide bonds within the HA1 and one in the HA2. Three 
HA1 and HA2 dimers come together to form a trimeric HA. It is 
likely that a coated vesicle transports the proteins to the 
plasma membrane. Further glycosylation modifications occur during 
the transport of the vesicle to the plasma membrane (Compans, 
1973b; Rott and Klenk, 1977). What results is a typical integral 
membrane glycoprotein with a three domain structure. Each monomer 
is glycosylated at 5-7 sites so that the total carbohydrate 
content is approximately 19% w/w.
Following fusion of the coated vesicle with the plasma 
membrane a large hydrophilic carbohydrate-containing N-terminal
domain becomes the external portion of the polypeptide, whilst a 
small uncharged hydrophobic peptide of 25-28 amino acids spans 
the membrane at the C terminus of the HA. A smaller hydrophilic 
domain at the C-terminus about 10 amino acids long lies on the 
internal side of the membrane. Gething and Sambrook (1981) found 
that removal of the portion of the HA gene that codes for the 
anchor sequence results in the HA glycoprotein being secreted 
from the cell. Thus when the mature virion buds from the cell 
(section 3.6) the HA will be firmly anchored in, and penetrate 
through, the viral membrane (Figure 2.1.1).
The HA monomers within the HA spike form a cylinder 13nm 
long consisting of alpha triple stranded coiled-coil of a helices 
extending 7.6nm from the membrane and then forming into a distal 
globular region of anti-parallel beta sheets (Wilson et al., 
1981) (Figure 2.1.1). The receptor binding site and the variable 
antibody binding regions are located on the surface of this 
globular region which is composed entirely of HA1 sequences 
(Wiley et al., 1981). Each monomer has a loop-like topography; it 
begins at the membrane,extends 13.5nm distally then folds back to 
enter the membrane via the N-terminus of HA1. The C-terminus of 
HA1 is 2.1nm from the N-terminus of HA2. indicating a substantial 
rearrangement in this region when HA is activated by cleavage.
A highly conserved region in a surface pocket on the distal 
end of the monomer has been implicated as the cell-receptor 
binding site (Wiley et al., 1981). Rogers at al. (1983) have
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observed modifications of sialic acid binding specificity as a 
direct consequence of amino acid substitution at a residue (226) 
which lies in the proposed receptor pocket.
Four neutralization antigenic (N-Ag) sites have been 
identified by the analysis of the amino acid sequence of HAs of 
naturally occurring H3 variants (Wiley et al., 1981) and of 
antigenic escape mutants selected by monoclonal antibodies 
(Yewdell et al. , 1979). The N-Ag sites have been labelled 
A,B,C,and D (Figures 2.1.1; 2.1.2).
A N-Ag site is a region of protein that induces and binds 
neutralizing antibodies. Within N-Ag sites there are neutralising 
epitopes (N-Ep) which are the individual sequences of amino acids 
that a neutralizing monoclonal antibody will bind to. A N-Ag site 
may therefore express many N-Eps. Knossow et al. (1984) found 
that the simple addition of an amino acid side chain in the HA 
results in only minor local distortions of the HA and that this 
is a sufficient structural alteration for a virus to escape 
neutralization. Proposals (Webster and Laver, 1980) of large 
conformational changes to account for variation in HA 
antigenicity are unnecessary in this and perhaps other cases.
Site A is a "loop" that protrudes out from the monomer 
surface by 0.8 nm containing residues 133-137 and 140-146. Site 
B, the "tip", comprises the external residues, 156-160 and 
186-197, of an al£ha helix which lie near to (but do not encroach
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Figure 2.1.1. Diagrammatic representation of influenza virus HA (H3) trimer.
A carbon chain representation of the polypeptide (Wilson et 
al., 1981) is shown for a single HA subunit within the trimer. 
The HA2 polypeptide is designated in a thicker line whilst HA1 is 
shown in a thin line. The receptor sites (in red) and the 
antibody binding regions* (in green, designated A-D on the 
highlighted HA subunit) are shown. Each H3 HA trimer has 12 
antibody binding regions and 3 receptor sites. The outlines of 
the two other HA monomers are marked by the dotted line. The HA 
trimer is inserted into the viral lipid membrane. The N-terminus 
of HA2 has fusion activity whilst the C-terminus of the HA2 
penetrates through the lipid layer to come in approximate contact 
with the M monolayer.
* There are five antibody binding regions on HI (Caton et al., 
1982).
Figure 2.1.2. Diagrammatic representation of the antigenic regions on the H3 HA molecule.
Orientated as in Figure 2.1.1 with end inserted into 
membrane at the bottom and the sialic acid binding site at the 
top. The four antibody binding sites determined by sequence 
analysis of natural variants and escape mutants selected with 
monoclonal antibodies are shown in green. Two of the regions 
recognized by human Th cell clones 57 and 58 are shown as red 
lines. Adapted from Wiley et al. (1981) and Mitchell et al.
(1985).
Figure 2.1.1. Diagrammatic representation of influenza virus HA 
(H3) trimer.
A carbon chain representation of the polypeptide (Wilson et 
al. , 1981) is shown for a single HA subunit within the trimer. 
The HA2 polypeptide is designated in a thicker line whilst HA1 is 
shown in a thin line. The receptor sites (in red) and the 
antibody binding regions* (in green, designated A-D on the 
highlighted HA subunit) are shown. Each H3 HA trimer has 12 
antibody binding regions and 3 receptor sites. The outlines of 
the two other HA monomers are marked by the dotted line. The HA 
trimer is inserted into the viral lipid membrane. The N-terminus 
of HA2 has fusion activity whilst the C-terminus of the HA2 
penetrates through the lipid layer to come in approximate contact 
with the M monolayer.
* There are five antibody binding regions on HI (Caton et al.,
1982).
Figure 2.1.2. Diagrammatic representation of the antigenic 
regions on the H3 HA molecule.
Orientated as in Figure 2.1.1 with end inserted into 
membrane at the bottom and the sialic acid binding site at the 
top. The four antibody binding sites determined by sequence 
analysis of natural variants and escape mutants selected with 
monoclonal antibodies are shown in green. Two of the regions 
recognized by human Th cell clones 57 and 58 are shown as red 
lines. Adapted from Wiley et al. (1981) and Mitchell et al.
(1985).
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on) the pocket implicated in VAP-CRU interaction. Site C is 
located on a "bulge" on the tertiary structure. This is at the 
disulphide bond between cysteine residues 52 and 277 and is 
located 6nm from the top of the molecule. In site D amino acid 
substitutions occur at a monomer-monomer interface. It is 
possible that this area contains antigenic determinants which are 
composed of residues from two or three of the subunits 
(Nestorowicz et al., 1985) and that antibodies recognize 
quarternary epitopes. Site A is considered to be immunodominant 
as judged by the epidemiological significance of viruses 
expressing altered antigenicity at this site and by the 
predominance of monoclonal antibodies binding to this site 
(Webster and Laver, 1980). An operational antigenic map of the HI 
subtype of influenza A/PR/8/34 by Caton et al. (1982) defines the 
presence of five antigenic sites. Two of the sites on HI 
correspond to sites A and D on H3 but the locations of the others 
do not correspond to those on H3. Antigenic sites that 
corresponded directly contained no potential glycosylation sites 
(Asn-X-Ser/Thr), but such a sequence does occur in a region of 
the H3 corresponding to antigenic site Cb on HI, and in the HI 
at the region corresponding to the H3 antigenic site C. The 
reciprocal nature of this relationship where the antigenic sites 
on the HA of one subtype do not contain glycosylation sites that 
are found on the equivalent location of the HA of the other 
subtype suggested that carbohydrate might be modulating the 
antigenic structure of the HA by masking regions of the protein 
from recognition by antibody (oligosaccharide chains are host
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specific and presumably not. very immunogenic in another infected 
animal of the same species). Direct evidence was presented by 
Skehel et al. (1984) who showed that the substitution of a 
glycosylation site at residue 63 in the HA of the 1968 Hong Kong 
(H3) influenza blocked the recognition by a monoclonal antibody 
directed to the site near that residue. Therefore the 
localization of carbohydrate on HA is an important consideration 
as antigenicity can be affected. Carbohydrate may also cover 
proteolytic cleavage sites.
In addition to antibody binding sites on HA there are 
determinants that are recognized by helper T (Th) cells. Th cells 
play a crucial part in the generation of both antibody (B cell) 
and cytotoxic T cell immune responses (section 5). 
Characterization studies of the human Th response (Green et al., 
1982) and the murine Th response (Hurwitz et al., 1984) have 
shown that influenza strain specific T cells recognize 
determinants different from those seen by anti-HA antibodies 
(Figure 2.1.2). Using a T cell proliferation assay Katz et al 
(1985) found that T cells from mice primed with one strain of 
influenza virus cross-reacted with another HA of the same subtype 
and serologically distinct subtypes. The major components in the 
T cell response to both homologous and heterologous HA was the 
recognition of determinants within the HA2 polypeptide which is 
not a feature of the B cell response.
2.3. Nucleocapsid protein (NP) (encoded by RNA segment 5).
The nucleoprotein (NP) is an internal non-glycosylated 
protein (60,000 daltons MW) and is one of the group specific 
antigens of influenza viruses that distinguishes between 
influenza A, B and C. It comprises up to 25% of the total protein 
of the virion (Skehel and Schild, 1971). NP interacts with itself 
and is intimately associated with the PB1, PB2 and PA proteins. 
RNP (consisting of the polymerase proteins, NP and the 8 RNAs)
has also been found on the basis of biochemical evidence to
interact with matrix protein (Rees and Dimmock, 1981). NP
undergoes antigenic variation and possesses at least 3
non-overlapping antigenic sites, one being common to all strains 
tested (Van Wyke et al., 1980). Monoclonal antibody to this 
conserved domain inhibited in vitro transcription of viral RNA, 
suggesting that NP is involved in RNA transcription. Based on the 
immunological evidence that T cells recognize NP (Townsend et 
al., 1984) and NP is detected at the surface of infected cells by 
antibody (Virelizier et al., 1977; Lamb et al., 1982) it is 
suggested that NP is expressed on the surface of cells.
2.4. Neuraminidase (NA) (encoded by RNA segment 6).
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The other integral membrane glycoprotein that protrudes from 
the surface of the influenza virus is neuraminidase (NA). It is a 
tetramer of molecular weight 240,000, reducing to 200,000 when 
solubilized by pronase (Blok et al., 1982). The mushroom shaped 
spikes of NA are present in roughly one fifth the amount of HA 
spikes and constitute about 5% of the protein of the virion 
(Skehel and Schild, 1971). Chemically neuraminidase 
hydrolytically cleaves the glycosidic bond joining the keto group 
of N-acetyl neuraminic acid (sialic acid) to D-galactose or 
D-galactosamine (Gottschalk, 1957).
When Varghese et al. (1983) described the detailed structure 
of the NA at 0.29 nm using X-ray crystallography they provided 
the first known example of a tetrameric protein with 4 fold 
symmetry. The polypeptide chain folds into six topologically 
identical, four stranded antiparallel beta sheets which are 
themselves arranged like the blades of a propeller. The tetramer 
can be visualized as an oligomer of identical polypeptide chains 
with a box-shaped globular head connected to the virus membrane 
by a long slender stalk, givng the well documented mushroom shape 
of the spike (Laver and Valentine 1969; Wrigley et al., 1973). 
The three dimensional structure of the stem is unknown at 
present, but evidence suggests that it is a relatively unfolded 
extended polypeptide and may be flexible (Wiley, 1983). It is 
known that amino acids 1-6 are on the cytoplasmic side of the 
membrane followed by an uncharged and primarily hydrophobic 
peptide (7-35) which spans the membrane and anchors the NA to the 
lipid. The N-terminal location of the membrane anchor peptide is
an uncommon feature for a glycoprotein, the HA and most other 
viral glycoproteins having C-terminal anchoring hydrophobic 
sequences. Approximately half of the carbohydrate associated with 
the neuraminidase of influenza B/Lee/40 is located on the stalk 
(Allen et al., 1977).
The biological role of neuraminidase activity is unclear but 
appears to confer on influenza virus the ability to free itself 
from neuraminic acid containing structures. This may promote the 
elution of progeny virus from host-cell surface (Palese and 
Schulman, 1974) during virus assembly. The removal of sialic acid 
from the carbohydrate moieties of newly synthesized HA and NA is 
necessary to prevent self aggregation of virions (Palese et al.,
1974). Removal of sialic acid by NA may also expose HA to 
cleavage (Schulman and Palese, 1977). Studies on fusion of cell 
membranes with liposomes containing influenza glycoproteins and 
observations that the fusion of erythrocytes was prevented by 
anti NA antibodies, (Huang et al., 1980; 1985) suggest a 
requirement of NA for membrane fusion (section 3.3). This however 
is difficult to reconcile with fusion of CV-1 cells expressing 
cloned HA gene (White et al., 1982). The respiratory tract is 
lined with sialomucoproteins which bind the influenza virus and 
therefore decrease infectivity (Shen and Ginsberg, 1968). NA may 
have a role here in enabling the virus to be freed from these 
inhibitory proteins and allowing it to reach target epithelial 
cells. In general then the enzyme catalytic properties of 
influenza neuraminidase facilitates the "mobility" of the virus 
both to and from the site of infection. The biological
1 8
1 9
significance of the apparent distribution of NA in discrete areas 
on the influenza particle (Murti and Webster, 1986) is not 
understood, but the clustered arrangement of NA may be important 
in the optimum performance of NA functions.
Antibodies to NA are not neutralizing (Webster and Laver, 
1967; Kilbourne et al., 1968) but by aggregating virus at the 
cell surface can prevent viral budding and restrict multiple 
cycles of replication in susceptible cells (Webster and Laver, 
1967) and in mice (Schulman et al., 1968). Antigenic variants 
have been selected with monoclonal antibodies to neuraminidase 
(Webster et al., 1982). Therefore anti-NA antibodies can exert 
selective pressure on influenza and so have a role in the 
epidemiology of the disease. Colman et al. (1983) were able to 
propose the location of antigenic determinants on the NA molecule 
by examining the position of amino acid substitutions in the NA 
of antigenic escape mutants selected by monoclonal antibodies and 
the changes which occur in NA-antigenic drift naturally. The 
antigenic sites form a nearly continuous surface that encircle 
the catalytic site on the globular head of the molecule. The 
active site itself is conserved from strain to strain and is 
thought to be inaccessible to antibody, since inhibition of 
enzyme activity by monoclonal antibodies is only seen when large 
substrates such as fetuin are employed, not with small substrates 
such as N-acetylneuraminyl lactose (Jackson and Webster, 1982), 
which implies an indirect steric effect of antibody. The 
inaccessibility of the catalytic site to antibody also suggests
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"that antibodies cannot exert pressure on that site for its 
modification.
2.5. Matrix protein (Ml) and M2 (encoded by RNA segment 7).
Matrix or membrane (Ml) protein is the most abundant virion 
protein composing up to 35% of the total virion (Skehel and 
Schild, 1971) and is thought to form a protein shell beneath the 
lipid bilayer. This hydrophobic protein interacts strongly with 
viral lipid and phosphatidylcholine vesicles in vitro 
(Gregoriades, 1980) and this would agree with the interpretation
of Lenard et al. (1974), that M may be interacting with the lipid
bilayer in the virus particle. Association of M with the lipid 
could also contribute towards the stabilization of the virus 
bilayer. As well as being a structural protein Ml may recognize 
the viral glycoproteins and form a domain on the inner surface of 
the plasma membrane that subsequently provides a binding site for 
nucleoprotein during virion assembly. Little is known about 
interactions between spike glycoproteins, the M proteins and 
nucleocapsid proteins. However, based on immunological and 
protease accessibility experiments (Ada and Yap, 1979; Reginster 
et al., 1979) it is suggested that the M protein is exposed on 
the external surface of cells.
Mi is type specific, being antigenically similar for all 
influenza A viruses tested (Schild, 1972). However, monoclonal
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Segment 7 also codes for the protein M2 (15,000 daltons MW). 
Lamb et al. (1985) showed that M2 is a glycoprotein which occurs 
in the infected cell and is inserted into the plasma membrane 
with its N-terminus external. Despite this membrane involvement 
it has not been detected in virus particles (Zebedee et al., 
1985). It was demonstrated that anti-peptide antibodies could 
recognize the external M2 protein, and it was suggested that the 
protein could be an antigen in natural infection, however there 
is presently no direct evidence to support this idea (section
5.4). Hay et al. (1985) examined the genetics of sensitivity of 
influenza virus strains to amantadine, which acts at an early 
stage of infection, possibly virus uncoating. It was concluded 
that M2 was the primary determinant of amantadine sensitivity. 
While this supports the view that M2 is present in the virion and 
has a functional role, Zebedee et al. (1985) were not able to
detect M2 in virus particles. Another protein, M3 , has been 
predicted to be coded by segment 7 by sequence alone (Lamb et 
al., 1981) and this, as yet unidentified peptide may also be 
synthesized in infected cells.
2.6. Nonstructural proteins NSl and NS2 
(encoded by RNA segment 8).
antibodies can discri m i n a t e  small a n t i g e n i c  d i f f e r e n c e s  bet w e e n
subtypes (Van Wyke et a l ., 1980; Le Com t e  and Oxford, 1981).
Two nonstructural proteins NSi (26,000 daltons MW) and NS2
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(14,000 daltons MW) are coded by the smallest RNA segment. NSi is 
made in large amounts in infected cells (Compans et al., 1970),
is phosphorylated (Almond and Felsenreich, 1982) and has been 
found associated with polysomes and in the nucleolus (Dimmock, 
1969; Lazarowitz et al., 1973; Compans, 1973a; Shaw and Compans,
1978) Late in infection NSl of some but not all influenza virus 
strains form electron dense crystalline arrays with cellular RNA 
species (Shaw and Compans, 1978; Yoshida et al.,1981; Petri and 
Dimmock, 1981).
The functions of NSl and NS2 have not been fully 
established but it has been suggested that NSl is involved in 
the shut-off of host cell protein synthesis and in the synthesis
of virion RNA (Lazarowitz et al., 1973; Compans, 1973a
Wolstenholme et al., 1980).
3. Early Influenza virus-cell interactions 
leading to virus infection.
In order to infect a cell the virus genome of an enveloped 
virus such as influenza virus has to cross both the cell plasma 
membrane and its own viral envelope. The question of how viruses 
enter cells remains controversial (Reviews: Dimmock, 1982; Marsh, 
1984). For influenza virus the initial stages of infection appear 
to involve the binding of an influenza virus particle to a sialic 
acid containing receptor at the cell surface, absorptive 
endocytosis (viropexis), endosome formation followed by fusion of 
the influenza virus membrane with the membrane of the endosomes 
(lysosomal vesicle). An alternative route of entry suggests 
attachment is followed directly by fusion between the virus 
envelope and the plasma membrane leading to release of viral RNA; 
thus penetration and uncoating would occur in a single step.
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3.1. Attachment.
To firmly attach to a cell influenza virus binds via the HA 
to N-acetyl neuraminic acid (sialic acid) residues on
oligosaccharide side chains of cellular glycolipids 
(gangliosides) or glycoproteins. Sialic acids are also essential 
CRUs for paramyxoviruses, polyoma viruses and
encephalomyocarditis viruses. These viruses can exhibit strict 
and varied specificities for the sialyoligosaccharide linkages. 
The terminal sialic acid alone determines a glycoprotein’s 
ability to act as a CRU for influenza virus (Suttajit and
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Winzler, 1971, Huang, 1973). Closely related strains of influenza 
virus and escape mutants selected by monoclonal antibodies can 
differ in their specificity for sialyl linkages (Carroll et al., 
1981; Rogers et al., 1983).
Glycophorin A is the main sialoglycoprotein molecule 
carrying CRUs for influenza virus on erythrocytes (Jackson et 
al. , 1973). As a result of the use of haemagglutination as a 
quantification of virus titre and inhibition of haemagglutination 
as a measure of antibody titre, glycophorin A has become the 
"model receptor" for influenza virus. Inhibition of 
haemagglutination, however, does not necessarily correlate to 
neutralization, as it has been found that neutralized virus binds 
normally to cultured cells (Possee and Dimmock, 1981; Dimmock, 
1984). Also it has been found that antibody to some avian and 
seal influenza viruses fail to inhibit haemagglutination of the 
virus yet effectively neutralize infectivity (Yoden et al., 1982; 
Kida et al., 1982). Therefore erythrocytes with short 
glycophorins reaching 5nm from the erythrocyte surface (Viitala 
and Jarnefelt, 1985) may be a poor model for the infectious 
process. Further weight is added to this view when it is 
considered that the "hedgehog-like" glycophorins lie deep amongst 
the much taller (10-15nm) poly N-acetlylactoseamine chains which 
in turn are immersed in a "web" of carbohydrate molecules. The 
amount of carbohydrate covering the surface of erythrocytes is 
considerable compared to that of other cells (Viitala and 
Jarnefelt, 1985) and may have consequences for the attachment of
viruses. Other molecules carrying CRUs on the wide range of cells 
to which influenza virus binds to have yet to be characterized.
Attachment of influenza virus to cells, as with some other 
viruses, occurs at low temperatures (4°C) as well as at
physiological temperatures (Kato and Eggers, 1969; Dourmashkin 
and Tyrrell, 1970; Stephenson and Dimmock, 1975). At 
physiological pH both virus and cells are negatively charged and 
tend to repel one another, if the pH is altered the charge will 
be affected and therefore this will have an impact on attachment. 
Huang (1974) found that charged agarose beads could adsorb 
influenza virus and the adsorption of influenza virus to
neuraminidase-treated erythrocytes was restored when cells were 
treated with buffers at pH3, 4 and 9. These results indicated 
that when a suitable ionic status of the cell surface is achieved 
influenza virus can bind in the absence of sialic acid. 
Physiological differences in pH may have a role in host-virus 
interactions, e.g. in the infection of intestinal tracts of birds 
with avian influenza viruses (Webster et al., 1978).
Preferentially virus attaches to certain recognizable 
morphological features such as microvilli (Bachi et al., 1969; 
Helenius et al., 1980; Matlin et al, 1981).
DEAE-dextran enhances virus infectivity by increasing 
binding and underscores the lack of requirement for specific
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surface molecules as receptors (Lenard and Miller, 1983). 
DEAE-dextran increased BHK cell associated vescicular stomatitis 
virus (VSV) particles by 3-4 fold. Since both VSV envelopes and 
cell surfaces are negatively charged at neutral pH the 
DEAE-dextran mediated binding is probably electrostatic.
A reflection of the ability of neuraminidase to hydrolyze 
sialic acid is that the attachment of influenza virus to a cell 
may be reversible. The attachment of influenza virions bound to 
erythrocytes at 4°C may be reversed by increasing the temperature 
to 37°C (Laver and Kilbourne, 1966). The reversal of attachment 
in this example is non-physiological as it is only seen when 
virus is in vast excess.
3.2. Internalization of influenza virus by the cell.
Paramyxoviruses can penetrate the cell surface by fusion, 
thereby achieving penetration and uncoating in a single step 
(Reviews: Choppin and Compans, 1975; Poste and Pasternak, 1978).
The envelopes of these viruses fuse with the host cell membrane 
at pH7. Fusion in paramyxoviruses is mediated by the F or fusion 
glycoprotein present on the external surface of the viral 
envelope. While it is clear that paramyxoviruses can fuse at the 
cell surface, it is not clear that that this route is infective. 
There is no direct evidence that influenza A viruses normally 
infect cells by fusion with the plasma membrane of cells (Figure
3.1.1). Influenza virus only displays a capacity for fusion to 
lipid membranes under acidic conditions, optimally between pH5 
and pH5.5 (Maeda and Ohnishi, 1980; Huang et al., 1981a). 
Virus-induced lysis of erythrocytes leading to the leakage of 
haemoglobin (haemolysis) has been used as a convenient 
experimental approach to measure fusibility of viral envelopes. 
The affirmed dogma is that a consequence of fusion of viruses 
with cell membranes can be leakage of molecules across the 
membrane (Poste and Pasternak, 1978). Although definitive 
evidence that virus-induced haemolysis is associated with 
virus-erythrocyte fusion has only so far been obtained for Sendai 
virus (Lyles, 1979) fusion is generally regarded as necessary for 
viral haemolysis. Consistent with this erythrocyte-erythrocyte 
fusion has been observed in association with viral haemolysis 
(Maeda and Ohnishi, 1980). The ability of influenza virus to 
cause haemolysis is dependent on acidic pH and a temperature 
above 10°C (Huang et al., 1980; Lenard and Miller, 1981). It 
would not be expected that influenza viruses would enter cells by 
fusion since the surface of cells is not acidic. However, 
influenza A/fowl plague virus/Rostock (H7NI) (FPV/R), which was 
prevented from undergoing endocytosis by being bound to a 
substratum can infect cells (through fusion with the plasma 
membrane) at neutral pH (Huang et al., 1981a).
It has been proposed that the fusion ability of influenza 
virus is brought into play when viruses reach the acidic 
environment of the endosome following its initial endocytosis
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A t t a c h m e n t
Figures 3.1.1 and 3.1.2. Postulated early events of the 
interaction between cells and influenza virus:
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Figure 3.1.1. Schematic diagram of entry of influenza by direct 
fusion through plasma membrane.
Figure 3.1.2. (Opposite) Schematic diagram of the adsorptive 
endocytosis pathway of entry leading to fusion in secondary 
lysosomes at low pH inducing the release of viral RNA.
Virus attaches to CRUs on the plasma membrane. Endocytosis 
is initiated at clathrin coated regions of the plasma membrane 
which pinch off to form coated vesicles* . These vesicles lose 
their coats and deliver their contents to endosomes. Penetration 
takes place here dependent on acid-triggered conformational 
changes in the HA (section 3.3). Endosomes are a heterogeneous 
population of endocytic vacuoles through which internalized virus 
may pass on route to secondary lysosomes. The individual endosome 
matures and upon secondary lysosome formation acid-triggered 
conformational changes must lead to penetration before the 
hydrolytic enzymes degrade any unfused virus.
* Influenza virus also observed to enter via smooth surface 
vesicles.
Diagram based on interpretation of experiments described by 
Matlin et al., (1981); Patterson et al., (1979); Maeda and 
Ohnishi (1982) and Yoshimura and Ohnishi (1984).
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Figures 3.1.1 and 3.1.2. Postulated early events of the 
interaction between cells and influenza virus:
Figure 3.1.1. Schematic diagram of entry of influenza by direct 
fusion through plasma membrane.
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A t t a c h m e n t
D i r e c t
Figure 3.1.2. (Opposite) Schematic diagram of the adsorptive 
endocytosis pathway of entry leading to fusion in secondary 
lysosomes at low pH inducing the release of viral RNA.
Virus attaches to CRUs on the plasma membrane. Endocytosis 
is initiated at clathrin coated regions of the plasma membrane 
which pinch off to form coated vesicles* These vesicles lose 
their coats and deliver their contents to endosomes. Penetration 
takes place here dependent on acid-triggered conformational 
changes in the HA (section 3.3). Endosomes are a heterogeneous 
population of endocytic vacuoles through which internalized virus 
may pass on route to secondary lysosomes. The individual endosome 
matures and upon secondary lysosome formation acid-triggered 
conformational changes must lead to penetration before the 
hydrolytic enzymes degrade any unfused virus.
* Influenza virus also observed to enter via smooth surface 
vesicles.
Diagram based on interpretation of experiments described by 
Matlin et al., (1981); Patterson et al., (1979); Maeda and 
Ohnishi (1982) and Yoshimura and Ohnishi (1984).
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(Figure 3.1.2) (Dourmashkin and Tyrrell, 1970; Patterson et al., 
1979) and based on evidence of the low pH-induced fusion activity 
of influenza virus (White et al., 1981; Maeda et al., 1981; 
Yoshimura et al., 1982).
Virtually all mammalian cells are continously engaged in 
phagocytosis, pinocytosis and adsorptive (receptor-mediated) 
endocytosis. Adsorptive endocytosis is a process for the uptake 
of essential macromolecules and if influenza virus enters by this 
mechanism it would be utilizing a normal cellular process to 
invade the cell.
Most of what is known about the pathways involved in the 
receptor-mediated uptake of enveloped viruses comes from the 
studies of Semliki Forest virus (SFV) by Helenius et al. (1980). 
SFV particles bind via viral glycoproteins to CRUs (particularly 
on microvilli) which are then concentrated in the locality. The 
virus then moves down into specialized regions of the cell 
membrane known as coated pits, the principle distinguishing 
features of which are the coating of clathrin molecules on their 
intracellular surfaces. Clathrin is a fibrous protein and takes 
the form of a polyhedral lattice or net for, and under, the 
receptors in the pit. The pits fold inwards to produce coated 
vesicles. The coated vesicles enter the cytoplasm, form into 
acidic prelysosomal vacuoles (endosomes) which can later form 
secondary lysosomes when they combine with lysosomes. Matlin et 
al . (1981) found that this sequence of events of internalization
by endocytosis, sequestration into intracellular vacuoles and 
secondary lysosome formation is also seen with influenza virus 
using MBDK cells (Figure 3.1.2). In addition to coated pits and 
vesicles, influenza virus particles were found in uncoated 
depressions in the plasma membrane and smooth uncoated vesicles 
were observed completely filled with virus particles. The 
importance of these smooth surfaced pits and vesicles to 
influenza virus entry is unclear. They may be caused by the 
plasma membrane progressively wrapping itself around the virus 
particles as more HA spikes are bound. Indeed, their formation 
may be induced by the virus particle itself. Patterson et al. 
(1979) noted that the majority of influenza virus particles were 
taken into cells in uncoated pits. SFV only entered BHK-21 cells 
in coated pits (Helenius et al . 1930).
EM observations by Patterson et al. (1979) showed that after 
attachment of influenza virus to chick embryo fibroblasts 
particles were endocytosed. After attachment the virus is 
gradually surrounded by the fluid cellular membrane. This process 
followed a pattern predicted by the thermodynamic analysis of the 
binding of polyvalent ligands to cell membranes (Hewitt, 1977) 
and influenza virus with repeating HA spikes may be regarded as a 
polyvalent ligand. Binding induces a curvature in the membrane 
which is concave towards the side to which ligand is bound. 
Invagination of membrane following virus attachment may be 
considered as the most thermodynamically stable configuration for 
the membrane to adopt. Thickening of the plasma membrane was
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associated with the attachment site and this appeared to be 
internalized with virus giving rise to a vesicle with a thickened 
membrane. This method of entry was also observed by Matlin et al. 
(1981) illustrating that influenza virus does enter cells via 
smooth surface vesicles. Some vesicles contained more than one 
virus.
Adsorptive endocytosis unlike macropinocytosis and 
phagocytosis does not require energy (Allison and Davies, 1974). 
It has been found in electron microscopic observations that 
influenza virus endocytosis is unaffected by cytoskeletal 
inhibitors such as colchicine and cytochalasin B (Dourmashkin and 
Tyrrell, 1970; Patterson et al., 1979) illustrating that 
influenza virus entry does not require metabolic energy. 
Influenza virus also has the ability to enter lymphocytes and 
other cells at 4<>C (Hackeman et al. , 1974; Kato and Eggers, 1969; 
Stephenson and Dimmock, 1975, Stephenson et al., 1978; Mark et 
al., 1979, Possee and Dimmock, 1981). Micropinocytosis of 
colloidal gold occurs at 4°C in chick embryo fibroblasts (CEF) 
(Stephenson et al., 1978). Uptake at 4®C was similar to that at 
37°C. The uptake of low density lipoprotein (LDL) into CEF cells 
by adsorptive micropinocytosis was also found to be temperature 
independent (N.J. Dimmock, personal communication). Adsorptive 
micropinocytosis (endocytosis) is the mechanism which accounts 
best for the penetration of infectious viruses at 4°C.
There are alternative patterns of processing (Hopkins, 1983)
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of ligands apart from the route to a secondary lysosome and not 
all molecules that enter via coated pits reach lysosomes. For 
example, there are shuttle systems that return ligand and protein 
to the cell surface as in the case of transferrin (Daultry-Varsat 
et al., 1983; Klausner et al., 1983) or route the endocytosed 
molecule elsewhere, e.g. various hormones, apotransferrin, 
polymeric IgA and maternal IgG (Goldstein et al., 1979; 
Daultry-Varsat et al., 1983; Klausner et al., 1983; Rodewald, 
1980). Experiments reported by Yoshimura and Ohnishi (1984) show 
that the majority of influenza virions could be uncoated in 
endosomes before reaching secondary lysosomes and prelysosomal 
fusion is accepted as the method of penetration of SFV (Marsh et 
al., 1983; Marsh, 1984). The heterogenicity in processing and 
endosome structure indicates that an invading influenza virus 
particle may be routed in various pathways.
The bias of current thought is therefore that the major site 
of entry of enveloped viruses is in the endosome (Marsh, 1984). 
Thus, virus would not be exposed to the destructive hydrolytic 
enzymes in the lysosomal compartment (Dales, 1973; Lonberg-Holm 
and Phillipson, 1974). It should be stressed that secondary 
lysosmes could serve a role in the processing of internalized 
influenza virus (Matlin et al., 1981).
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3.3. Uncoating.
Evidence suggests that influenza virus enters the cytosol by 
fusion with the endosome or secondary lysosome membranes (Figure
3.1.2). The results of recent investigations have indicated that 
for a number of viruses, fusion occurs optimally over a narrow 
range of pH, which in the case of influenza viruses lies between 
5 and 5.5 (White and Helenius, 1980; Vaananen and Kaariainen, 
1980; Maeda and Ohnishi, 1980; Huang et al., 1981a) and it is
proposed that this correlates with the pH at the site of cell 
entry in intracellular vesicles such as endosomes and secondary 
lysosomes (Review: Marsh, 1984). Acidification (due to the 
activity of a H+ -ATPase) of the endosome results in fusion of 
the viral membrane with the endosomal membrane and exclusion of 
the viral RNA into the cytoplasm. The penetration of SFV within 
endosomes enables the virus to accomplish fusion before entering 
the hydrolytic lysosomal compartment (Marsh et al., 1983). Other
evidence put forward by Helenius et al. (1980) and White et al.
(1981) for pH dependent fusion in the endosome or in the lysosome 
is that lysosomotropic agents (compounds that accumulate in
endosomes and lysosomes) that also raise pH such as chloroquine, 
NH« Cl and methylamine are efficient inhibitors of virus
infection (Review: Dimmock, 1982). The multiplication of
influenza virus is inhibited by lysosomotropic agents such as NH« 
OH, NH« Cl and amantadine (Eaton and Scala, 1961; Fletcher et 
al., 1965; Hoffman et al., 1965). Amantadine interferes with a
stage shortly after attachment and before any virus directed 
synthesis can occur (Skehel et al., 1977) and it is suggested 
that it inhibits fusion. Further, Bukrinskaya et al. (1982)
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reported that rimantadine, an amantadine analogue, blocks 
influenza virus infection by preventing the release of M-protein 
during uncoating.
The ability of these lysosomotropic agents to raise 
endosomal or lysosomal pH, however, does not correlate with their 
degree of inhibition and compounds such as chloroquine might 
inhibit another process. The paramyxovirus, Sendai, fuses readily 
with cell membranes at neutral pH, but was inhibited at a similar 
early stage in infection by all lysosomotropic agents tested at 
similar concentrations to those required for inhibition of SFV 
and influenza virus (Miller and Lenard, 1981). This indicated 
that lysosomotropic agents could inhibit another stage of 
infection. The inhibitory activity of lysosomotropic agents on 
virus infection cannot be automatically interpreted as evidence 
that endosomes or lysosomes are the site of penetration (Dimmock, 
1982). With SFV it was found that fusion of virus adsorbed to 
viral envelopes occurred after brief treatment of cells in the 
presence of chloroquine which resulted in an infection as 
effective as that that occurred in the absence of chloroquine, 
showing that the chloroquine does not effect the fusion reaction 
itself (Helenius et al., 1980).
Edwards and Brown (1986) found that Sindbis virus mediated 
fusion of cultured cells is a two step event. The virus must 
first be exposed to pH 5.3 (inducing a conformational change in 
the virus glycoprotein) but the fusion event itself requires a
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shift, of pH to neutrality. The requirement for a shift to a 
higher pH indicates either a second change in virus particles at 
that pH or some other requirement placed on fusion by the host 
cell. Chloroquine and NH< Cl do not prevent the penetration of 
Sindbis (Cassel et al., 1984). These results suggest that passage 
through an acidic intracellular compartment may not be essential 
for penetration of cells by these viruses.
The M protein in influenza virus may play an important role 
in uncoating. It is tightly associated with both the envelope and 
the nucleocapsid (section 2.5). Its association with 
nucleocapsids causes inhibition of RNA synthesis in influenza 
virus (Zvonarjev and Ghendon, 1980). It seems likely that the 
viral nucleocapsid must free itself from M protein after fusion 
before it can start transcription. In view of the association of 
M protein with the viral envelope this decoupling process may 
well constitute a second step in uncoating. It has been suggested 
that amantadine acts in highly sensitive strains of influenza 
virus by potentiating the M protein-mediated inhibition of viral 
RNA polymerase (Zvonarjev and Ghendon, 1980; Lenard et al., 1982) 
and this may act on the second rather than first uncoating step 
at the low concentrations that effectively inhibit these strains.
Bukrinskaya et al. (1982) found that the uncoating of 
influenza virus proceeds in two major steps. Firstly, it is 
proposed that the outer lipid membrane of the virus is removed 
along with the embedded glycoproteins. This results in sub-viral
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particles (SVP) that contain M protein and the RNP complex. In 
this respect, SVP are similar to the virus cores obtained by the 
treatment of influenza virus with detergents (Schulze, 1972). The 
results further implied that SVP are transported to the nuclear 
membrane where the second step in uncoating occurs; the removal 
from the M protein of the RNPs releasing naked RNPs. These steps 
take place in different cellular compartments. Intact virions 
were found in the cytoplasm, while SVP and RNPs were found in the 
nuclear associated cytoplasm. Rimantadine prevented the second 
step of uncoating, preventing the accumulation of SVP in the 
nuclear associated cytoplasm.
HA has now been directly implicated in membrane fusion as 
cloned HA can cause fusion without the presence of any other 
viral proteins (White et al., 1982). This confirmed previous 
conclusions from a variety of observations that HA is also 
involved in this activity. Post-translational cleavage of 
precursor HA (HAO) to HA1 and HA2 is required for both virus 
infectivity (Klenk et al., 1975; Lazarowitz and Choppin, 1975) 
and in vitro virus mediated fusion (Huang et al., 1981a; White et 
al . , 1981). The amino terminal sequence of HA2 consists of 10 
uncharged hydrophobic amino acids (Skehel and Waterfield, 1975) 
and it has been suggested that this region is involved in the 
membrane fusion reaction. The hydrophobic amino terminus of HA2 
is analogous to that of the amino terminus of the Fl virus 
glycoprotein component of Sendai, a paramyxovirus that enters 
cells as a consequence of fusion of virus and cell membranes
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(Scheid et al., 1978; Gething et al., 1978). This sequence is 
located lOnm from the distal tip of the HA molecule and 3.5nm 
from the viral membrane. The significance of this sequence in 
fusion was highlighted by the demonstration that synthetic 
peptides mimicking the appropriate sequence of the HA2 N-terminus 
inhibit virus induced membrane fusion and virus penetration, 
albeit very poorly (Richardson et al.,1980). Skehel et al. (1982) 
demonstrated that a conformational change in bromelain released 
HA (BrHA) occurs in the pH range 5.2-4.9, and after incubation at 
low pH BrHA is able to form hydrophobic associations with other 
BrHA molecules, lipid vesicles and nonionic detergent miscelles. 
It is envisaged that a molecular rearrangement occurs to allow 
direct action of the hydrophobic region of the HA2 (normally 
hidden in the stem region) with lipid membrane. The only charged 
amino acids in the first 18 residues of HA2 of influenza A/fowl 
plague/Rostock/34 (FPV/R) are two glutamic acid residues (Porter 
et al., 1979; Maeda and Ohnishi, 1980). If these residues are 
protonated (as might occur in the lysosome) the amino terminal 
segment would become uncharged and possibly hydrophobic enough to 
induce membrane fusion. As yet direct evidence of a causal 
relationship between the conformational change and fusion 
activity in vivo is lacking.
Huang et al. (1981b; 1985) maintain that both cleaved HA and 
NA activity are required for influenza virus cell fusion and 
haemolysis. Anti-NA antisera inhibited the fusion of erythrocytes 
and partially reduced haemolysis, but this was restored by the
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addition of Vibrio choleras neuraminidase (Huang et al., 1985). 
It was found that erythrocytes of various species showed 
different optima for haemolysis by FPV/R and further that 
erythrocytes could be sensitized for fusion and haemolysis by 
FPV/R at neutral pH if they had been pre-treated with low pH 
buffer. It was also found that not only virus proteins but 
cellular membranes undergo changes at acidic pH, since 
erythrocytes were fused by an acid wash. These data illustrated 
that the surface properties of erythrocytes are important in the 
low pH dependent fusion and haemolysis by influenza virus. 
Therefore, the acid pH activation of the virus is not obligatory 
for fusion. Acid treatment of the virus alone destroyed its 
ability to haemagglutinate and also caused irrevesible viral 
aggregation. Haywood and Bayer (1985) demonstrated that influenza 
virus membranes are capable of fusion with liposomes at a range 
of pH. These data question the dogma that fusion in endosomes or 
secondary lysosomes is the only route of entry of enveloped 
viruses into cells (Helenius et al., 1980; White et al., 1981).
The observations discussed above can be unified if it is 
considered that influenza virus enters after interactions of HA 
and CRUs. Uptake is initiated and events ensue that destabilize 
the influenza virion sufficently to release the influenza virus 
RNP into the cytosol which is rapidly transported to the nucleus 
and transcriptional replication of the vRNA occurs. The route by 
which influenza virus is transported to the nucleus is not known 
but travel is not likely to be random as 50% of the cell
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associated input RNA is found associated with the nucleus after 
15 minutes (Stephenson and Dimmock, 1975). A virus may travel 
directly through the network of membranes that comprise the 
cytoplasm or travel via the cisternae. Microtubules (Allison and 
Davies, 1974) might be responsible for directing vesicles 
containing influenza virus from the plasma membrane to the
nucleus.
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3.4. Transcription and replication of influenza virus.
Influenza virus replication is dependent on an active host 
cell nucleus both for viral transcription and for the processing 
of the viral mRNAs. The major host cell nuclear-dependent 
function involved in influenza virus replication is the synthesis 
of host cell mRNA which serves as a primer in the transcription 
of virus specific mRNA (Bouloy et al., 1978; Krug et al., 1979). 
The initial transcription of viral RNA in the cell to form mRNAs 
[poly A(+)cRNA] is known as primary transcription. This system 
can be readily duplicated i ri vitro using disrupted virions.
Secondary transcription is dependent on protein synthesis 
and results in progeny RNA molecules. Here the virus copies its 
vRNA into full length cRNA transcripts [poly A(-)cRNA] which act 
as templates for an RNA replicase to produce full-length vRNA for 
transcription into progeny virus. The synthesis of the three 
different classes of viral RNAs (mRNA, poly A(-)cRNA and vRNA), 
and the relative abundance of specific RNAs and vRNAs are 
controlled throughout infection.
3.4.1. Early intracellular events: mRNA formation.
The first phase of influenza replication - primary
transcription results in the synthesis of all eight mRNAs
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complementary "to each segment of RNA in approximately equimolar 
amounts. In less than 20 minutes after infection mRNAs can be 
detected (Hay et al., 1977; Barrett et al., 1979; Mark et al.,
1979) and their rate of synthesis reaches a peak after 2 hours. 
Primary transcription is independent of protein synthesis and 
takes place in the nucleus (Herz et al., 1981). Subsequently 
transcripts are transported to their site of function in the 
cytoplasm.
In order for transcription to take place cellular mRNAs are 
required. Virion RNA transcription in vitro, catalyzed by the 
virion-associated transcriptase, is greatly enhanced by the 
addition of a primer dinucleotide, ApG or GpG (McGeoch and 
Kitron, 1975; Plotch and Krug, 1977; 1978). in vitro ,
eukaryotic mRNAs and other RNAs containing a fully methylated cap 
structure (Gm7 GpppXm ) stimulated the transcription of influenza 
viral RNA (Plotch et al., 1981). 5 terminal RNA fragments
containing the cap and the ensuing 10-14 nucleotides are cleaved 
from the host mRNA (e.g. beta-globulin mRNA) and are used as 
primers to initiate viral RNA transcription. The virion contains 
a cap-dependent endonuclease that cleaves capped RNAs 
preferentially at a purine residue that is 10-13 nucleotides from 
the 5 terminus. The mRNAs therefore have a 5' terminal type I 
cap structure (Krug et al., 1976). The priming of influenza viral 
RNA transcription by capped host RNAs also occurs in the infected 
cell (Krug et al., 1979). Host cell mRNAs and/or the precursors 
serve as primers for viral RNA transcription in the infected cell
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and donate their cap and 10-15 nucleotides, one of which is m6 A, 
to resulting viral mRNA molecules.
The 5' ends of influenza viral RNAs have to be donated 
from newly synthesized capped host RNA species, as pre-existing 
RNAs in the nucleus remaining after the addition of alpha
amanitin do not prime (alpha amanitin inhibits DNA-dependent RNA 
polymerase II). Two of the influenza mRNA species are further 
modified by splicing (presumably by host cell enzymes) which
allows overlapping regions of the genome to direct synthesis of 
additional polypeptides. In this manner NS2 is derived from 
segment 8 and M2 is derived from segment 7 (Lamb and Lai, 1980, 
Lamb et al., 1981).
The process of cleavage of the capped primer RNA,
initiation, elongation and termination/polyadenylation of the 
transcript are all carried out by the proteins of the viral core 
(Plotch et al., 1981) i.e. NP, PB1, PB2 and PA (sections 1.3;
2.1; 2.3). NP is considered to have a structural role, PB2 is the
cap recognition protein (Ulmanen et al., 1981; Braam-Markson et
al., 1985). PB1 probably catalyzes the initiation of
transcription (Ulmanen et al. , 1981) and then acts as the
transcriptase enzyme, adding nucleotides. It has not been 
determined which viral protein(s) act as the endonuclease (i.e. 
cleaving the capped RNA) but PB2 (in recognizing the 5 cap) and 
PB1 (in perhaps cleaving the phosphate bond) may constitute the 
endonuclease component. Although the PA protein is part of the
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•transcriptase complex catalyzing mRNA synthesis that moves down 
the growing viral mRNA chain (Braam et al, 1983), a specific 
function for the PA protein has not yet been identified.
3.4.2. Template poly A-cRNA synthesis.
A second population of RNA transcripts [poly A(-)cRNA] are 
detected after the mRNAs appear in the cell and are synthesized 
whilst mRNAs are being produced. Synthesis of poly A(-)cRNA 
reaches a maximum rate 30-90 minutes post infection, before the 
peak of mRNA production. Poly A(-)cRNA molecules are 
complementary to the vRNA segments found in infected cells. They 
are complete transcripts of the vRNA segments, lack host derived 
primer sequences, are non-polyadenylated and probably act as 
templates for vRNA synthesis. The full length transcripts are 
probably also synthesized in the nucleus (Herz et al., 1981). As 
the synthesis of these transcripts is inhibited by cycloheximide 
it is suggested that synthesis is dependent upon a 
virus-specified protein(s) which perhaps modify the transcriptase 
complex so that transcription is initiated without a primer.
3.4.3. vRNA Synthesis.
Naturally enough the synthesis of vRNAs follows poly 
A(-)cRNA production, although the precise timing of events is 
uncertain. The actual mechanisms by which vRNAs are replicated is 
not understood but synthesis is dependent on viral protein (Hay 
et al., 1977; Barrett et al., 1979; Mark et al., 1979). The
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location of the site of synthesis of vRNA has also not been 
delineated. Segments can be detected both in the cytoplasm and 
the nucleus. vRNA segments are produced in non-equivalent 
amounts.
There is a correspondance between vRNA and mRNA synthesis 
suggests that the two events may be closely coupled (Smith and 
Hay, 1982). The time at which cRNA is synthesized suggests that 
the the template for synthesis of mRNA in secondary transcription 
is newly synthesized vRNA and that cRNA is synthesized only from 
input genome RNA (Wolstenholme et al., 1980).
The characteristics of influenza virus replication can 
differ depending on the host cell (Smith and Hay, 1982). There 
are also differences between virus strains (Lamb and Choppin, 
1977; Hay et al., 1977). Sub-genomic RNAs which interfere with 
subsequent virus multiplication are sometimes synthesized during 
replication. These are defective-interfering (DI) RNAs (Nayak and 
Chambers, 1985). The generation of DI RNAs is favoured by high 
multiplicity and the host cell (Choppin and Pons, 1970; Janda et 
al., 1979) which may reflect a function provided by the host cell 
for replication.
3.5. Translation and processing of viral proteins.
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Approximately 2 hours post infection NSi NP and P proteins 
are detectable in infected cells and the Ml , HA and NA proteins 
appear a little later (Skehel, 1972). Viral mRNAs bind to 
ribosomes in the cell cytoplasm and are translated into proteins 
in essentially the same fashion as eukaryotic mRNA, utilizing 
cellular tRNAs and initiation factors. The reliance of virus on 
normal cell processes continues in the modification and 
transportation of the spike proteins. The processing of HA 
glycoprotein (section 2.2), for example, exploits existing 
cellular pathways such as those normally used for the synthesis 
of secretory and membrane glycoproteins.
The biosynthetic pathway of NA is less well characterized, 
but glycosylated NA has been found associated with the 
endoplasmic reticulum and intracellular migration and further 
glycosylation has been observed. NA is inserted via an N-terminal 
hydrophobic domain anchoring the protein in the lipid. The anchor 
peptide also acts a signal peptide during membrane translocation 
but is not removed by a signal peptidase (Fields et al., 1981).
3.6. Virus assembly and budding.
The newly synthesized virus coded polypeptides are 
transported to, and are assembled into, virions at the plasma 
membrane. The assembly of virus coded polypeptides at the plasma 
membrane is a specific and highly organized process as viral
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products are found in discrete patches (Compans and Dimmock, 
1969; Klenk et al., 1970) and no cellular proteins are detected 
in the mature virus (Holland and Kieln, 1970). Glycoproteins have 
to be inserted into the plasma membrane before virus assembly can 
begin (Lenard and Compans, 1974). The NP, P proteins and M 
proteins become attached to the cytoplasmic face of the plasma 
membrane only where there is a patch of spike proteins on the 
opposite side of the membrane. The mechanism of incorporation of 
the eight RNAs has not been determined there may be specific 
sites of interaction between the proteins and RNA which result in 
the enveloping of eight different RNA gene segments. The virions 
then bud (exocytosis) from the cell surface. It would appear that 
the enzymatic activity of neuraminidase ensures release of 
virions since antibody to NA aggregates virus at the cell surface 
(Dowdle et al., 1974; Webster et al., 1982). However, anti-HA 
antibodies are equally effective at preventing virus release 
(Dowdle et al., 1974)
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4. Influenza infection and pathogenesis.
Pathogenicity, i.e. the property of a virus to induce
clinical disease, is the result of complex interactions between 
the infecting virus and the host organism. A number of factors 
usually intervene before clinical signs become manifest. Thus, 
virus-host interactions vary widely as do their pathological 
consequences. Some viruses always cause acute self-limiting 
disease, or subclinical infection. Others produce chronic 
infections, in which the virus persists for months or years 
before clinical manifestions. Epidemic influenza in man produces 
attack-rates which vary with age and type of community concerned. 
There is a great deal of variation in both the severity of
illness in different persons and in the proportion of those with 
complications (Pereira, 1979). Influenza A viruses are not stable 
agents like many other viruses but undergo continual antigenic 
variation. This explains why persons of all age-groups can be
involved in an epidemic because immunity which might be solid
enough against a given influenza strain becomes inadequate if the 
haemagglutinin is altered. Attack-rates are therefore higher 
after a new subtype has appeared or a major degree of antigenic 
drift has occurred.
4.1. Influenza, the disease and the inflammatory 
response to influenza infection.
To initiate infection of the human respiratory tract,
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influenza has to combat non-immune defence mechanisms (Review: 
Sweet and Smith, 1980). Inhaled virus particles attach to 
epithelial cells via the HA spikes which bind to receptors on the 
cell containing N-acetylneuraminic acid. The mechanisms by which 
influenza initiates infection in cell culture are discussed in 
section 3, however a comprehensive description of the comparable 
events in the body has not been made. The ciliary beat, flow of 
secretions and the mechanical actions of breathing would help in 
preventing the initial contact between virus and respiratory 
tract cells. Once infection has been established in the absence 
of an immune response (section 5) these systems are counteracted 
to facilitate further infectious spread of virus. Uncomplicated 
influenza in previously healthy adults is confined to the 
epithelial and sub epithelial layers of the mucosa of the 
respiratory tract (Walsh et al., 1961) with occasional secondary 
involvement of the lungs and rarely viraemia (Sweet and Smith,
1980). Influenza can destroy the ciliary activity of the trachea 
and the necrosis of superficial epithelial cells restricts the 
self-cleansing of lungs, as the upward movement of the mucous 
blanket is inhibited (Walsh et al., 1961; Ebisawa et al., 1969). 
This decreases the clearance of virus. Secretions over the mucosa 
increase as an inflammatory response to destruction of cells and 
the beat of those cilia that remain is less effective (Ebisawa et 
al., 1969; Sweet and Smith, 1980). Inflammation is typified by 
the migration of polymorphonuclear leucocytes (PMN), monocytes 
and mast cells to the site of infection along a chemotactic 
gradient. Serum components such as the kinin system and
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vasoactive amines produced by mast cells contribute to 
inflammation (Burrows, 1972; Mims, 1972; Sweet et al., 1977). 
Lysosomal enzymes from the lysosomes of PMNs cause erythema and 
irritation. Lung and peritoneal macrophages obtained from 
unprimed mice are able to inactivate influenza viruses (Rogers 
and Mims, 1981) but the contribution of macrophages in this 
manner may be minimal because of lack of direct access to 
infection sites. PMNs have a half-life of 6-7 hours (Stossel, 
1974) and their degeneration causes the gross secretion in the 
respiratory tract to become purulent (Elsbach, 1973). In response 
to the arrival of virus and viral products, the lymphoid tissues 
induce further inflammation and early immune responses (section 
5). Influenza in man can also affect the chemotatic and 
phagotatic activity of macrophages and PMNs (Kleinerman et al., 
1975; Larson and Blades, 1976). This, compounded with the 
necrosis and exposure of underlying tissue encourages bacterial 
invasion and disease.
The dry coughing and sneezing of the earlier phases of 
illness will also carry the infection to other areas (Review: 
Stuart-Harris 1965). This stage is followed by a stuffy, blocked 
nose and later by the expectoration of mucoid or mucopurulent 
sputum from degenerating PMNs. The fever that occurs in influenza 
infection in man is accompanied by headache, weakness myalgia in 
limbs and back and can last from 24 hours to 5 days in more 
severe infections. Body temperature during fever may range from 
38-40°C. (Stuart-Harris et al., 1985; Fenner et al., 1974).
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Nasal secretions contain non-specific inhibitors of the HA 
and infectious activity of influenza which by nature are mucoid 
(Review: Shvartsman Ya and Zykov, 1976). The activity of these 
inhibitors is destroyed by the addition of Vibrio choler ae or 
influenza neuraminidase. The thermolability can differentiate 
between virus infectivity inhibitors which lose activity at 56°C 
after 60 minutes and anti-haemagglutinin inhibitors which are 
stable at 70 °C. These inhibitors neutralize a wide range of 
influenza virus A strains, influenza B and Newcastle disease 
(Shvartsman Ya and Zykov, 1976) and are probably critical factors 
of non specific immunity to influenza.
The experimentally induced influenza virus infections in 
ferrets is closely analogous to the pathological effects in man 
(Sweet et al., 1979). Fever in the ferret is associated with the 
release of a pyrogen from leucocytes. Therefore before overt 
effects in the lung influenza virus must overflow systemically. 
But it has been difficult to demonstrate viraemia. In humans it 
is thought that the virulence of influenza is relatively fixed 
with the severity of the disease being linked to the condition of 
the human host (Kilbourne, 1960), however experimental influenza 
in ferrets varies greatly during adaptation from human specimens 
(Toms et al., 1977; Matsuyama et al. , 1980).
Influenza in man can be complicated by pneumonia caused by
Staphylococcus pneumoniae and S. pyrogenes (Giles and
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Shuttleworth, 1957; Robertson et al., 1958). There is 
aetiological evidence for links between encephalitis lethargica 
and post-encephalitis Parkinson disease (Flewett and Holt, 1958; 
Ravenholt and Foege, 1982) Associations have been observed 
between cardiac complications (Hers et al., 1958; Louria et al., 
1959) .
The epidemiology of influenza in the past has provided 
important insights into the disease and epidemiological 
surveillance remains a crucial factor in the control and 
understanding of human influenza (Reviews: Stuart-Harris, 1979; 
Pereira, 1979). The majority of influenza infections have low 
morbidity in working adults and convalescence in these cases is 
usually rapid once fever has disappeared. Influenza can have high 
rates of infection amongst children under 5 (Hall et al., 1973) 
and in the elderly where high mortality rates may occur, 
particularly in geriatric residential homes (Stuart-Harris, 1979). 
High rates of infection can also occur amongst people in any 
large residential institution such as in schools and in army 
camps. This is perhaps due to increased transmission rates 
(Stuart-Harris, 1979) or an environmental factor that effects the 
group (Shope, 1944). Reemergence or recycling of a strain can 
have an influence on age specificity. For example, during the 
1957 outbreak of A/Asian virus/57 (H2N2) the highest rate of 
attack occurred in children. The lowest rate was in adults over 
70 years of age. This was because these adults had been exposed 
in childhood to infection by an influenza virus bearing the H2
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haemagglutinin (Mulder and Masurel, 1958).
Influenza A viruses have also been shown to produce 
epidemics of respiratory disease in swine, horses, and seals. 
There are clinical similarities between swine, horse and human 
influenza. In avian species different strains of influenza 
produce strikingly different patterns of disease; ranging from a 
completely asymptomatic infection to a fatal epidemic disease as 
in the case of fowl plague where there is viraemia, CNS 
involvement and general dissemination (Stubbs, 1965). Influenza 
infection can be induced in laboratory mice by the intranasal 
inoculation of influenza. This initiates a pneumonic infection in 
the lungs and is characterized by a gross pathological effect. 
Influenza does not infect mice in the wild, and inbred strains of 
mice differ in their susceptibility to infection. For example, 
mice bearing the gene Mx survive challenge with strains of 
influenza that are usually lethal for non-Mx bearing mice (Haller 
et al., 1979). This resistance :n v 1 1 ■<> correlates well with an 
interferon-dependent resistance of infected cells. Although 
studies of influenza infection and immunity in mice (section 5) 
have provided information not available from humans the 
difference in pathology should always be considered.
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4.2. Molecular determinants of virulence and pathogenicity.
There is a correlation between the structure of the HA and 
pathogenicity of influenza (Rott, 1980). The ability of influenza 
to replicate in tissue culture or in the host is dependent on 
host enzyme cleavage of the HA (Bosch et al., 1981) and efficient 
cleavage of precursor HA polypeptide into HA1 and HA2 in a wide 
range of cells appears to be essential for the virulence of virus 
(Klenk et al., 1975; Lazarowitz and Choppin, 1975).
The amino acid sequence of the connecting peptide between 
HA1 and HA2 may determine the range of cells in which cleavage 
can occur. Highly pathogenic avian influenza viruses that cause 
generalized infections and sudden death in birds exist among 
viruses of H7 and H5 subtypes, while other avian viruses of other 
subtypes are relatively non-pathogenic despite being infectious. 
FPV/R (H7N1) causes a lethal infection in chickens and has the 
sequence Lys-Lys-Arg-Gln-Lys-Arg between the C terminus of HA1 
and the N terminus of HA2 (Porter et al., 1979; Bosch et al.,
1981) while non pathogenic avian influenza viruses of the same 
subtype (H7) contain only a arginine-glycine residue. 
Investigation of groups of pathogenic viruses, human viruses 
(which are avirulent in birds) and non pathogenic avian influenza 
viruses of the H7 subtype suggested that the HA molecules from 
human and non pathogenic avian viruses had fewer insertions in 
the connecting HA peptides than those of the pathogenic strains.
The long connecting peptide being susceptible to proteolytic 
removal in cells of a wide variety of tissues.
However the structure of the HA is almost certainly not the 
only factor determining pathogenicity. From studies on influenza 
reassortants obtained in vivo it was found that a large number of 
reassortants obtained from a highly pathogenic influenza for 
chickens and an non pathogenic virus showed that exchange of RNA 
segments modified pathogenicity. Increase or loss of 
pathogenicity seemed to depend not only on the HA but also on the 
influenza genes involved in viral synthesis, i.e. the
nucleoprotein and PA genes. Recombinants obtained from non 
pathogenic viruses can assume pathogenic properties (Rott et al., 
1979; Vallbracht et al., 1978; Scholtissek et al., 1979) or in 
contrast reassortment of genes between highly pathogenic strains 
can lead to non pathogenic reassortants as well as pathogenic 
viruses (Rott et al., 1976). These data indicate that an 
optimimal constellation of RNA segments is required for the 
genome of a highly pathogenic virus strain. Oxford et al. (1978), 
found that virulence of reassortants of a H3N2 virus in human 
volunteers covaried with genes for both HA and NA.
4.3. Interspecies transmission.
Recombination events demonstrated in vitro may represent 
evidence for the derivation of new strains of human virus from 
recombination events in nature between animal or avian viruses.
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This was proposed by Laver and Webster (1973;1979). For example, 
human epidemics frequently originate in S.E. Asia where densely 
populated rural communities live in close proximity to ducks and 
pigs. This ecosystem allows the possibility of genetic 
recombination to occur between influenza viruses of different 
species. In support of this concept, the Hong Kong (H3N2) virus 
contains the NA ( and other) genes that are almost identical to 
those from an asian (H2N2) strain of human influenza and a HA 
which is antigenically related to that of A/Duck/Ukraine/63 
(H3N8) and A/equine/2/Miami/63 (H3N8) viruses. The amino acid 
sequence homology between the HAs of A/Duck/Ukraine/63 and 
A/Aichi/2/68 viruses (both H3) is 96%. The HA could have been 
donated during a recombination event in an animal or avian 
species and then transmitted to a human initiating the epidemic. 
Interspecies transmission has been implicated in the infection of 
humans of H1N1 influenza viruses derived from pigs at Fort Dix, 
New Jersey (Topp and Russell, 1977) and in Wisconsin (Hinshaw et 
al., 1978).
The A/Seal/Massachusetts/1/80 (H7N7) virus recovered from 
the lungs and brains of harbour seals off the north-eastern coast 
of the U.S.A. possessed close genetic homology to A/FPV/Dutch/27 
(H7N7), a highly lethal influenza of domestic fowl not previously 
found in mammals (Webster et al., 1981a). Direct tropism for the 
brain has not been detected before in influenza in mammals. These 
events may represent evidence for the natural transmission of an 
avian influenza to a mammalian species although this remains to
be confirmed. The seal influenza virus has been associated with 
some cases of human conjunctivitis (Webster et al., 1981b) and an 
influenza that had originally been found in striped whales in the 
Pacific (H1N3) has been implicated in illness in humans (Lvov et 
al., 1983). These observations should deal with any complacency
regarding influenza and that new influenza virus strains in 
humans could manifest a completely different pathology than that 
seen in the present circulating subtypes.
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5. The immune response to influenza infection.
5.1. The molecular basis of influenza antigenicity.
The remarkable antigenic variability of influenza A viruses 
ensure the epidemic potential of influenza allowing new strains 
to circumvent the serum antibody to existing and previous virus 
strains. Variation within a subtype may be brought about by 
several mechanisms: Point mutations in genes coding for HA or NA 
and other proteins and reassortment of genes coding for other 
proteins. Variation leading to different subtypes may be due to 
reassortment of HA or NA genes or the reemergence of previously 
circulating strains. Monoclonal antibodies, because of their high 
level of discrimination have been used to show minor
(insignificant) antigenic changes. resulting from point
mutations, in matrix (Ml) proteins (Van Wyke et al., 1980; Le 
Comte and Oxford, 1981), and in NS1 protein (Shaw et al., 1982).
Schild et al. (1979) using polyclonal sera demonstrated minor
antigenic differences between NP proteins. However, overall, it 
is clear that the NP proteins are serologically closely related 
and the relatively small antigenic differences may have no 
immunological or epidemiological significance.
It is the considerable antigenic variability of HA and NA 
that is the most relevant. The most significant proportion of 
protection against reinfection with influenza is due to 
neutralizing antibody against the HA (Hobson et al., 1972; 
Virelizier, 1975; Ennis, 1982). Virelizier (1975) demonstrated 
that specific antibody to HA transferred to naive mice in
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physiological concentrations can passively protect both normal 
and immunodepressed recipient mice. The protective effect of 
anti-NA antibody is less than that of anti-HA antibody (Schulman, 
1970; Potter and Oxford, 1979) although passively adminstered 
anti-NA does protect mice (Schulman et al., 1968). Antibody to HA 
acts by neutralization of virus particles whereas antibody to NA 
inhibits virus release from infected cells (Dowdle et al. , 1974).
Animal experiments have established that antibody to Ml or 
NP have no protective effect against challenge with influenza A 
viruses (Oxford and Schild, 1976).
5.2. Variation in the haemagglutinin.
The variation in the HA molecule of influenza occurs in two 
ways. Small changes in antigenicity (antigenic drift) are the 
result of a gradual accumulation of point mutations or short 
deletions/insertions in the HA gene, while complete change in 
antigenic properties (antigenic shift) involves the replacement 
of the gene coding for one HA with that of another.
5.2.1. Antigenic drift.
During the prevalence of an influenza virus A subtype minor 
changes take place in the HA (Review: Webster et al., 1982). The 
mechanism of antigenic drift involves the selection by 
immunological pressure of mutant viruses with altered antigenic
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determinants (Laver and Webster, 1968). The structural changes 
leading from the accumulation of amino acid sequence changes 
allows new virus strains to be infective by evading
neutralisation by antibody present in the population. Sequence 
analysis of the HAs from naturally occurring variants of the H3N2 
subtype from 1968-1979 show that most of the amino acid sequence 
changes have occurred in the HA1 region of the molecule (Webster 
et al., 1982).
The selection of escape mutants by culture of virus with 
monoclonal antibodies in eggs have also shown that substitutions 
occur in the HA (Gerhard and Webster, 1978; Laver et al, 1979; 
Wilson et al., 1981). Further, these studies have shown when the 
three dimensional structure is examined (Wiley et al., 1981) that
the changes are clustered on the H3 HA into four non-overlapping 
antigenic regions A-D (Wilson et al., 1981 and section 2.2). The
sequencing of the HA showed that only a single amino acid 
substitution was sufficient to prevent the monoclonal antibody in 
question from binding to the mutant (Laver et al., 1979). Other
monoclonal antibodies recognizing topologically distinct 
antigenic sites could still bind and neutralize the mutants as 
could polyclonal antibody against the strain.
5.2.2. Antigenic shift.
The term shift is applied to the emergence of a new 
influenza A virus possessing glycoproteins so different from
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"those of the prelavent viruses that they are designated as new 
subtypes. The peptide sequences of HAs of different subtypes show 
major differences that could not have arisen from mutation of the 
HA gene of the proceeding virus. There is circumstantial evidence 
that the recombination events observed in vitro may occur in 
nature (section 4.3) and viruses from non-human hosts have been 
found to contain HAs related to HI, H2 and H3 human subtypes 
(Laver and Webster, 1973; 1979). Recycling of the antigenic
subtypes may also occur. This could explain the recurrence of the 
H1N1 virus in 1977, twenty seven years after the last recorded 
appearence of a genetically identical H1N1 virus (Nakajima et 
al., 1978; Scholtissek et al., 1979). It is difficult to explain
where this virus was or why it remained unchanged for so long.
There is an additional selective mechanism on the HA for 
generation of variants of influenza A viruses dependent on the 
host cell used for growth (Schild et al., 1984). The cultivation
of influenza virus in eggs selects sub-populations of virus with 
HA antigenically distinct from that of virus grown from the same 
(human) source but in MDCK cells. Host cell selection pressure 
provides an additional (non-immune) mechansim for antigenic 
selection and could have epidemiological significance.
5.3. Variation in the neuraminidase.
Neuraminidase also undergoes antigenic shift and drift. In 
1957 human influenza A viruses bearing N1 neuraminidase were
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replaced by N2 in a shift, event likely caused by reassortment and 
antigenic drift has been documented in the N2 NA since 1957 
(Martinez et al., 1983). Animal viruses containing the N1 and N2 
subtypes have been identified (Webster and Pereira, 1968; Schild 
and Newman, 1969). An operational map from the selection of 
variants with monoclonal antibodies has been constructed which 
defines at least four non-overlapping antigenic sites (Jackson 
and Webster, 1982).
5.4. Immune response in recovery from influenza virus infection
A variety of interacting immune mechanisms may contribute to 
the recovery from influenza infection. Antibody, cell mediated 
immunity (T cells, macrophages, natural killer cells) and 
interferon all co-operate together to bring about recovery. The 
dependence on co-operative interplay between different cell types 
(often via soluble mediators) means that the assignment ofa 
determinative role of a given cell may be impossible.
Nevertheless, in vivo and in vitro experiments have provided a 
detailed analyses of the repertoire and potential of immune 
mechanisms.
McMichael et al. (1977) first demonstrated KLA restriction 
of cell mediated lysis of influenza virus infected human cells by 
T cells. Cytotoxic T cells (Tc) mediate this lysis via a lytic 
signal to infected cells and the phenomenon is demonstrated in 
cultured cells in a 51 Chromium release assay for cytolysis. 
Target cells and Tc must be histocompatible. Tc recognize virally 
coded antigenic determinants on the surface of infected cells, in 
association with major histocompatibility antigens (Doherty and 
Zinkernagel, 1975). In mice the histocompatibility antigen is 
coded by the K, D or L gene of the mouse H2 gene and by the 
HLA-A, B or C in man (Review: Zinkernagel and Doherty, 1979).
There is now evidence that illustrates the important role of 
Tc in the recovery from influenza infection (McMichael et al., 
1983a) where Tc activity correlated with reduced viral shedding 
in volunteers who lacked antibody to the HA or NA. Ennis et al.
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(1981a; 1982) described the dynamics of Tc response in volunteers 
infected with influenza or vaccinated with inactivated whole 
virus or subunit vaccine. T cell cytotoxicity was very low 7 days 
post inoculation but was fully expressed between 14 and 21 days. 
By this time most volunteers had also produced good neutralizing 
antibody responses. Six months post infection or vaccination 
memory Tc activity had returned to preimmune levels. Yap et al. 
(1978) showed that the transfer of murine immune Tc to synergic 
recipients leads to a reduction of viral titres in their lungs. 
This observation has been reproduced with a cloned murine Tc 
line (Lin and Askonas, 1981).
Studies in mice have shown that T cell cytotoxicity develops 
early after the onset of influenza virus infection and reaches a 
peak level of cytotoxicity before antibody is detected (Doherty 
et al. 1977). Levels then return to baseline and are not detected 
in the resting state.
Newly synthesized virus coded proteins are present in the 
plasma membrane of infected cells, therefore Tc lysis of virus 
infected cells can occur before any progeny are released 
(Zinkernagel and Althage, 1977). The clearance of infectious foci 
from tissue sites of pathology requires the collaboration of 
monocytes or activated macrophages (Blanden, 1974). In the mouse 
model depletion of macrophages delays viral clearance.
It was found that the majority of Tc appear to be unable to
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distinguish between influenza A virus subtypes (Zeefwink et al., 
1977, McMichael and Askonas, 1978) and investigation of cloned To 
lines have confirmed that the majority are fully cross reactive 
(Braciale et al., 1981; Fleischer, 1982). No cross-reaction has 
been demonstrated between A and B influenza types. Using target 
cells infected with variant and recombinant influenza viruses it 
has been shown that Tc may be strain specific for HA and that 
some Tc clones map to polymerase and NP genes (Bennick et al.,
1982). NP is present on the membrane of infected cells along with 
the glycoproteins and the NP antigen, because it is antigenically 
common to all influenza A viruses (section 2.3), would represent 
an ideal protein for cross-reactive Tc to recognise. L cells 
transfected with cloned DNA for HA were recognized by a minor 
subpopulation of Tc and not by the cross reactive Tc (Townsend 
and Skehel, 1982). This illustrated that HA is not the antigen 
recognized by the majority of cross-reactive Tc. NP antigen 
transfected into L cells made these cells targets for Tc proving 
that NP alone can act as the target antigen (Townsend et al., 
1985). Further functional diversity of Tc was indicated by Taylor 
and Askonas (1983) who found that some Tc with strong cytotoxic 
activity in v i v o did not provide protection in vitro. 
Cross-reactive Tc would provide heterotypic immunity in contrast 
to neutralizing antibody which is strain specific for the HA.
Mitchell et al. (1985) report that HA specific Tc were not 
blocked by a panel of monoclonal antibodies directed to the HA 
showing that Tc and antibody recognize different epitopes. This
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is probably a function of in vivo competition between high 
affinity antibody and T cell clones leading to the selection of 
Tc that recognize alternative epitopes.
The key event in virus elimination by Tc may not be 
cytotoxicity itself but the secretion of gamma interferon. It was 
found (Morris et al, 1982) that the ability to decrease the virus
titres in the lungs of mice by adoptive transfer of cloned Tc 
correlated with the production of gamma interferon. On transfer 
into infected mice a Tc clone inhibited the replication of 
homologous or heterologous influenza virus. The same Tc clone 
released gamma interferon only when in contact with its matched 
target cell. This may be the event in virus elimination not 
cytotoxicity. Those Tc clones that produced little or no gamma 
interferon after appropriate antigenic stimulation did not clear 
virus from the lungs. It should also be considered that the 
functions of cytotoxicity and interferon release operate together 
during influenza virus infection. Tc could therefore aid host 
defence by directly killing cells that express viral antigen on 
their surfaces and by producing gamma interferon. Gamma
interferon has a direct effect as an inhibitor of viral 
replication and also increases target cell expression of MHC 
antigen making these cells more sensitive to Tc (Review: 
Rager-Zisman and Bloom, 1985). It also activates natural killer 
(NK) cells which mediate non-specific lysis of infected cells. 
Alpha interferon is also produced early in infection with 
influenza (Ennis and Meager 1981) and could contribute by making
epithelial cells resistant to virus infection and, with gamma 
interferon, increasing the removal activity of NK cells.
The generation of a potent Tc population requires the 
collaboration of the helper T cell (Th) subset (Zinkernagel and 
Doherty, 1979). Th recognize viral antigen presented in 
conjunction with the I-A (or I-E) gene product on macrophages. 
The regions that Th cells recognize on the HA have been mapped 
(Figure 2.1.2). Helper T cells play a crucial part in the 
generation of both antibody and Tc immune responses and are 
essential for recovery from viral infection (Mims and White, 
1984). IL-1 secreted by monocytes/macrophages activates Th to 
secrete several lymphokines known as ThF. Antigen specific ThF 
trigger appropriate clones of E cells to differentiate into into 
antibody secreting cells. There are subtype specific and cross 
reactive influenza Th clones (Lamb and Green, 1983).
T cells can have another effector function - induction of 
delayed type hypersensitivity (DTH) by a subset known as Td 
cells. DTH is a T cell mediated inflammatory reaction 
characterized by infiltration and proliferation of mononuclear 
cells and influenza DTH has been demonstrated in mice (Leung et 
al., 1980) and man (Habershon et al., 1973). The DTH reaction is 
eventually shut off by suppressor T cells. Inactivated influenza 
gives a greater DTH response than does live virus (Ada et al., 
1981) illustrating that DTH is probably of importance in 
attracting macrophages and T cells in the early phase of the
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immune response to viruses but needs to be suppressed after this 
task is completed. Suppressor T cells specific for influenza 
virus subtypes have been described and may be involved in 
regulation of influenza immunity (Liew and Russell, 1980).
NK (natural killer) cells are leucocytes that have the 
capacity to kill virus infected cells and to a lesser extent some 
normal cells by spontaneous cytotoxicity. Rager-Zisman and Bloom 
(1985) characterize the recognition of NK cells as selective for 
certain (as yet unknown) target structures. NK cells are 
partially regulated by interferon and all three classes of 
interferon can augment NK activity (Rager-Zisman and Bloom, 
1985). Ennis et al. (1981b) showed that volunteers infected with 
influenza A develop increased NK activity within 1-2 days of 
infection and this was still elevated on day 6. The level of 
cytotoxicity of the NK cells correlated with the production of 
gamma interferon. Therefore there is suggestive evidence that NK 
cells are important in the defence of influenza virus infection 
before Tc and antibody emerge, but their role is still uncertain. 
Nude mice have high levels of NK activity which is futher 
elevated by influenza but virus is not cleared unless there is 
adoptive transfer of H2 restricted T cells (Ennis, 1982).
Influenza virus infection is generally restricted to 
epithelial tissues (Stuart-Harris et al., 1985) and incubation is 
usually no more than a few days. The dynamics and evolution of an 
effective antibody response in man appears to lag behind the
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course of an acute influenza infection, and and indeed the
infection may have already finished (Rossen et al., 1970). Three
days after the infection of mice with influenza there is a great
increase in the number of IgA and IgM producing plasma cells in
the subepithelial tissues (Owens et al., 1981). This is followed
a few days later by an increase in IgG plasma cells. During
primary infection antibodies are not detected in secretions or in 
the serum until 8 days by which time the replication of influenza 
has been brought under control. These observations do not 
preclude the possibilty that antibody is synthesized several days 
earlier but is in too low a concentration to be detected, or in 
this early phase of infection antibody could be complexed to 
viral HA and is only detected when in excess of antigen.
The most relevant site for antibody to participate in 
recovery from influenza, considering the route and site of 
infection, is perhaps at the mucosal surface of the upper 
respiratory tract (Review: Rossen et al., 1971). Neutralizing
secretory IgA (slgA) in the nasal washings of humans with 
influenza infections rose in titre up to a 10 day peak 
concomitant with a rise in serum IgG titre (Alford et al., 1967;
Rossen et al., 1970). The slgA titre returned to baseline levels
after 25 days whilst the serum IgG titre remained at a high titre 
even after 28 days (Alford et al., 1967). Virus was not isolated 
in the nasal washings after the fourth day. These findings were 
essentially confirmed by Murphy et al. (1973) who observed a
pattern of neutralizing slgA production after firstsimilar
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detection 4-7 days after infection. Although slgA is the 
predominant immunoglobulin in mucosal secretions significant 
amounts of other isotypes are found (Review: Dhar and Ogra, 1985) 
and evidence suggests that protection against mucosal infection 
in patients with IgA immunodeficiency may be effectively provided 
by the compensatory local production of virus specific IgM and 
IgG in the respiratory tract (Ogra et al., 1974).
Specific anti-influenza activity is observed in all 
immunoglobulins in the nasal secretions (Murphy et al., 1973). 
This is perhaps best illustrated by the observations of Murphy et 
al.(1982) who using a live attenuated vaccine strain studied the 
dynamics of antibody response in humans (as detected by 
enzyme-linked immunosorbent assay). In nasal secretions IgM and 
slgA specific for influenza HA appeared simultaneously after 2 
weeks, IgG detection occurred a week later. IgM peaked at 2 
weeks, IgG at 4-6 weeks and the slgA titre continued to climb 
into the 9th week. A slgA response was seen in all individuals in 
the study, but the frequency of IgG and IgM was reduced. By two 
weeks post-infection IgA, IgG and IgM were all present in the 
serum. The activity of IgM and IgA in the serum was transient, 
peaking at two weeks then declining. IgG antibody in the serum 
increased in titre to reach a peak after 4-7 weeks.
The parallel rise of antibody in the serum and in the nasal 
washings of man (Murphy et al., 1982) and in the lungs of mice 
(Liew et al., 1984) suggest that serum antibody has a
contribution as significant as that of secretory antibody in the 
recovery from influenza virus infection. The dynamics of 
production of specific antibody indicate that antibody may aid in 
recovery only if the infection lingers on. However the barely 
detectable levels of antibody seen early in infection may be 
significant in immune mechanisms involving complement and 
antibody dependent cell-mediated cytotoxicity (ADCC).
The classical complement pathway (Review: Cooper, 1979) can 
be activated after the combination of antibody and antigen, and 
the first antibodies produced in infection could depend on 
complement for neutralization. This could result in damage or 
lysis to the envelope of influenza, deposition of complement 
proteins leading to prevention of attachment or activation of 
complement following the attachment of antibody to viral antigens 
on infected cells may result in the lysis of that cell. In 
addition it should be noted that complement can carry out 
inactivation of viruses without the participation of antibody via 
the alternative pathway (Review: Sissons and Oldstone, 1980). 
This is an important phenomenon because it can occur before 
immune responses have been generated. The alternative complement 
pathway can be directly activated by the classical complement 
pathway in an activation loop. Initiation of the classical 
complement pathway occurs when the Fc regions of bound IgM and 
some classes of IgG (in humans IgGi and IgG3) are recognized by 
Clq. There must be at least two Fc sites (i.e. there must be more 
than two IgG molecules close together). With IgM several Fc sites
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are present on a single molecule, and therefore IgM can activate 
complement much more efficiently. Secretory IgA does not activate 
complement (Tomasi, 1976).
Antibody dependent cell-mediated cytotoxicity (ADCC) is a 
very efficient process that takes place in the presence of 
antibody by certain types of immune cell. These effector cells 
are not immune specific, they bind to target cells to which 
immunoglobulin is attached and such cells are destroyed. This can 
be mediated by cells such as PMNs, K lymphocytes (non-T, non-B) 
and macrophages bearing Fc receptors (FcR) for the Fc regions on 
immunoglobulins. As well as IgG, slgA is a potent mediator of 
ADCC (Tagliabue et al., 1983). Greenberg et al. (1977) 
demonstrated that ADCC has a role in influenza virus infection. 
Haemagglutinin specificity was maintained and potent ADCC 
occurred when antibody concentration was too low to be assayed by 
neutralization assay. Indeed, ADCC was found by Shore et al. 
(1976) to be hundreds of times more efficient per antibody 
molecule than complement-mediated cytolysis. Therefore ADCC may 
be an important factor in vivo particularly in early infection 
phase.
In summary the immune response leading to recovery from 
infection with a new influenza strain is a complicated process 
involving a variety of humoral and cell-mediated mechanisms. 
There is an apparent need for immunologically specific T cells 
for recovery from influenza, but early control may be effected by
72
interferon and NK lymphocytes. Conclusions regarding the precise 
importance of each mechanism cannot really be made in isolation 
as all normally co-operate together, meaning that to some extent 
any attempt to assess relative importance is an artificial 
exercise. The early response may be crucial in aiding the host to 
limit and control virus infection until immunologically specific 
Tc are generated to destroy the virus infected cells. T cells 
which aid in the production of antibody are aetected later in 
infection and neutralization by antibody appears to be more 
important in resistance (protection) to later challenge.
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5.5. Immune response in resistance to 
influenza virus infection.
The continual antigenic turnover of influenza A viruses 
(sections 5.1. to 5.2.2) accords short-lived resistance to 
further re-infection. The first (and perhaps major) line of 
defence of acquired immunity to re-infection with the same strain 
of influenza would appear to be antibody generated from
anamnestic response from specific B lymphocytes (Reviews: Potter 
and Oxford, 1979; Couch and Kasel, 1983). However, it is apparent 
that cell-mediated reactions do occur in man and animal models 
and contribute to resistance (McMichael et al., 1982). Mechanisms
by which antibody can mediate host resistance to virus infection 
are neutralization, opsonization for phagocytes,
antibody-complement mediated effects and ADCC. The utilization of 
these mechanisms on the re-challenge of virus of the same strain 
would mean the end of the infection. The premise that
neutralizing antibody offers prophylactic immunity assumes that 
if its surveillance is breached the mechanisms that contribute to 
recovery (section 5.4.) are brought into play.
Many studies have shown that a significant proportion of the 
protection mediated by the immune system against re-infection is 
due to the presence of neutralising antibody against the HA 
(Laver and Kilbourne, 1966; Hobson et al., 1972; Virelizier, 
1975; Reviews: Potter and Oxford, 1979; Ennis et al., 1982).
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Antibody to NA has a less clear cut protective response in man 
(Potter and Oxford, 1979) and it seems most likely that anti-NA 
reduces the quantity of newly synthesized virus released from 
infected cells. This limits the spread of infection. There is no 
apparent correlation between neuraminidase inhibition by anti-NA 
antibody and resistance to infection (Hobson et al., 1972).
Antibody to HA need only be considered in respect to the 
other viral proteins as it satisfies the four "mediator 
constraints" of Couch and Kasel (1983). The overall polyclonal 
antibody response to influenza to be protective must possess: 
strain specificity; cross-reactivity within a subtype but reduced 
cross-reactivity for variants that are distinct from the initial 
strain; long term durability of immunity and activity at the 
respiratory surface. Serum haemagglutination inhibition (HI) 
antibodies can neutralize in vitro (Hobson et al., 1972) and 
inhibit virus release from infected cells (Dowdle et al., 1974). 
However direct correlation of the ability of antibody to inhibit 
haemagglutination ability and neutralize infectivity is not 
always observed (Kida et al., 1982). The determination of the 
precise mechanism of action of neutralizing antibody at the 
molecular level has only recently been addressed (Possee et al., 
1982; section 9.2; section 12).
Within the view that antibody to the HA is mainly 
responsible for preventing infection is the undetermined relative 
importance of systemic or secretory immunoglobulins.
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Fazekas de St. Groth (1950) concluded that the resistance in 
mice to influenza depended on the presence of antibody in the 
respiratory tract rather than in the serum. Further 
investigations in man and animal models (Review: Couch et al., 
1969) seemed to firmly establish the primary role of secretory 
antibody in preventing influenza. The predominant immunoglobulin 
present in respiratory secretions in man is secretory IgA (Tomasi 
et al., 1965) and this form of IgA is only found in low 
concentrations in serum. IgA is synthesized in the local 
lymphoidal tissues as a dimer and appears as slgA on the external 
surface after acquiring secretory component (Sc) during transport 
across the mucosal epithelium (Lamm, 1976; Nagura et al., 1979). 
Secretory IgA is resistant to proteolytic enzymes and its 
multivalence (associated with high avidity) may be especially 
relevant in neutralization of viruses. The local anamnestic IgA 
response is promptly recalled (Wright et al., 1983). All these 
properties would seem to make slgA uniquely qualified to develop 
a local anamnestic response and Rossen et al., (1970) 
demonstrated that secretory IgA (slgA) was responsible for the 
neutralizing activity of nasal secretions for influenza virus. 
However, this and subsequent studies that have demonstrated the 
importance of slgA (Reviews: Rossen et al., 1971; Shvartsman Ya 
and Zykov, 1976; Couch and Kasel, 1983) have relied on 
artificially high intranasal doses of influenza for re-challenge 
in contrast to the low doses that lead to natural (re-)infaction. 
While there is no question about the antiviral effects of slgA
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its presence in the respiratory secretions cannot always be 
correlated with protective role of secretory antibody. IgM and 
IgG are also found in respiratory secretions and antiviral 
activity has been observed in all immunoglobulins present (Ogra 
et al., 1975). These immunoglobulins secreted in the respiratory 
tract could have diffused from the systemic system or been 
synthesised locally (Rossen et al., 1971).
Couch et al., (1979) showed that the level of serum antibody 
in human volunteers related best to protection as there was an 
inconsistent detection of nasal neutralizing antibody. It was 
also shown (Couch et al., 1981) in human volunteer challenge 
studies that there was a better correlation between specific IgG 
in the respiratory secretions than with the slgA. Potter and 
Oxford (1979) maintain that serum IgG is the most important 
determinant of resistance. Evidence is also available to suggest 
that protection against mucosal infection in asymptomatic 
patients with selective IgA deficiency may be effectively 
provided by the compensatory local production of IgM and IgG 
virus-specific antibodies (Ogra et al., 1974). However, in 
another human study with improved sensitivity for antibody 
detection, Murphy et al. (1982) demonstrated a solid (100%) 
correlation between protection and slgA. At the same time IgG and 
IgM HA antibody were detected inconsistently in the respiratory 
secretions. Using a mouse model Liew et al. (1984) demonstrated 
that slgA is the single most important factor contributing to 
protection against homotypic influenza infection, there was a
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lack of correlation between protection and serum antibody.
On the basis of the profile of influenza pathogenicity 
(section 4) it is logical to assume that systemic and secretory 
immunoglobulins participate synergistically in specific immunity 
to influenza infection. Clearly slgA contributes to immunity and 
may assume the primary role. However IgG in respiratory 
secretions, either produced locally or derived from the systemic 
circulation, is also an important mediator of resistance. A 
definitive study of the slgA response establishing its relative 
importance and characteristics in protection to naturally 
occurring infection has yet to be carried out.
The immune response to the first infection by influenza 
virus can have a dominating influence on subsequent immune 
responses to antigenically related strains. Infection with a 
novel influenza strain can induce an antibody response that is 
mainly directed against the the strain responsible for the first 
infection at the expense of a response to the latest infection. 
This domination of the immune response to the original virus 
strain is called the "original antigenic sin" (Davenport et al., 
1953). This has important implications in terms of immune status 
and susceptibility to influenza explaining the inefficiency of 
certain vaccines and paradoxical anti HA responses in man (Schild 
et al., 1977; Virelizier et al., 1979). Lamb et al. (1932) 
propose that the cross reactivity of the intermolecular help 
between Th cells and B cells could help to explain the
phenomenon. A strong Th signal might reactivate an antigenically 
"incorrect" B cell and plasma cell response whose secreted 
immunoglobulins cross-react only weakly with the newly presented 
HA.
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It is apparent that cell-mediated responses do occur in man 
and contribute to resistance (McMichael et al. , 1982). For 
influenza virus the protective effect of Tc cells against lethal 
doses in mice was demonstrated by adoptive transfer by Yap et al. 
(1978) and using a cloned murine Tc cell line by Lin and Askonas
(1981) . Infection generates Tc that do not discriminate between 
serologically distinct influenza viruses within a subtype 
(section 5.4). In humans natural influenza infection boosts T 
cell memory (McMichael et al., 1983b) but this is time-1imited. 
McMichael et al. (1983b) state that human Tc cell memory has a 
half-life of 2-3 years after natural infection, whereas Ennis
(1982) found that six months after vaccination with inactivated 
virus T cell memory was back to baseline levels. This could 
indicate that Tc offer a degree of (short-lived) heterotypic 
immunity. However, Armerding and Liehl (1981) achieved protection 
between heterotypic influenza strains in the presence of 
cyclosporin A which reduces immune responses without affecting 
antibody levels. It was suggested that this heterotypic immunity 
may be due to virus cross-reactive T helper cells inducing 
antibodies. In addition arguing against the role of Tc is the 
fact that some cloned Tc cell lines with strong cytotoxic 
activity were not found to provide protection in vivo (Taylor and
Askonas, 1983). Liew et al. (1984) have found that the transfer 
of a polyclonal Tc cell population with a combined strong 
cytotoxic activity did not reduce the titres of virus in the 
lungs of mice.
Further it was reported (McMichael et al., 1982) that mice 
treated with anti-IgM and produced no detectable HI antibody in 
any subclass recovered from infection and were immune to 
re-challenge, suggesting that T-cell response may have an 
important role. In contrast to immunoglobulin molecules that can 
be produced rapidly in enormous quantities following 
re-challenge, T cell numbers are restricted by the frequency of 
precursors and the doubling time of such cells (Burnet 1970; 
Doherty and Korngold, 1983). Studies in man and animal models 
show a clear correlation between antibody and resistance to 
infection. A decisive role for T cell immunity in protection on 
current evidence has not been clearly demonstrated, although in 
the recovery phase Tc cell activity could be crucial. Further 
investigations could include studies designed to detect the 
contribution of cellular immunity in the respiratory tract from 
local lymphoidal tissue (lymph nodes and lamina propria). Studies 
have demonstrated that cellular immunity in the respiratory tract 
can be produced independently of systemic immunity (Waldman and 
Henney, 1971). It has been reported that macrophage inhibitory 
factor (MIF) from sensitised lymphocytes is present in the 
bronchial washes of humans in response to influenza vaccine 
(Waldman et al. 1972). These locally sensitized lymphocytes
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remain in close proximity to the respiratory tract and do not 
migrate in significant numbers into the systemic circulation.
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VIRUS NEUTRALIZATION BY IMMUNOGLOBULINS
6.1. The nature of the neutralization reaction
The attachment of neutralizing antibody to virus particles 
results in a loss of infectivity. Neutralization is mediated by 
antibodies of the IgG, IgM and IgA classes (Ogra et al., 1975). 
Some of the properties of these immunoglobulins are summarized in 
Table 6.1. The IgD and IgE classes have not yet been implicated 
in neutralisation. The loss of infectivity of viruses due to 
neutralizing antibody alone in the absence of accessory factors 
(i.e. complement) can be due to several different mechanisms 
(Reviews: Mandel, 1979; Dimmock, 1984).
6.2. General properties of antibodies.
An Overview:
Immunoglobulins are multidomain glycoproteins that display a 
remarkably diverse range of binding specificities for discrete 
antigenic determinants or epitopes on the surface of molecules. 
The mammalian immune system is capable of expressing millions of 
different paratopes (antibody binding sites) from a relatively 
small number (a few hundred) genes. (Review: Kindt and Capra, 
1984). The genetic mechanisms responsible for the diversity of
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Table 6.1. Summary of the properties of immunoglobulins implicated as 
being involved in the immune response to virus in man *.
Property :
IgG
Immunoglobulin
IgM
class
IgA ( *> slgA
Approx.
Mol. wt. 150,000 900,000 160,000 385,000
Heavy ch. gamma mu alpha alpha
Structure 4 ch. unit (4 ch. unit)5 
+ J ch.
4 ch. unit (4 ch. unit) 2 
+ J ch. + Sc
Valency 2 10 2 4
% total Ig 
in serum
80 6 13 neg.
Subclasses 1,2,3,4 1,2 1,2 1,2
Complement
fixation
+ < b) + - -
* Not including IgD and IgE.
(a) Also present in very low concentrations in serum as a dimer 
polymerized by J chain only, total Mol. wt. 335,000.
(b) The IgG4 subclass of human IgG is not capable of activating 
complement.
neg = negligible; ch. = chain; Sc = secretory component.
n.b. concentration of immunoglobulin (Ig) may vary in
individuals.
antibodies will not be discussed here except to say that the 
variable regions of different antibodies have different paratopes 
by virtue of germ-line gene selection and combination, and 
further by somatic recombination events in cell division and 
somatic point mutations in B cells. This creates a vast 
repertoire of paratopes each of which are able to give a stable 
union with an epitope of sufficient complimentation.
Common to the immunoglobulins of vertebrates from sharks to 
the human is a four-chain structure consisting of two light (L) 
chains and two heavy (H) chains; however some immunoglobulins are 
polymers of the four chain monomeric unit (Reviews: Porter, 1973; 
Nisonoff et al., 1975; Burton, 1985). IgG has the basic 
four-chain immunoglobulin structure in the shape of a Y, as 
illustrated in Figure 6.1. Each L chain is linked to an H chain 
by strong noncovalent forces and, in most immunoglobulins, by one 
or more interchain disulphide bond. Similar forces are involved 
in holding together pairs of H chains. Each H chain and each L 
chain consists of a variable (V) and constant (C) part. The V 
regions are responsible for the diversity of antibody 
specificities. The C regions are invariable for a given class of 
H chain or type of L chain, except for minor genetic 
polymorphisms. There are five classes of H chain which define 
five classes of immunoglobulin: IgM, IgA, IgG, IgD, and IgE. The 
C region of the H chain defines the class of the immunoglobulin. 
Mammals possess two types of L chain called kappa and lambda, 
which can combine with H chains of any class. An antigen binding
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site is made up of amino acids from one H chain and one C chain. 
Thus, the four-chain monomer possesses two combining sites. 
Within each V region are three clusters of hypervariable amino 
acids that contribute directly to the formation of the antigen 
combining site. Both H chains and L chains are made up of 
domains, each domain containing 110-120 amino acid residues. Each 
domain also has an intra-chain disulphide bond, spanning 55-65 
amino acid residues. Each L chain has two domains (V and C). Each 
H chain has one V domain and three or four C domains depending on 
its class. A diagram of the structure of one of the two 
sub-classes of rabbit IgG is given in Figure 6.1, illustrating 
some of the points made above.
Antigenicity of proteins is determined by the accessibility, 
hydrophobicity and mobility of a particular region (Review: Van 
Regenmortel (1986). The importance of each feature can only be 
defined with reference to a particular antibody-antigen reaction. 
The mobility component is undeniably an important factor (Review: 
Tainer et al., 1985) involved in a region of a protein adopting a 
conformation suitable for recognition by antibody, i.e. to an 
epitope which is complimentary to the paratope.
There are continuous epitopes, defined as a linear sequence 
of amino acid residues, or discontinuous (or assembled) epitopes, 
made up of residues that are not contiguous in sequence but are 
brought together at the protein surface by the folding of one or 
more polypeptide chains. When monoclonal antibodies directed to
84
85
whole proteins are used to locate the position of epitopes mainly 
discontinuous epitopes are revealed (Benjamin et al., 1984). Few 
monoclonal antibodies are produced that recognize linear 
fragments of the antigen. Since monoclonal antibodies are 
selected for high affinity binding the pattern of 
epitope-paratope interaction revealed by them may not be 
representative of the reactions that occur with low affinity 
antibodies.
The properties of IgG, IgM, IgA and slgA are summarized 
briefly below. Factors affecting neutralisation mediated by 
antibody are addressed in this thesis and encompass class of 
immunoglobulin, valency, and quantitative aspects.
6.2.1. IgG
IgG is the major circulatory and anamnestic immunoglobulin 
in mammals. It has the basic four-chain immunoglobulin structure 
(Figure 6.1) in the shape of a "Y". Human IgG occurs as four 
major sub-classes: IgGl, IgG2, IgG3, and IgG4 which vary in 
concentration in the serum. The normal order of relative 
concentration of IgG subclasses in humans is IgGl >IgG2 >IgG3 
>IgG4. There can however be individual variation in the values. 
The subclasses differ in the C region of the H chain and 
consequently in the effector functions mediated via these regions 
such as complement fixation, placental passage and binding to 
phagocytes (Review: Burton, 1985). In the mouse there are four
Figure 6.1. 
molecule. In
8 6
Diagram of the structure of the rabbit IgG
an individual molecule the two H chains are 
identical to one another, as are the two L chains. The shaded 
areas represent regions that are held together by non-covalent 
bonds.
sub-classes of IgG (IgGl, IgG2a, IgG2b, and
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IgG3) and in the 
rabbit two (IgG and IgGl) although IgGl is present in very low 
concentrations.
Native IgG molecules can be cleaved into large fragments by 
certain proteolytic enzymes. Papain cleaves IgG on the N-terminal 
side of the disulphide bridge that joins the two H chains to 
yield two monovalent Fab' fragments and a Fc fragment (Figure
6.2.1). A Fab' (ab for antigen binding) fragment contains a 
complete L chain and the Vh and Ch 1 regions. Being monovalent, 
Fab fragments cannot form crosslinked networks and are therefore 
incapable of forming aggregates. The Fc (crystalisable) fragment 
contains the C-terminal halves of both H chains. Pepsin cleaves 
IgG on the C-terminal side of the disulphide bridge that joins 
the two H chains removing a partially degraded Fc portion and a 
F(ab ' ) 2 fragment that retains bivalency (Figure 6.2.2)
6.2.2. IgM
A diagrammatic representation of the structure of a human 
IgM molecule is shown in Figure 6.3. IgM is the earliest 
immunoglobulin to appear in the serum of a mammal after 
stimulation with an antigen but is progressively replaced by IgG 
during the response. In most species IgM has a pentameric 
structure (five four chain monomeric units) and a valency of 10. 
Because identical H and L—chain pairs form combining sites, the 
specificities of the 10 combining sites in an individual molecule
Figures 6.2.1. and 6.2.2. Location of cleavage sites in mouse IgG 
sensitive to enzymes papain (Figure 6.2.1.) and pepsin (6.2.2).
Figure 6.2.1. The Fab' fragments produced from IgG by papain are 
monovalent. The Fc region contains amino acids derived only from 
the constant regions of the heavy chains. Each Fab' fragment 
contains one complete L chain and approximately half of an H 
chain.
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Figure 6.2.2. The F(ab ' ) 2  fragment produced by pepsin i3 
bivalent; the Fc segment is partially degraded. If the disulphide 
bond between the two heavy chains is subsequently reduced (i.e. 
with cysteine), two monovalent Fab' fragments are released.
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Figure 6.3. Diagram of the structure of the human IgM 
molecule.The dashed lines represent the intrachain disulphide
bonds.
* j  c h a i n
are identical. In the pentameric structure each four chain unit 
is joined to an adjacent unit by a single disulphide bond between 
two mu chains. Mild reduction at neutral pH (Nisonoff et al.,
1975) yields 5 four-chain units (monomeric IgM). Trypsin or 
papain can be used to prepare Fcmu and Fab' mu fragments of IgM 
(Plaut and Tomasi, 1970) and pepsin can be used to produce 
F (ab'mu )2 fragments (Dorrington and Tanford, 1970). Pentameric 
IgM molecules each contain a J chain (MW 15,000) which appears to 
be essential for initiating polymerization through disulphide 
bonds of the four chain units of IgM (and dimeric IgA). IgM is a 
potent activator of the classical complement pathway since there 
are, on a single molecule, 5 Fc regions that have attachment 
sites for Clq.
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6.2.3. IgA and slgA
The majority of serum IgA in humans is monomeric and 
consists of the basic four chain unit. slgA is the predominant 
immunoglobulin on the mucosal surfaces of the body of most 
mammals and is therefore present in the first line of defence 
against infection of the respiratory, intestinal and urogenital 
tracts (Reviews: Ogra et al., 1984; Dhar and Ogra, 1985). slgA 
(Figure 6.4) is a dimer of the basic four chain unit structure 
linked by a J chain and the secretory component (Sc). Sc is 
acquired when the molecule is transferred across the mucosal 
epithelium. Dimeric IgA may also be present in negligible amounts 
in the serum as slgA or as a dimer polymerized by the J chain
Figure 6.4. Diagram of the structure of the human secretory IgA 
molecule. Secretory component (Sc) is joined to the alpha chains 
by strong non covalent bonds as well as by disulphide bonds. A J 
chain is also contained in the molecule.
Figure 6.4. Diagram of -the structure of the human secretory IgA 
molecule. Secretory component (Sc) is joined to the alpha chains 
by strong non covalent bonds as well as by disulphide bonds. A J 
chain is also contained in the molecule.
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Figure 6.4. Diagram of the structure of the human secretory IgA 
molecule. Secretory component (Sc) is joined to the alpha chains 
by strong non covalent bonds as well as by disulphide bonds. A J 
chain is also contained in the molecule.
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only- Higher polymers of IgA can occur notably the tetrameric 
slgA that is found in man (Tomasi, 1976).
The origin of the slgA in secretions can be attributed 
partly to local production of IgA in plasma cells located in the 
mucosal lamina propria, which underlies the luminal surface 
epithelium (Reviews: Lamm, 1976; Borsch, 1984). Investigations of 
the origin of these cells has lead to the concept of a common 
mucosal immune system, whereby cells that are stimulated to 
produce IgA antibody to antigens at one mucosal site subsequently 
migrate to and populate distant mucosal sites (Bienenstock and 
Befus, 1980). Serum polymeric IgA may also gain access to mucosal 
sites and selective transport of serum derived IgA can occur and 
represents a connection between the serum and external secretions 
(Hall et al., 1979; Review: Hall and Andrew, 1980; Sullivan and 
Arrowsmith, 1984), however this is dependent on the availability 
of Sc (Sheldrake et al., 1984).
It should be noted that the distribution of immunoglobulins 
in secretions differs in different mammalian species (Tomasi,
1976). In humans and rodents slgA is the predominant class of 
immunoglobulin; however significant amounts of other classes are 
also found and these can contribute to the mucosal immune 
response. In sheep IgG is the predominant immunoglobulin in 
secretions and slgM (IgM + Sc) is the predominant immunoglobulin 
in rabbit external secretions.
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Despite the obvious differences between the subunit and 
polypeptide chain assembly of slgA and serum (monomeric) IgA, at 
present there is no evidence of any difference in the primary 
structure of either the Hal pha chains or L chains.
slgA is the most resistant of all immunoglobulins to 
proteolytic digestion, reflecting the harsh environmental 
conditions (pH, ionic strength, detergent, proteases) in which 
slgA must function. Pathogenic bacteria such as Streptococcus 
pneumoniae and Neisseria gonorrhoaae produce IgAi proteases that 
have exquisite specificities for IgA of the IgAi subclass of 
humans (Review: Plaut, 1983). Fab'alpha and F(ab' alpha )2 
fragments can be obtained however from secretory and monomeric 
IgA by several methods and monomeric IgA can be obtained from 
slgA by partial reduction (Reviews of methods: Tomasi, 1976; 
Johnstone and Thorpe, 1985)
7.1. Significance of valency and flexibility of immunoglobulins 
in viral neutralization.
There is an equilibrium between dissociation and reformation 
of antibody-virus complex (Review: Mandel, 1979). Virus (V) 
reacts with antibody (A) in two steps:
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(1) V + A  ~  (V A )r
(2) ( V A  ) r «g- (VA)
(VA)r represents virions complexed with antibody in a freely 
reversible way; (VA) represents virions complexed with antibodies 
in an almost irreversible way.
The equilibration of (1) is reached rapidly and is not 
temperature dependent, whereas the equilibration of (2) is slow 
at 0° C but at 37° C proceeds rapidly so that in minutes most of 
the antibody virion complexes formed are stable. Although 
increase in temperature favours the rate of reaction, a decrease 
in temperature favours the formation of the complex because of an 
accompanying decrease in enthalpy. Szweczuk and Mukkur (1977) 
have suggested that the relative contributions of the changes in 
enthalpy and entropy to the forward reaction vary with 
temperature. At low temperature the enthalpy change is the 
principal driving force, whereas at high temperature (37°C) the 
change in entropy is more significant. The degree of 
reversibility diminshes the longer the reaction is allowed to 
proceed.
Affinity is simply the strength with which the antibody 
binds to its antigenic determinant. The avidity of an antibody 
relates to its valency. When a single IgG molecule binds to two 
sites on a single influenza virus HA spike (Figure 7.1.1) or 
adjacent HA spikes on the same virus particle (Figure 7.1.2), the 
stability of the complex increases by several orders of 
magnitude. The probability of simultaneous dissociation of the 
paratopes is small. Fab' fragments having one paratope produced
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antigenic regions are shaded in pink, the location of amino acid 
residue 266 in the VAS is shaded blue.
Diagram drawn to scale (1 cm = 2.4nm):
HA structure adapted from Wiley et al., 1981; Wilson et al. ,
1981; Rogers et al., 1983. IgG structure determined from Werner 
et al., 1972; Nisonoff et al., 1975; Silverton et al., 1977;
Deisenhofer, 1981; Marquart and Deisenhofer, 1982. N.B. The Fc 
region of IgA has approximately the same dimensions as that of 
IgG.
Figure 7.1.1. Diagram of IgG with both binding sites attached to
a single HA spike (trimer) of an influenza virus particle. The
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antigenic regions are shaded in pink, the location of amino acid 
residue 266 in the VAS is shaded blue.
Diagram drawn to scale (1 cm = 2.4nm):
HA structure adapted from Wiley et al. , 1981; Wilson et al. ,
1981; Rogers et al., 1983. IgG structure determined from Werner
et al., 1972; Nisonoff et al., 1975; Silverton et al., 1977;
Deisenhofer, 1981; Marquart and Deisenhofer, 1982. N.B. The Fc 
region of IgA has approximately the same dimensions as that of 
IgG.
Figure 7.1.1. Diagram of IgG with both binding sites attached to
a single HA spike (trimer) of an influenza virus particle. The
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antigenic regions are shaded in pink, the location of amino acid 
residue 266 in the VAS is shaded blue.
Figure 7.1.1. Diagram of IgG with both binding sites attached to
a single HA spike (trimer) of an influenza virus particle. The
Diagram drawn to scale (1 cm = 2.4nm):
HA structure adapted from Wiley et al., 1981; Wilson et al.,
1981; Rogers et al., 1933. IgG structure determined from Werner
et al., 1972; Nisonoff et al., 1975; Silverton et al., 1977;
Deisenhofer, 1981; Marquart and Deisenhofer, 1982. N.B. The Fc 
region of IgA has approximately the same dimensions as that of 
IgG.
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Figure 7.1.1. Diagram of IgG with both binding sites attached to 
a single BA spike (trimer) of an influenza virus particle. The 
antigenic regions are shaded in pink, the location of amino acid 
residue 266 in the VAS is shaded blue.
Diagram drawn to scale (1 cm = 2.4nm):
HA structure adapted from Wiley et al., 1981; Wilson et al., 
1981; Rogers et al., 1983. IgG structure determined from Werner 
et al., 1972; Nisonoff et al., 1975; Silverton et al., 1977; 
Deisenhofer, 1981; Marquart and Deisenhofer, 1982. N.B. The Fc 
region of IgA has approximately the same dimensions as that of 
IgG.
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Diagram of IgG binding to two adjacent HA spikes of 
virus particle. It should be noted that anti-HA IgG 
also capable of cross-linking virus particles, 
to scale (see Figure 7.1.1).
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an influenza virus particle. It should be noted that anti-HA IgG 
molecules are also capable of cross-linking virus particles. 
Diagram drawn to scale (see Figure 7.1.1).
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by papain digestion of IgG form much less stable complexes. Their 
stability depends on the stability of the native immunoglobulin, 
i.e. very high affinity IgG could give effectively stable binding 
by Fab'. Important properties of slgA (Figure 6.4) and IgM 
(Figure 6.3) are their multivalency (4 and 10 binding sites 
respectively) resulting in high avidity for antigen, even if the 
affinity (of the four chain unit) is low. This may be especially 
relevant in the neutralization of virus.
A general theory for antibody action (Metzger, 1974) was 
that cross-linking of antigens is required for physiological 
effects, i.e. mechanical cross-linking by F(ab ' ) 2  arms is the 
minimal requirement for antibody action. However, observations of 
the actions of Fab' fragments derived from anti-lymphocyte and 
anti-thymocyte IgGs (Van Wauve et al., 1980; Guillet et al.,
1983) show that bivalent cross-linking is not always a necessary 
requirement for complete function of antibody. Much earlier 
Lafferty (1963b) showed that monovalent Fab' fragments neutralize 
influenza virus with comparable efficiency to antibody but that 
neutralization was reversed on dilution. No cross-linking such as 
that achieved with multivalent antibody was necessary. Although 
Fab' fragments derived from polyclonal IgG neutralized poliovirus 
(Vogt et al., 1964; Keller, 1966) recent studies with Fab' 
fragments derived from monoclonal IgG (Icenogle et al., 1933; 
Emini et al., 1983a) have generally suggested that cross-linking 
is required for neutralization of poliovirus (section 9.2.2). The 
mechanisms of neutralization of influenza virus by Fab' and
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F(ab') 2 fragments derived from monoclonal IgG are investigated 
in this thesis.
The flexibility of immunoglobulin molecules is an important 
consideration in the interaction of antibody with viral antigens. 
Complement activation by antibody is dependent on the flexibility 
of the antibody (Review: Feinstein et al., 1986). A flexible
stretch of amino acids between the Ch 1 and Ch 2 domains known as 
the hinge region (Huber et al. , 1976) allows an IgG molecule to 
assume various "Y" configurations. The pivotal area about which 
Fab -Fc movement occurs or the degree of movement within a IgG 
molecule that occurs in a given antibody-antigen reaction is not 
known with any certainty (Review: Burton, 1985). Valentine and 
Green (1967) in electron microscopic (EM) studies determined that 
the Fab' arms of rabbit IgG binding to hapten could assume angles 
of 10 to 180° relative to each other. The observations in 
solution with haptens indicate that ”T" shaped configurations 
(180° separation) can bridge haptens at least 9nm and up to 
approximately 15nm apart (Werner et al., 1972). Wrigley (1979) 
showed that IgG binding to isolated influenza A BrHA could bridge 
molecules with an extended T shaped configuration. IgG molecules 
were seen by Lafferty and Oertelis (1963) to accommodate 
antigenic sites up to 12nm apart on adjacent HAs of intact 
influenza virus (Figure 7.1.2) or with both Fab' arms attached 
to antigenic sites on the same HA in a classic Y shaped 
configuration (Figure 7.1.1). Extended IgG molecules were seen 
also to link two influenza virus particles.
Nanosecond fluoresence measurements have been interpreted to 
indicate segmented flexibility and motion of the Fab'’ arms about 
the hinge region of IgG in solution (Hansen et al., 1981). This 
motion is unaffected by binding of Clq or protein A to IgG. 
Wrigley et al. (1983) obtained evidence by EM studies for the
ability of mouse IgGi to twist around its long axis and for C-V 
region bending in Fab' arms in the interaction of monoclonal 
antibodies with BrHA molecules in solution. Flexibility is known 
to vary with IgG subclass in the mouse (Oi et al. , 1984) and 
inflexibility in the hinge region has been associated with loss 
in Fc effector functions such as Clq binding (Dorrington and 
Klein, 1982).
EM studies have shown that an uncomplexed IgM molecule 
adopts a star-shaped planar conformation (Chesebro et al., 1968;
Feinstein et al., 1971) (Figure 7.1.3). IgM has been visualized 
as binding to antigen in various configurations and assumes a
variety of shapes (Feinstein et al., 1971) notably with a
"spider-like" docking orientation, i.e. with all 10 Fab'mu arms 
attached to the antigen (Figure 7.1.3). The span of the IgM 
molecule in a "spider like" conformation is approximately 25 nm 
(Feinstein et al., 1986). This configuration of IgM is the best
activator of complement (Feinstein et al., 1986). The high
valency of IgM ensures that cross-linking of virus particles is 
possible as demonstrated by Brown and Smale (1970) with IgM 
cross-linking foot and mouth disease virus. EM examination of
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side views of IgM cross-linking flagella support the model of IgM 
having each F(ab'mu)2 unit rotated through 90° about its two fold 
axis of rotation so that each pair of F(ab'mu)2 arms lies in 
right angles to the main disc (Feinstein et al., 1986). The 
degree of flexibility of the hinge region of IgG is greater than 
that of IgM (Review: Feinstein et al., 1986). However, it should 
be borne in mind that the five-fold higher valency of the IgM 
molecule may more than compensate for its lower flexibility.
Relatively little information is available concerning the 3 
dimensional structure of slgA. The predominant form in free 
solution is of the slgA molecule fully extended (Tomasi, 1976, 
Hall and Andrew, 1980) (Figure 7.1.3). IgA molecules possess a 
hinge region similar to that of IgG and slgA molecules have been 
observed (Tomasi, 1976) with bending at a point in the middle of 
the molecule so that four chain units are able to flex 60-120° 
relative to each other. This probably occurs at the joining 
position of the two monomers as dimeric IgA in the serum (without 
Sc) shows a tendency to bend at a point where the Fc regions are 
in close proximity. An electron micrograph (Hall and Andrew,
1980) shows one slgA molecule attached to the flagellum of the 
bacterium Salmonella paratyphi. The molecule was orientated in 
the double Y extended conformation parallel to the antigen so 
that only one Fab'ai pha arm of each four chain unit was binding 
to the flagellum. This docking orientation if common would not 
take advantage of the valency of the slgA molecule but the degree 
of flexibility suggests that slgA may indeed bind with all four
pFigure 7.1.3. Diagram of some of the possibile conformations of 
3 IgA and IgM that could occur on binding to viral antigen.
Diagrams are adapted from 3-D models proposed by Burton (1986) 
and Pumphrey (1986).
slgA in: (a) double Y conformation bound to viral antigen through 
only one four chain immunoglobulin unit, (b) in double Y 
conformation but bound to viral antigen via only one Fab’aipha 
arm of each four chain immunoglobulin unit, and (c) binding in 
hair-pin conformation with both four chain immunoglobulin units 
attached to viral antigen.
IgM in: (d) a "star-like" planar conformation only one four chain 
immunoglobulin unit attached to viral antigen, (e) an 
intermediate conformation attached via three four chain 
immunoglobulin units, and (f) a "spider-like" conformation 
adopted after making multiple attachments to viral antigen (span
25nm).

8.1. Attributes of the neutralization reaction.
To achieve neutralization an antibody has to bind to a site 
that is involved in the infectious process of the virus, i.e. a 
critical site (Daniels, 1975). Neutralization results from the 
binding of a number of molecules of immunoglobulin to one or more 
critical site(s) on a virus particle leading to loss of 
infectivity.
In order to neutralize influenza virus it is evident that 
antibody has to bind to not only to the HA but to certain 
specific regions on it (section 2.2; Figure 2.1.1). There are 
antibodies that bind to the HA of influenza but do not neutralize 
(Breschkin et al., 1981) presumably because they are directed to 
non-critical regions on the HA molecule. Binding to non-critical
sites does not lead to neutralization. However, binding to
non-critical sites may under certain conditions lead to
"extrinsic" neutralization for example via the binding of
complement (Haukenes, 1977). Laver and Webster (1966) found that 
antiserum to uninfected chick endodermal cells of the 
chorioallantoic membrane (CAM) inhibited the HA activity of 
influenza virus grown in chick embryos. They concluded that the 
presence of host antigen in the virus envelope (presumably 
carbohydrate) was responsible for this inhibition, probably due 
to steric hindrance of HA. Antibody binding to non-critical sites 
may because of topological disposition sterically interfere with 
a crucial function, for example attachment.
With appropriate concentrations of antibody and antigenic
sites the binding of antibody to non-critical regions could lead 
to secondary interactions such as aggregation. This is termed 
psuedoneutralization, where, although the individual viruses are 
themselves neutralized each multimeric aggregate registers as one 
infectious unit. Anti-NA does not neutralize influenza virus 
(Laver and Webster, 1966), but Compans et al. (1969) found that 
anti-NA could reduce the HA activity of an influenza virus 
population. It was concluded that this pseudoneutralization of HA 
activity was due to aggregation since ultrasonic vibration 
increased HA activity to 50% of control levels.
It should be noted that loss of infectivity may also be 
mediated by another component. For example complement may be 
required to inactivate the infectivity of an infectious 
virus-antibody complex. Although the mechanisms by which 
complement, together with immunoglobulin induces viral 
inactivation has not been addressed in this thesis, complement 
activation is an important facet of immunity (Review: Lachmann, 
1985). The induction of viral neutralization by antibody and 
complement can occur in a number of different ways. For example, 
antibody may function together with complement to lyse enveloped 
viruses (Haukenes, 1977) aggregate (Oldstone et al., 1974) or 
smother virus in a coating of antibody and complement so as to 
block attachment of virus to the host cell (Berry and Almeida, 
1968; Linscott and Levinson, 1969). In some virus infections the 
first antibodies that are formed are of low avidity and at low 
titre and depend on complement for neutralization (Lachmann,
1985). The majority of anti-HA IgG (detectable only by ELISA) 
from human sera to influenza A/WS/33 (H1N1) did not neutralize 
virus in direct neutralization assays (Beebe et al., 1983), but 
did so in conjuction with the first four reacting components of 
the classical complement pathway. Complement was activated 
leading to the deposition of C3 and C4 on the viral envelope. In 
addition complement can recognize and inactivate certain viruses 
directly (Welsh et al., 1976) in the absence of immunoglobulin.
The use of proper controls, defined conditions and 
monoclonal antibodies can largely exclude extrinsic phenomena 
from studies. The following discussion will deal largely with 
primary neutralisation, pertinent to research described in this 
thesis.
It is now apparent that different viruses are neutralized by 
different mechanisms and that neutralization is further dependent 
on the host cell (Review: Dimmock, 1984). Available evidence 
suggests that any of the early events in virus replication may be 
interfered with by neutralizing antibody. These can be broadly 
categorized:
1. A critical viral function is negated when 
immunoglobulin molecules bind to sufficient critical sites 
to prevent the function dependent on that site. For 
example, the blocking of attachment of reovirus HAs to 
CRUs by the steric hindrance of IgG to reovirus HA (Lee et
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al., 1981).
2. Virus neutralization is an active process and the 
interaction between virus and antibody leads to 
physiochemical alteration in the virus or conformational 
changes within the virion structure that modify the 
characteristics of a critical virus-cell interaction. 
Antibodies can induce conformational changes in virus 
proteins and these may be concerned with the 
neutralization process. A consequence could be the 
aberration or inhibition of an essential stage (or stages) 
in the viral replication cycle subsequent to attachment.
8.1.1 Quantitative aspects of the antibody-virus interaction.
A crucial aspect of viral neutralization is the lack of an 
adequate explanation to reconcile single-hit inactivation 
kinetics (one antibody is sufficient to cause neutralization) 
with the multiligand nature of a virus particle.
The kinetics of the neutralisation reaction can be used to 
examine these events. In kinetic experiments antibody is mixed 
with virus, a portion of the mixture removed and assayed for 
infactivity. Mathematically, the number of target sites that must 
be hit for inactivation of the virion is expressed by:
( 1 ) Vt/Vo = l-( l-e-“<- /D ) n
where: Vt = concentration of virus at time t;
concentration of virus at time 0; D = dilution factor; 
number of critical targets; k = reaction rate constant.
Vo
When n = 1 the kinetics of neutralization of a virus can be 
graphically represented as an exponential decline in viral 
infectivity as a function of time. This is preceded by an 
immediate drop in viral infectivity. When n > 1 there is an 
exponential decline, but only after a delay which is proportional 
to the value of n. From the studies with a variety of animal 
viruses (e.g. Dulbecco et al., 1956; Rubin and Franklin, 1957; 
Mandel, 1961; Thormar, 1963; Granoff, 1965; Phillipson, 1966; 
Review: Mandel, 1979) the most common type of survival curve is 
shown in Figure 8.1. Neutralization occurs immediately and 
proceeds at a constant rate for a set period of time. A decrease 
in the rate of neutralization then takes place and a persistent 
fraction results, which resists further neutralization. Based on 
the absence of a lag period in the first part of the the survival 
curve it is considered that the interaction of one molecule of 
antibody is sufficient to cause neutralization, i.e. a one-hit 
reaction. Mandel (1976) found that a transition in the 
isoelectric point of poliovirus from pH 7.0 to pH 4.5 occurred 
when virus was neutralized by antibody (section 9.2.2). 
Transition was an all or nothing phenomenon correlating 
directly to neutralization. It was considered that the 
neutralization of poliovirus was one hit
Figure 8.1. Kinetics of the neutralization of a typical virus. 
The loss in viral survival (Vt/Vo) is graphed against the time 
elapsed after the addition of antibody (t=0) (Adapted from 
Daniels, 1975).
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The interpretation of the one hit curve has been called into 
question by kinetic experiments that have shown an initial lag in 
the rate of neutralization which suggests a multi-hit mechanism 
(Burnet et al., 1937; Lafferty, 1963a,b; Phillipson, 1966; 
Review: Della-Porta and Westaway, 1977). The delay implies that 
more than one antibody molecule must bind to neutralize the 
virion. Kinetic studies with low concentrations of antibody and 
at low temperature (4°C) indicated that the neutralization of 
influenza virus (Lafferty, 1963a,b) could be multi-hit. A lag was 
also seen using IgM antibody to poliovirus (Phillipson, 1966). 
The phenomenon of enhancement of Sindbis and West Nile viruses 
were utilized to demonstrate that more than one antibody was 
required for neutralization (Chanas et al., 1982; Peiris et al., 
1982). Neutralizing antibody activity of monoclonal IgG was 
totally removed by dilution, but the presence of monoclonal IgG 
on the surface of virus particles could be shown by the 
enhancement of virus infectivity when virus particles treated 
with monoclonal IgG were incubated with cells bearing Fc 
receptors.
The reaction between antibodies and haptens is very rapid 
occuring in less than 3 seconds (Pecht et al., 1972). It has 
therefore been argued that the antibody-antigen reactions in
because the transition of isoelectric point occurred in the
presence of minimal concentrations of antibody and intermediate
states were not observed.
virus neutralization are also extremely rapid processes and the 
methods used for rate measurements do not indicate true rates. 
Thus, where there is no apparent lag phase in viral 
neutralization and a single-hit mechanism appears to operate, 
this may be due to the rapidity of the neutralization reaction 
thus making it impossible to accurately measure the reaction over 
the first few seconds. Ashe and Notkins (1967) with HSV and Hahon 
(1970) with Venezuelan equine encephalomyelitis virus (VEEV) 
established that very early on before any neutralisation occurred 
antibody attached to the particle. Infectious virus-antibody 
complexes could be neutralized by anti-IgG containing serum. This 
further suggested that neutralization required more than one 
antibody to bind to the virus. Neutralization may be best 
described as sequential reaction:
Virus + antibody —►  Infectious virus-antibody complex (V-ab) 
V-ab + more identical antibody — ►  Neutralized virus.
If it is maintained that one (or at best a few) molecule(s) 
of antibody neutralize an infectious virus particle then the 
interpretation that neutralization occurs by the prevention of 
attachment of virus to a susceptible cell is brought into 
question. The surface of most animal viruses is composed of 
identical virus attachment protein (VAP) subunit3 each one of 
which carry virus attachment sites (VAS) which have the potential 
capability to bind to a cellular receptor unit (CRU). For 
example, it has been determined that influenza type A virus
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particles have between 700 and 1200 spikes, 4 in 5 of which are 
HA (section 1.2); each HA spike is a trimer composed of three HA 
monomers each bearing a VAS (section 2.2). Therefore a 
conservative estimate of the number of sites available on an 
influenza particle to bind to a CRU would be between 1700-3000. 
One or a few antibodies could only potentially mask a one or a 
few of the VASs available on an influenza particle (Figures 
7.1.1; 7.1.2). Therefore it would be expected that binding of 
one, or a few, molecules of antibody should not negate the 
capacity of a virus particle to attach, if the effect of antibody 
is simply to create a steric barrier. The capsid of a 
picornavirus, polio, consists of 60 protomers (Rueckert, 1976) 
each of which is composed of four proteins, VP1-4. It is proposed 
that picornaviruses (Rossmann et al., 1985; Hogle et al., 1985) 
have a conformational pocket on each protomer which functions as 
a VAS. Icenogle et al. (1983) showed that the maximum number of 
monoclonal IgG molecules that would bind to a poliovirus particle 
was 30, but that significant neutralization occurred when 3 IgG 
molecules were bound. It was suggested that each IgG molecule in 
this situation bound bivalently to 2 epitopes on 2 different 
protomers related by a two-fold axis. Thus when 3 antibody 
molecules bound there were 54 other VAS on 54 other protomers 
available for cell-virus interaction. Since it has been shown 
that poliovirus-antibody complexes can attach to cells (Mandel, 
1967) it is reasonable to consider neutralization is brought 
about by the failure of the virus to function normally at the 
penetration or uncoating stage (section 9.2.1; section 9.2.2).
The determination of the number of molecules needed for 
neutralization is therefore an important consideration and 
evidence that only one or a few IgG molecules are able to block 
only one or a few potential binding sites questions the classical 
paradigm that the function of antibody is to block viral 
attachment (Lachmann, 1985).
The portion of infectivity that remains after reaction 
between a population of virus and neutralizing antibody has been 
termed as the non-neutralized or persistent fraction (Dulbecco et 
al., 1956) (Figure 8.1). The emergence of a persistent fraction 
can be due to one of a combination of factors (Reviews: Daniels, 
1975; Mandel, 1979). These factors may involve the avidity of the 
antibody (Lafferty, 1963a,b). He found that the neutralisation 
mediated by a low avidity antibody was undone by dilution of the 
antibody-virus complex. Dulbecco et al. (1956) postulated that 
certain non-neutralizing antibodies in a polyclonal population of 
IgG may bind to the virus and prevent the attachment of 
neutralizing antibody. Mandel (1958) found that anti-IgG 
neutralized the persistent fraction of poliovirus, indicating 
that non-neutralizing antibody was bound to the virus. Steric 
factors between virus bound antibody and free antibody could 
determine the persistent fraction. Ashe and Notkins (1967) showed 
that HSV-IgG complexes resistant to further neutralization by 
intact IgG could be neutralized by Fab fragments. It was 
presumed that these smaller molecules can gain access to the
unavailablevirus particle  to the whole IgG molecule. 
Non-neutralizing antibody in binding to non-critical sites may 
exclude the binding of neutralizing antibody to critical sites 
(Daniels, 1975). Massey and Schochetman (1981) used 
[l25 I]-labelled monoclonal IgG to Kirsten sarcoma virus to show 
that certain monoclonal IgGs while binding to the virus did not 
neutralize. Furthermore they prevented the subsequent attachment 
of neutralizing monoclonal IgGs as judged by [l25 I]-labelled 
monoclonal IgG binding in neutralization assays. Aggregation 
caused by immunoglobulin allowing virus in the centre of the 
aggregates to escape neutralization was reported with echovirus 
type 4 and cited as a possible cause of the persistent fraction 
(Wallis and Melnick, 1967). However, filtration to remove 
aggregated virus does not prevent the formation of persistent 
fractions with VEEV (Hahan, 1970), with poliovirus 
(Lewenton-Kriss and Mandel, 1972) as well as echovirus type 4 
(Kjellen and von Zeipel, 1984).
It should be noted that all studies with polyclonal antibody 
are difficult to interpret because of heterogenicity of the 
antibody population (i.e. specificity, affinity, non-neutralizing 
antibody etc.). The emergence of escape mutants in the incubation 
of virus populations with monoclonal antibodies indicates that a 
proportion of the persistent fraction consists of variants that 
escape neutralization on account of the absence of specific 
antibody to neutralization epitopes peculiar to the variants.
Studies with VSV (Kjellen and Schlesinger, 1959) and with 
echovirus type 4 (Kjellen and von Zeipel, 1984) showed that the 
non-neutralizible fraction depends not only on the virus-antibody 
reaction but also on the cells being inoculated (section 9.1).
The biological implications of the persistent fraction are 
manifest in the occurrence of infectious virus-antibody complexes 
in the blood of pigs infected or immunized with African swine 
fever virus (ASFV) (De Boer, 1967; Hess, 1981). Infection or 
immunization with ASFV produces non-neutralizing antibodies and 
hypergammaglobulinaemia in pigs but does not induce neutralizing 
antibodies (Fan et al., 1970). Specific antibody produced in the 
infection of mink with Aleutian disease virus (ADV) also fails to 
neutralize infectivity (Review. Porter and Cho, 1980). ADV is 
also characterized by circulating immune complexes and 
hypergammaglobulinaemia. Caprine arthritis-encephalitis virus 
(CAEV) fails to induce neutralizing antibody in its natural host 
(goat) or in sheep (Narayan et al., 1984). The biological reasons 
for these observations have not been fully explained but the 
apparent failure to neutralize virus may be due to the lack of 
appropriate antigenic epitopes (either qualitatively or 
quantitatively) or a consitutive deficiency or impairment of the 
host immune defence. Certain non-neutralizing antibodies as well 
S3 impeding the access of neutralizing antibody can form damaging 
circulating immune complexes.This can occur notably in CAEV and 
ADV infections, and lymphocytic choriomeningitis virus 
(LCMV)-antibody complexes in mice persistently infected with LCMV
1 1 5
1 1 6
leads -to manifestations of immunologic injury (Oldstone and 
Dixon, 1967; Oldstone et al., 1972).
9.1. Influence of host cell on neutralization of virus
In experiments with VSV, Kjellen and Schlesinger (1959) 
showed that host cells may influence the extent of 
neutralization. VSV produced similar titres on CEF and leukaemic 
bone marrow cells before neutralization but after incubation with 
antibody there was up to a thousand fold higher titre on CEF 
cells compared to the leukaemic bone marrow cells. This 
phenomenon has also been observed with echovirus type 4 (Kjellen 
and von Zeipel, 1984). The extent of measurable neutralization of 
echovirus by polyclonal serum was dependent upon whether the host 
cell used to assay residual infectivity was rhadomyosarcoma (RD) 
cells or green monkey kidney (GMK) cells.
Recent studies on the neutralization of enterovirus 71 by 
polyclonal IgG (Kjell£n, 1985) showed that the extent of 
neutralization by different populations of IgG varied from one 
host system to another. Populations of IgG were separated by 
difference in absorption to protein A. One population of antibody 
reduced infectivity by interaction at exposed antigenic sites 
(residual infectivity could be measured after virus and antibody 
had been allowed to interact). A second antibody population only 
attached to antigenic sites after interactions between
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enterovirus 71 and host cells. This second type of antibody 
activity could be detected on RD cells but not on GMK cells. The 
inference from these studies was that in order to neutralize, the 
second type of antibody required a particular host system. 
Critical sites on the virus only become vulnerable to antibody 
during virus-host interactions, probably via an allosteric 
modification of the VAP.
In assessing the neutralization of La Cros3e (LAC) virus by 
a panel of monoclonal IgGs specific for the G1 glycoprotein it 
was found that antibodies showed host-dependent neutralization 
ability (Grady and Kinch, 1985). One antibody was neutralizing 
only when virus was assayed on BHK-21 cells. Another antibody was 
neutralizing only when cells from Aedes albopictus (a species of 
mosquito that is a vector of LAC virus) were used. Four other 
monoclonal antibodies showed no host dependency. The monoclonal 
antibody that neutralised only when mosquito cells were used 
recognized an epitope in a region of the G1 glycoprotein that was 
distinct from those recognized by the other antibodies, 
highlighting that this region may be an important determinant in 
the interaction of virus with its arthropod vector. It may be 
relevant that virus in mosquitos only comes into contact with 
antibody when it is ingested in a vertebrate blood meal.
These experiments highlight the need for studies considering 
the mechanism of protection by antibody of differentiated target 
cells involved in infection of a virus with its natural host. For
example, human adenoid organ culture can provide an attractive 
model to study both the pathogenesis of influenza A infections in 
man and the resultant mechanisms of neutralization in the host 
(Edwards et al., 1986). Buchmeier et al. (1984) found that one 
neutralizing monoclonal antibody to murine hepatitis virus type 4 
(quantified by plaque reduction on L-24 cell monolayers) did not 
protect mice against challenge whereas another of the same 
sub-class, but directed against a different epitope, did protect. 
This illustrates that mechanisms observed in cultured cells may 
indeed differ from those in the actual host.
9.2. Mechanisms of the virus neutralization reaction.
Although the neutralization of viruses has been studied 
empirically for many years it is not well understood at the 
molecular level. Virus neutralization is a tripartite system 
involving the virus the target cell and the antibody. It is 
becoming increasingly apparent that a given mechanism of 
neutralization has to be strictly defined as to the nature and 
origin of the host cells, the virus, the class and clonal nature 
of the neutralizing antibody, and the conditions of the assay 
(Review: Dimmock, 1984). However, the more defined and controlled 
an experiment becomes (i.e. with the use of monoclonal antibodies 
and monoclonal cells) the greater the divergence from the events 
that occur in infection of the natural host.
9.2.1. Ability to prevent the first step in 
virus infection: Attachment.
A review of the observations on the effect of antibody on 
the attachment of an animal virus to its host cell indicates that 
while in certain cases antibody can inhibit attachment to the 
host cell, there are many instances where neutralized virus does 
attach to cells.
Rubin and Franklin (1957) studying the neutralisation of 
Newcastle disease virus (NDV) found that the capacity of NDV to
attach to colls decreased with increasing antibody concentration. 
Studies by Smith et al. (1961) with vaccinia virus and Morgan et 
al. (1968) with HSV showed that neutralized viruses of both types 
were less efficient in attaching to cells than non-neutralized 
controls. Other studies have demonstrated that neutralized virus 
can attach to cells. For example, rabbit pox virus neutralized by 
polyclonal sera attached to HeLa cells (Joklik, 1964), influenza 
virus neutralized by polyclonal sera bound to and penetrated 
endodermal cells of the chorioallantoic membrane in chicken eggs 
(Morgan and Rose, 1968) and influenza virus neutralised by 
polyclonal and monoclonal IgG attached normally to CEF cell 
monolayers (Possee, 1981; Possee and Dimmock, 1981).
The use of monoclonal antibodies combined with increased 
understanding of virus structure and function has allowed 
investigation of the mechanisms of neutralization. For example, 
studies by Lee et al. (1981) determined that the sigma 1 protein 
of reovirus type 3 is the VAP for L cells and that neutralizing 
monoclonal antibody to sigma 1 prevented attachment. However, 
there was no quantitation between the efficiency of 
neutralization and inhibition of attachment. NDV can be 
neutralized by monoclonal antibody to the HN protein or its F 
protein (Russell et al., 1983). Monoclonal antibody to the F 
protein neutralized virus at a stage between attachment of virus 
and its entry into MDCK cells (Russell, 1986). Neutralisation 
of NDV (Ulster) via two epitopes on HN (HN-1 and HN-2) was 
enhanced when the virus was assayed on sialidase-treated
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Madin-Darby bovine kidney (MDBK) cells which had been partially 
denuded of receptor function (Russell, 1986). This implied that 
monoclonal antibodies to both HN epitopes were competing with 
cell receptors for virus and had more chance of neutralizing when 
virus took longer to make the necessary attachments which 
preceded fusion. Neutralization via monoclonal antibody to F was 
not enhanced by treating cells with sialidase.
The envelope of the bunyavirus, La Crosse (LAC) virus 
contains two glycoproteins: G1 and G2 (Gentsch et al., 1980), 
however infectivity is dependent on G1 and only anti-Gl antibody 
neutralizes infectivity (Kingsford and Hill, 1983). The 
topography of the antigenic sites of G1 was determined using a 
panel of monoclonal antibodies and it was revealed that there 
were 7 regions (A through G) on G1 involved in neutralization 
(Kingsford and Hill, 1983; Kingsford and Ishizawa, 1984). IgM to 
G1 blocked binding of monoclonal IgGs to 4 of the regions on G1 
suggesting that the glycoprotein is folded back on it3elf. A 
maximum of 40-45% of infectious virus inoculum bound to BHK-21 
cells by 2h at 1<>C. Polyclonal IgG to LAC reduced attachment by 
50%. When virus was pre-incubated with a neutralizing monoclonal 
IgG to one of each of the 7 antigenic regions on the G1 only 
antibodies to region A reduced attachment (by 92%). Although 
monoclonal IgGs to regions F and G neutralized greater than 90% 
of the virus they only inhibited attachment by 6 and 12% 
respectively. IgGs to regions B, C, and E showed intermediate 
degrees of neutralization and inhibition of binding. The results
indicate that antibodies binding to regions A and B probably 
neutralize LAC virus by sterically preventing attachment of virus 
to CRUs. Antibodies to sites distal from these regions 
(specifically to F and G) have little effect on attachment and 
therefore must inhibit a different step(s) in LAC virus 
replication as their mechanism of action.
Fuller and Spear (1985) tested the ability of polyclonal 
and monoclonal IgG directed to individual HSV type 1 (HSV-1) 
glycoproteins to inhibit the attachment of radiolabelled HSV-1 to 
human epidermoid carcinoma (HEp-2) cell monolayers. Some 
polyclonal IgGs specific for glycoprotein (g)D or gC and 
monoclonal IgGs for gD and gC inhibited HSV-1 attachment. 
However, the monoclonal IgGs to gD that were most effective at 
inhibiting HSV-1 attachment had only weak neutralization 
activity. The most potent anti-gD neutralizing antibodies had 
very little or no effect on the attachment of HSV-1 at 
concentrations significantly higher than those required for 
neutralization. These results suggest that although some anti-gD 
antibodies can neutralize by blocking attachment, a more 
important mechanism of neutralisation by anti-gD antibodies may 
be interference with a step subsequent to attachment, possibly 
penetration. The neutralization activity of the anti-gD 
antibodies correlated strongly with their ability to inhibit Vero 
cell-cell fusion induced by HSV-1 (Noble at al. , 1983) . It is 
speculated that these antibodies block the spread of HSV-1 
infection by inhibiting virus induced cell fusion. Anti-gB did
not inhibit cell fusion.
Poliovirus neutralized by polyclonal IgG was found by Mandel 
(1967) to bind to HeLa cells. At low concentrations of antibody 
the poliovirus-antibody complexes attached to cells as well as if 
not better than that of non-neutralized virus. Increase in 
attachment was proportion to the time that the mixtures were 
incubated with cells. The time dependent increase in attachment 
was seen with IgG but not with IgM. When higher concentrations of 
antibody were used attachment decreased but was never completely 
inhibited. In a more recent study Emini et al. (1983a) found that 
only one out of 12 monoclonal IgGs inhibited the attachment of 
radiolabelled poliovirus to HeLa cells under non-saturating but 
neutralizing conditions. Also poliovirus neutralized by 
monoclonal antibody that did attach also penetrated the cells. 
Emini et al. (1983a) found that polyclonal IgG failed to prevent 
the attachment of poliovirus but inhibited penetration. It is 
proposed that the VAS of picornaviruses is located in a pocket
2.5 nm deep on the surface of the protomer (Rossmannet al., 1985; 
Hogle et al., 1985). This region is not immunogenic on the intact 
virus and an antibody molecule with Fab arms 3.5nm in diameter 
would have difficulty in gaining access to this region, as its 
entrance would be blocked by the residues on the rim of the 
pocket. This topography could permit the virus to retain it3 
ability to seek out its specific CRU despite neutralizing 
antibody being bound to other regions on the capsid; thus 
reconciling the observations of neutralizing virus binding. In
studying the neutralization of another picornavirus, human 
rhinovirus-14 (HRh-14), it was found that only one out of eight 
monoclonal antibodies inhibited the attachment of [35s]-labelled 
virus (R.J. Colonno, unpublished data). However the degree of 
neutralization of HRh-14 has been found to be dependent on the 
antigenic region to which the antibody associates (Sherry and 
Rueckert, 1985) suggesting the possible utilization of different 
mechanisms for neutralization.
Transmissible gastroenteritis virus (TGEV) neutralized to 
more that 99.99% by either polyclonal slgA or IgG attached to 
swine testis cells or pig kidney cells (Nguyen et al. , 1986). 
Neutralizing slgA also increased the attachment of virus compared 
to that of non-neutralized virus.
Schlegel and Wade (1983) drew attention to another possible 
outcome of the interaction of neutralized virus to cells. 
Neutralized VSV attached to host cells via novel (lipid) 
receptors not used by non-neutralized VSV. The rate of attachment 
of neutralized VSV was equivalent to or greater than that 
observed for infectious VSV.
The binding of neutralized influenza virus to erythrocytes 
was inhibited by neutralizing IgG although the same neutralized 
virus bound normally to CEF cells (Possee, 1981) Possee and
Dimmock, 1981).
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Haemagglutination inhibition (HI) forms a useful index of 
immunity to infection (Hobson et al., 1972), however, HI and 
neutralization are not exclusive. Haemagglutination of influenza 
virus A/duck/Hokkaido/5/77 (H3N2) was not inhibited by 
neutralization positive sera of mice and ducks (Yoden et al., 
1982). Kida et al. (1982) demonstrated that efficient 
neutralization of influenza A/seal/Massachusetts/1/80 (H7N7) with 
concomitant lack of HI activity. These results could indicate 
that the CRUs on susceptible cells and erythrocytes differ in 
topography and interaction with virus and that erythrocytes may 
be a poor model for infection (section 3.1). Glycophorin A 
molecules (which carry CRUs for influenza virus; section 3.1) on 
the erythrocyte surface lie amongst a web of carbohydrate. 
Carbohydrate structures reach to a distance of 15nm from the 
bilayer membrane and allowing for the possibility of free random 
coiling of the peptide portions of the membrane glycoproteins 
this layer may perhaps reach a thickness of 50nm (Viitala and 
Jarnefelt, 1985). The carbohydrate cover therefore may constitute 
an obstacle to close contact, a situation that may not be 
reflected on the surface of susceptible cells allowing 
neutralized virus to attach (Possee, 1981, Possee and Dimmock,
1981). It was concluded that neutralisation of infectivity in 
such cells was due to the impairment of a post attachment event. 
There are twelve regions (antigenic sites) on the influenza H3 HA 
trimer to which neutralizing antibody may bind (section 2.2). The 
VAS is located at in a pocket (section 2.2) at the tip of each 
monomer (i.e. three VAS3 per HA spike). This region i3 not
immunogenic on the native influenza virus particle. In the same 
manner described for the VAS of picornaviruses this region is 
inaccessible to the Fab' arms of IgG and possibly when 
neutralizing IgG is bound to the HA is inaccessible to the CRUs 
on erythrocytes, but not the CRUs on susceptible cells.
There are discrete functional domains on the reovirus sigma 
1 protein (Spriggs et al., 1983) and it has been found that some 
neutralizing monoclonal IgGs neutralise infectivity but do not 
inhibit viral haemagglutination both properties of sigma 1. 
Monoclonal antibodies with the reciprocal properties were also 
found. Anti-G2 antibody can inhibit the haemagglutination of LAC 
virus despite the fact that G1 is the attachment protein and 
anti-G2 does not neutralize (Kingsford and Hall, 1983). The 
effect is probably due to a steric blocking of the binding sites 
for erythrocyte CRUs on the Gl. A similar situation has been 
described for influenza virus by Webster et al., (1982) who 
proposed that the HI activity associated with an antibody to NA 
was due to the steric blocking of sites on the HA. Anti-NA did 
not neutralize infectivity.
The attachment of neutralized virus to cells should not be 
confused with the well documented phenomenon of antibody 
dependent enhancement (ADE) of infection in certain cells 
(Hawkes, 1964). This can be due to an interaction between virus 
particles coated with sub-neutralizing concentrations of antibody 
and homologous Fc receptors on the surface of susceptible cells
(Halstead and O’Rourke, 1977; Halstead, 1980). A combination of 
antiviral antibody, complement, and receptors for components of 
the complement system on cells can also lead to ADE (Cardosa et 
al.. 1983).
ADE has been extensively studied in flaviviruses. The ADE of 
dengue and West Nile viruses is due to the presence of 
sub-neutralizing concentrations of IgG in association with cells 
of the monocyte/macrophage lineage (Halstead and O'Rourke, 1977) 
which are rich in Fc receptors. ADE has been reported with other 
viruses apart from flaviviruses, including some bunyaviruses, 
alphaviruses, reoviruses and coronaviruses (Review: Porterfield 
and Cardosa, 1984). King et al. (1984) demonstrated ADE of rabies 
virus infection in mouse macrophages and the antibody mediated 
rabies "early death” phenomenon in mammals (Prabhaker and 
Nathanson, 1981) may be a manifestation of ADE.
It was reported that enhancement could be produced in BHK-21 
cells infected with the alphavirus, Getah virus (Kimura et al., 
1981). However these observations were not confirmed in a number 
of experiments comparing interactions of viruses with macrophages 
and BHK-21 cells (Porterfield and Cardosa, 1984). There is no 
evidence that macrophages contribute to the attachment of 
neutralized influenza virus to CEF cell monolayers (Dimmock et
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al., 1984).
9.2.2. Neutralization mechanisms after attachment.
If attachment is not inhibited by neutralizing antibody loss 
of infectivity must be due to the inhibition of a subsequent 
stage of infection.
The uncoating of enveloped virus in endosomes involves 
destabilization via conformational changes in the external 
proteins sufficiently to release the virus genome into the 
cytosol (Review: Marsh, 1984). Such an endosomal step is involved 
in the entry pathway of West Nile virus (WNV) (an enveloped 
flavivirus) into macrophages (Gollins and Porterfield, 1935). 
Neutralized WNV is taken up into vesicles but neutralizing 
antibody inhibits endosomal fusion. (Gollins and Porterfield, 
1986) .
It i3 becoming apparent that neutralizing antibodies can 
interact with poliovirus in many different ways (Mandel, 1967, 
1976; Icenogle et al., 1983; Brioen et al., 1983; Thomas et al., 
1985; Brioen et al., 1985). Investigating further his 
observations that neutralizing polyclonal IgG failed to inhibit 
attachment, Mandel (1976) found that neutralizing antibody 
induced a conformational change in the poliovirus capsid protein. 
IgG, IgM, and Fab' fragments from IgG induced a conformational 
transition from state A with an isoelectric point (pi) of 
approximately 7 to state B with a pi of approximately 4.5.
Poliovirus is stabilized in state B by antibody and was not 
infectious. This transition could be mediated by a single 
neutralizing antibody. The change in conformation associated with 
the shift in pi still allowed the virus to attach to cells and 
penetrate but the neutralized virus was resistant to uncoating. 
Another manifestation of this alteration may be the enhanced 
affinity for binding to host cell receptor (Mandel, 1967). 
Substantial conformational changes also occur in the 
neutralization of another picornavirus, bovine enterovirus 
(Carthew, 1976) resulting in the exposure of VP4.
Recent studies with monoclonal antibodies (Emini et al., 
1983a; Icenogle et al., 1983; Brioen et al., 1985) have 
illustrated that not all neutralizing antibodies induce 
conformational changes in poliovirus. Icenogle et al. (1983) 
described a monoclonal antibody (F7.12) which gave first order 
neutralization kinetics but required an average of 4 bound 
[l 25x]-labelled F7.12 IgG molecules per virus particle to 
neutralize the virus efficiently. However this could be 
reconciled by a "one of four sites critical" model of 
neutralisation as well as a step-wi3e model (where infectivity is 
reduced as each antibody binds). It was determined that 
bivalent binding of monoclonal antibody F7.12 molecules was 
necessary. Papain digestion of F7.12 IgG bound to virus produced 
Fab fragments and restored infectivity, but not through 
dissociation of binding as addition of anti-Fab' IgG caused 
re-neutralization. It was suggested that the infectivity of
poliovirus was reduced by a cross-linking of virus protomers 
which inhibited the dissociation of pentamers (Rueckert, 1976) 
that occurs in uncoating. However Brioen et al. (1983) and Thomas 
et al. (1985) have found that the neutralization of poliovirus 
brought about by a monoclonal antibody IgG (35-lf4) was due to 
virus polymerization (aggregation). Monoclonal antibody 35-lf4 in 
contrast to monoclonal antibody F7.12 was incapable of stable 
bivalent binding to a single virus particle. [3H]-labelled 
monoclonal antibody 35-lf4 was never found in association with 
monomeric virus particles. Virus aggregates released by papain 
were fully infectious. Monoclonal antibody 35-fl4 failed to 
induce any pi shift. Emini et al. (1983a) demonstrated that 
neutralization-associated pi shift and neutralization via Fab7 
fragments were dependent on which capsid protein antibody/Fab' 
was attached to. The neutralization and shift in pi accompanied 
by the binding of IgG to VP1 was reversed by papain digestion. 
However, neutralization by anti-VP3 IgG (which did not cause a 
change in pi) was not reversed by papain digestion.
Six out of seven monoclonal antibodies to poliovirus type 1 
did not prevent attachment or penetration but all prevented 
transcription (Emini et al., 1983a). Neutralization mediated by 
the monoclonal antibodies was associated with a change in the pi 
of the virus, however bivalent attachment to the virus was 
essential for neutralization by the monoclonal antibodies. 
Therefore these observations support the mechanism of poliovirus 
neutralization proposed by Mandel (1976) that neutralization
causes conformational changes in the capsid which prevents 
uncoating.
In assays performed at low ionic strength another mechanism 
of neutralization of poliovirus by monoclonal antibody 35-lf4 was 
observed (Brioen et al., 1985). At physiological ionic strength 
monoclonal antibody 35-lf4 neutralized poliovirus by 
antibody-mediated polymerization (see above) but at low ionic 
strength neutralization was accompanied by disruption of the 
virus particles to non-infectious empty capsids devoid of 
antibody. The empty capsids resembled those formed by thermal 
dénaturation of native poliovirus in their sedimentation 
coefficients, antigenicity (resultant particles no longer 
expressed the epitope recognized by monoclonal antibody 35-lf4) 
and pi (6.3). Therefore at low ionic strength monoclonal antibody 
35-lf4 follows a "hit and run" mechanism of neutralization.
Possee et al. (1982) demonstrated that virion RNA from 
neutralized influenza virus accumulated in the nuclei of CEF 
cells at the same rate as that of non-neutralized virus. The 
similarity in the kinetics of migration of the RNA from the 
cytoplasm fraction of the cell to the nuclear compartment 
suggested that neutralized and non-neutralized influenza virus 
follow the same route. Transcription of viral RNA was not 
detected in cells inoculated with neutralized influenza virus and 
in vitro studies with monoclonal antibodies showed that
the activity of the viral transcriptase was impaired
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by neutralization. It was suggested that the binding of a 
neutralizing antibody to the HA initiates a signal possibly via a 
conformational change which is transmitted across the envelope 
via the transmembrane segment of the HA2 to the transcriptase. 
However, the drop in transcriptase activity (three to tenfold) 
was not in proportion to the 99.99% neutralization achieved. 
Similarily neutralizing antibody had little effect on messenger 
RNA primed transcription (R.Rigg and N.J. Dimmock, unpublished 
data). However inhibition of transcription ir; ijtro was dependent 
on intact virus particles, as addition of antibody after virus 
had been treated with detergent did not result in inhibition of 
transcription (A.S. Carver and N.J. Dimmock, unpublished data).
The situation that neutralizing antibody does not inhibit 
the attachment, penetration or transport of the influenza virus 
RNA to the nucleus does not preclude the possibility that an 
infectious process such as uncoating is defective. Recent 
evidence suggests that there is a second uncoating step 
(Bukrinskaya et al., 1982) in which M is removed from the viral 
core. This could be inhibited by neutralizing antibody resulting 
in delivery of a core which is unable to release its genome in a 
state suitable for transcription (R. Rigg and N.J. Dimmock, 
unpub1ished data).
Conformational changes mediated by the binding of an 
antibody to a virus have been implicated notably in the
neutralization of bovine enterovirus (Carthew, 1976) and 
poliovirus (Mandel, 1976; Emini et al., 1983a,b). However, the 
involvement of antibody-mediated conformational changes in the 
neutralization of influenza virus involves the further concept 
that antibody binding to an external protein (the HA) affects the 
processes dependent on internal viral proteins.
The ability of antibody to mediate conformational changes in 
antigens is well documented. Antibody has been observed to cause 
structural alterations in enzymes which in turn can effect enzyme 
activity (Rotman and Celada, 1968; Zimmerman et al., 1971; 
Erickson, 1974). Proteins are in a perpetual state of motion, so 
that conformation of a particular molecule cannot be specified 
absolutely except as an average of a multitude of available 
conformations, and it is convenient to visualize them as minature 
mechanical devices (Review: Cooper, 1980). In simplistic terms 
when the size of an IgG or IgM molecule is considered it is not 
difficult to envisage a conformational change in the antigen to 
which it binds. An IgG molecule has dimensions not much less than 
that of the HA of influenza virus (Figures 7.1.1; 7.1.2). 
Competitive binding radioimmunoassays on isolated influenza virus 
HA showed that the binding of certain monoclonal antibodies 
increased the binding of other monoclonal antibodies to different 
epitopes due to conformational changes within the HA (Lubeck and 
Gerhard, 1982). An enhancement effect of some monoclonal 
antibodies on the binding of other monoclonal antibodies was 
observed in studies on the interaction of antibody with the major
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surface glycoprotein of VSV (Lefrancois and Lyles, 1982). The 
reason for the increased attachment of antibody was probably the 
result of allosteric modifications of the glycoprotein induced by 
the binding of the first monoclonal antibody.
In considering a mechanism of neutralization of influenza, 
an aberration of secondary uncoating or an effect on 
transcription could conceivably occur only if a conformational 
change due to the binding of neutralizing antibody is transmitted 
into the viral core. Many properties of proteins, including 
regulation of their activity depend on transmission of 
conformational changes between distant sites (Review: Cooper, 
1980). However little is known about the detailed mechanisms of 
these processes. Studies of the conformational changes in insulin 
molecules (Chothia et al., 1983) demonstrate that because of the 
packing of alpha helices the extent to which a conformational 
perturbation can be accomodated locally is limited (to shifts of 
no more than 0.15nm). This limit to the dissipation of helix 
movements propagates the transmission of conformations over long 
distances through the molecule. The transmission of 
conformational changes along in the insulin molecule can even be 
amplified. Although individual proteins have individual 
mechanisms of function these ideas of transmission due to helical 
backbone rigidity should generally apply to conformational 
changes (including allosteric transitions) in proteins and such a 
process may occur on the binding of neutralizing Igb to influenza
HA.
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9.2.3. Cooperative neutralization
Studies with neutralizing monoclonal antibodies have 
highlighted the phenomenon of cooperative neutralization where 
the binding of two monoclonal antibodies results in a greater 
loss of infectivity than the combined individual effects. 
Enhanced neutralization of LAC virus (Kingsford and Ishizawa,
1984) resulted from the cooperative binding of two monoclonal 
antibodies to different epitopes on Gl. However unlike the 
synergistic binding of monoclonal antibodies observed with 
monoclonal antibodies to influenza HA by Lubeck and Gerhard 
(1982.) there was no increased binding of one antibody due to the 
presence of the other. It was suggested that the increased 
neutralization resulted from conformational changes in the virus 
protein as these monoclonal antibodies did not significantly 
reduce attachment. Russell (1986) demonstrated that the binding 
of monoclonal antibodies to different epitopes, HN-1 and HN-2 on 
the HN of NDV (Ulster) resulted in cooperative neutralization. 
These results paralleled those observed with LAC virus (Kingsford 
and Ishizawa, 1984) in that neither monoclonal antibody to the HN 
enhanced the binding of the other. After finding that 
sialidase-treatment of cells increases the neutralization of NDV 
(Ulster) the method of neutralization was thought to be 
cooperative interference of viral attachment via HN-1 or HN-2. 
However it is not known whether the interference resulted from 
steric hindrance of attachment or induction of a conformational
change in the HN.
9.3. Conclusion.
In view of the different mechanisms of neutralization 
observed with monoclonal antibodies to HSV, LAC virus and 
poliovirus it is inferred that the mechanism of neutralization in 
the natural animal host will depend on the affinity, abundance of 
the class of immunoglobulin and relative abundance of antibody 
within a class to any particular antigenic site. Neutralization 
by polyclonal sera is likely to be a sum of a number of different 
types of neutralizing mechanisms.
The different mechanisms of viral neutralization are 
dependent on the interactions between virus, antibody and cell. 
It is becoming apparent that neutralising antibody may affect any 
of the early events in virus infection. The lack of a general 
mechanism for the neutralization of viruses by antibody may be 
paralleled by the inhibition of infection of other pathogens by 
antibody. For example, different IgGs to the circumsporozoite 
protein of the protozoan Plasmodium faluipei'jm (the malarial 
parasite) exert their protective effect on the sporozoite stage 
of the parasite at three points: attachment to liver cells, entry 
into the cells, and when penetration was not inhibited some 
antibodies effected the subsequent intracellular development of 
the parasites (Mazier et al., 1986).

10.1. Viruses
The avian strain of influenza virus A/fowl plague/Rostock/34 
(H7N1) (FPV/R) was grown in the allantoic cavity of 11 day old 
embryonated hen eggs and incubated for 22h at 37»C. Allantoic 
fluid was collected after chilling the eggs at 4°C overnight, 
clarified by low speed centrifugation and snap frozen in dry 
ice/ethanol before storage at -70°C. This was used as inoculum. 
The avian influenza virus A/fowl plague/Dutch/27 (H7N7) (FPV/D) 
and the reassortant influenza virus A/V31/83 (H7N2) (V31) were 
also grown using this method. V31 had been obtained by 
co-inoculating CEF monolayers with a mixture of FPV/R and 
influenza A/X49 (H3N2) using the method of Rott et al. (1976) 
described in section 10.15. A/X49 is reassortant human strain and 
as such was grown in eggs for 48h at 33°C. A/WSN (H1N1) was a 
gift from L. McLain (Warwick).
The infectivity of FPV/R and V31 were determined by plaque 
assay on primary chick embryo fibroblast (CEF) cell monolayers 
under 0.9% agar in 199 medium (Flow Laboratories, Irvine, U.K.), 
containing 5% newborn calf serum (NCS) (Gibco-BRL Ltd., Paisley, 
Ü.K.), and expressed as plaque-forming units (PFU)/ml (Dimmock 
and Watson, 1969). Cell monolayers were incubated at 37°C for 3 
days before staining for plaques with 0.02% neutral red (Flow 
Laboratories) in phosphate buffered saline (PBS). Influenza virus 
A/WSN required the replacement of NCS with 0.1% BSA and the
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addition of DEAE/dextran to 0.01% in the overlay medium.
The haemagglutination titre of influenza virus was assayed 
by making doubling dilutions in PBS and adding chicken
erythrocytes to 0.5% (Borland and Mahy, 1968). This is equivalent 
to 7.3 x 106 erythrocytes per well. The titre was determined by 
estimating the 50% end-point between full agglutination and zero 
agglutination after 30 minutes at room temperature. Titre was 
expressed as "haemagglutination units" (HAU).
Semliki Forest virus (SFV) was a gift from A.D.T. Barrett 
(Warwick). Infectivity was assayed by plaque assay on CEF cell 
monolayers under 0.9% agar in 199 medium with DEAE dextran at 
0.04%. Cell monolayers were incubated for 2 days at 33°C.
10.1.1. Purification of influenza virus grown in eggs.
The procedure used was essentially that of Kelly and Dimmock 
(1974). Allantoic fluid harvested from the embryonated eggs was 
clarified by low speed centrifugation and then the virus was 
pelleted at 75,000g for 90 min at 4°C. After soaking in PBS for 
18h the pellets were resuspended, residual cell debris removed by 
low speed centrifugation and the virus suspension loaded onto a 
60 ml 15-45% (w/v) linear sucrose gradient in 1 raM Tris-HCl, 150 
mM sodium chloride (pH 7.4) (TBS). After centrifugation at 
60,OOOg for 90 min at 4°C the visible virus band was harvested,
diluted in PBS and loaded onto a 30 ml 30-70% (w/v) linear 
sucrose gradient in TBS. Following centrifugation at 60,000g for 
18h at 4°C the virus band was harvested and virus particles were 
pelleted at 75,000g for 90 min at 4°C before resuspension in PBS. 
Purified virus was kept frozen at 70°C.
Purified influenza virus B/Lee/40 was a gift from N.J. 
Dimmock.
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10.2. Cells.
Baby hamster kidney (BHK-21) (Flow Laboratories) cell
monolayers were cultivated in roller bottles in Glasgow minimum 
essential medium (GMEM) (Gibco-BRL Ltd.) supplemented with 100 U 
penicillin, 100 ug streptomycin sulphate, and 0.295 mg tryptose 
phosphate per ml. and 5% vol/vol NCS (Gibco-BRL Ltd. ). When 
confluent, cells were removed by trypsinization (0.05% wt/vol 
trypsin, 0.02% wt/vol versene in PBS) and reseeded in roller 
bottles or in 5 mm diameter Nunclon plastic Petri dishes 
(Gibco-BRL Ltd. ) to give a concentration of 6 x 10® cells per 
dish.
Primary CEF cells were prepared as described by Morser et 
al., (1973), seeded at 9 x 10« cells per dish or at 2 x 10« 
/200ml in roller bottles (in preparation for radiolabelling of 
FPV/R; section 10.3). CEF cells were stored under liquid nitrogen
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since different preparations vary in their ability to take up 
virus at 4°C (Stephenson et al., 1978) and were always screened 
for this attribute before use in experiments. CEF suspension was 
pelleted by low speed centrifugation and resuspended in 199 
medium /20% NCS/10% dimethyl sulphoxide at a concentration of 8 x 
107 cells/ml. Two ml aliquots in freezing vials were chilled at 
20° C for 2 h then at - 70<>C for 16 h before long term storage 
under liquid nitrogen. Cells were revived rapidly by thawing at 
37°C and then incubating in 199 medium containing 10% NCS which 
was renewed after 2 h and 8 h.
L»9 2 9 cells (Flow Laboratories) and Human foreskin 
fibroblasts (HFF-4) (Flow Laboratories) were cultivated in glass 
bottles containing GMEM (Gibco-BRL Ltd.) supplemented with 
non-essential amino acids (GMEM-NEAA) containing 10% v/v newborn 
calf serum. Cells were trypsinized (as described above) until the 
cells were detached. The L929 cells and HFF4 cells were seeded 
into plastic Petri dishes at 1 x 10® and 1 x 107 cells per dish 
respectively.
10.3. Radiolabelling and purification of 
[**P]-labelled influenza virus.
[32p]-labelled FPV/R was prepared in roller bottles
containing 2 x 10® CEF cells (Crumpton et al., 1978). Monolayers 
were washed with warm saline and incubated in phosphate-free 199
medium containing 5% dialyzed NCS for 24h before infecting with 
FPV/R at a multiplicity of 0.1 PFU/cell. After lh the inoculum 
was removed, the cells washed with saline and 70 ml medium 
containing 10 mCi [*2P]-orthophosphate (Amersham International 
pic, Amersham, U.K.) added; incubation was continued for 20h. 
Tissue culture fluid was then clarified by centrifugation at 
1000g for 10 min at 4°C and [®2P]-labelled virus was precipitated 
from tissue culture fluid on ice with 60% saturated (NH4)2 SCU 
and purified by sucrose velocity centrifugation (Dimmock et al., 
1977) except that no unlabelled carrier was added. Firstly, after 
centrifugation at 20,000g for 20 min the virus pellet was 
resuspended in 3 ml PBS and loaded onto a 60 ml 15-45% (w/v) 
linear sucrose gradient in TBS containing 0.1% BSA. Following 
centrifugation at 90,000g for 90 min at 4°C, the gradient was 
fractionated into 2 ml aliquots and assayed for HAU titre and 
radioactivity. Where these activities formed a coincident peak 
the fractions were pooled. The virus contained in this pooled 
peak was diluted in PBS and precipitated with (NHO 2SO4 on ice 
with fetuin (Gibco-BRL Ltd.) (as a carrier), pelleted at 20,000g 
and dialyzed for 18h against PBS. Preparations were assayed for 
infectivity and HA. Virus was stored at - 70°C until use.
10.3.1. Radiolabelling and purification of SFV.
SFV was radiolabelled with [*2 P]-orthophosphate in roller 
bottles of BHK-21 cell monolayers. Cells were phosphate starved
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by incubating in phosphate-free GMEM, 1% dialyzed NCS for 18h at 
37°C before infection with SFV at a moi of 0.1. After 2h at 33°C 
the inoculum was removed and 50ml medium containing 10 mCi 
[32P]-orthophosphate was added. Incubation was continued for 18h 
at 33°C. Tissue culture fluid was clarified by centrifugation at 
lOOOg for 10 min at 4°C. Virus was pelleted at 75,000g for 4h. 
After soaking in PBS for 18h the virus suspension was loaded onto 
a 24 ml 15-45% (w/v) linear sucrose gradient in TBS. After
centrifugation at 60,000g for 90 min at 4°C the visible virus 
band was loaded onto a 20-50% (w/v) linear sucrose gradient in 
TBS. Following centrifugation at 60,000g for 18h at 4°C the virus 
band was harvested and virions pelleted at 75,000g for 90 min at 
4°C before resuspending in PBS.
10.4. Estimation of the number of surface projections 
on FPV/R particles using an electron microscope.
The actual number of spikes cannot normally be counted in 
any electron micrograph of a negatively stained virus particle 
even when it is possible to resolve spikes over the whole visible 
surface of the particle since many of the spikes are 
superimposed. Assuming that influenza particles are roughly 
spherical (section 1.2; Figure 13.0.1) the number of spikes can 
be determined by measuring the mean spacing between the spikes 
and assuming that each spike is surrounded by six others (Tiffany 
and Blough, 1970b; Figures 13.0.2 to 13.0.5). This method of
calculation has the advantage that no very extensive array of 
spikes need be visible; i.e. the interspike spacing was measured 
in regions where the spikes were seen end on and not around the 
periphery (Tiffany and Blough, 1970b).
Mixtures of 109 nm diameter latex beads (Dow Latex, Serva 
Frienbiochemica, Heidelberg, Federal Republic of Germany) and 
FPV/R particles were used in a ratio of 5:1 and negatively 
stained with 1% sodium silicotungstate (Agar Aids, Stanstead, 
U.K.), pH 6.5. The standard deviation of the diameter of the 
latex beads was given as +/- 2.7nm. The mean diameter of the 
FPV/R particles and the interspike separation was determined 
(section 13.1). These measurements were used to calculate the 
mean number of spikes per particle (section 13.1).
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10.5. Estimation of the proportion of 
haemagglutinin (HA) and neuraminidase (NA) spikes.
400.5 ug (1.4 x 105 HAU) of FPV/R was analyzed by 
SDS-polyacrylamide gel electrophoresis (section 10.6). This 
amount of protein was required in order to obtain bands dense 
enough to produce measurable deflections on a Joyce-Loebl 
densitometer when the protein was stained with coomassie 
brilliant blue R-250 (Sigma London Chemical Co., Poole, U.K.). By 
scanning the bands at 620 nm and measuring the area (mm2) under 
the peaks the relative proportions of the HA and NA were 
estimated (Skehel and Schild, 1971). Coomassie blue-BSA (from 5
to 200 ug protein) complexes on a SDS-polyacrylamide gel (section/
10.6) gave a linear plot of the area under peak against ug 
protein and followed Beers law. Relative concentrations within a 
mixture of proteins can be evaluated to an accuracy better than 
+/- 3% (Fazekas de St. Groth et al., 1963).
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10.6. Polyacrylamide gel electrophoresis.
Proteins from purified virions or purified immunoglobulins 
were analyzed by the Laemmli system of sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 
1970). Final acrylamide concentrations in separating and linear 
gradient gels are detailed where pertinent. Samples were reduced 
by boiling for 5 min in 2% w/v SDS (BDH Chemicals Ltd. Poole, 
U.K.), 5% w/v beta mercaptoethanol, 5% w/v glycerol, 1.25 x 10-* 
% w/v bromophenol blue in 10 mM Tris/HCl (pH7.4). For 
investigation of multichain complexes samples were 
electrophoresed without reduction by substituting 10 mM 
iodoacetate for the beta mercaptoethanol in the solubilizer 
buffer. Electrophoresis was carried out until the bromophenol 
blue reached the bottom of the gel. Coomassie Brilliant Blue R 
(0.025%) in 50% (w/v) methanol, 5% (v/v) acetic acid was used to 
locate protein bands after electrophoresis.
10.7. Isolation of immunoglobulin G (IgG) from serum or ascites.
The source of polyclonal IgG was hyperimmune rabbit serum. 
The samples of antiserum to the HA (H7) of FPV/R were gifts from 
R.D. Possee and A.S. Carver. These had been raised in rabbits by 
inoculation with FPV/D (H7N7) which has an HA antigen which is 
very closely related to that of FPV/R and an antigenically
unrelated NA. 10* HAU of purified FPV/D were injected 
intravenously at days 1 and 22 (boost) and serum obtained by 
bleeding at 5,6, or 7 days post-boost. Sera from three rabbits 
designated WR6; WR26; WR45. Subsequent experiments used WR6 and 
WR45 sera from day 6 post-boost and WR26 from day 7 post-boost. 
Latterly a reassortant influenza virus (section 10.15) A/V31/83 
(H7N2) (V31) was used in the same manner to produce hyperimmune 
sera specific for the HA of FPV/R (sera designated WR69; WR70; 
subsequent experiments using sera from days 6 and 7 post-boost 
respectively). All detectable antibodies to type specific 
antigens NP and M protein were removed from sera by absorption to 
ether disrupted A/X49 (H3N2) when required.
Antiserum specific for FPV/R neuraminidase (NA) was a gift 
from A.S. Carver. This had been raised in rabbits by the 
inoculation with influenza A/chicken/Scotland/59 (H5N1) which has 
a NA antigen very closely related to the NA of FPV/R but a 
unrelated HA. Ascitic fluid containing neutralizing murine 
monoclonal IgG to H3 HA (the preparation was designated 171/1) 
was a gift from R.G. Webster, St. Jude Childrens’ Research 
Hospital, Memphis, TN, U.S.A. Antisera specific for N2 was a gift 
from A.S. Carver. This was rabbit hyperimmune sera against a 
recombinant influenza virus (H1N2) from a reassortment between 
influenza virus A/NWS (H1N1) and A/Japan/57 (H2N2) which has a NA 
antigen related to that of A/X49.
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Ascitic fluid containing the neutralizing murine monoclonal
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antibodies to FPV/R HA (designated: HC2; HC10; HC58; HC61, all 
IgG) were kindly provided by A.R. Douglas and J.J. Skehel 
(N.I.M.R., London, U.K.). Rabbit and mouse IgG were purified by 
affinity chromatography on a column of protein A-Sepharose CL-4B 
(Sigma). 1ml of antiserum or ascitic fluid was added to the 
column and passed through seven times with 10 mM Tris-HCl 150 mM 
sodium chloride (pH8) (binding buffer). The column was then 
washed with binding buffer until negligible protein eluted (as 
judged by measuring absorbance at 280 nm). Bound IgG was eluted 
with 0.6% sodium acetate in 150 mM sodium chloride (pH3). 
Fractions were promptly adjusted to pH7 with 1M sodium hydroxide. 
The extinction coefficient (E l%/280) value used for calculating 
the concentration of mouse and rabbit IgG was 13.5 (Schultz and 
Heremans, 1966). The number of IgG molecules was determined using 
this extinction coefficient and a molecular weight (MW) for 
rabbit and mouse IgG of 150,000 (Kirschenbaum, 1973, Nisonoff et 
al., 1975) (Avogadro constant = 6.022 x 102* /mol).
Purified IgG was stored at " 70°C. Pre-immune IgG (plgG) was 
prepared from pre-immunization sera. Non-specific monoclonal IgG 
was used as control plgG in experiments involving monoclonal IgG.
10.8. Preparation of IgG fragments
Mouse monoclonal IgG purified from HC2 ascites fluid was 
used as a source of F(abJ)2 and Fab' fragments. IgG was mixed


Figures 10.1.1 to 10.1.2. SDS-PAGE analysis of affinity purified IgG (section 10.7) and IgG fragments (section 10.8). The samples 
were electrophoresed on the gels (10-30% polyacrylamide) in 
non-reducing solubilizer buffer (section 10.6). The lanes carring 
IgG fragments also contained cytochrome C (12,384 MW). The gels 
were stained for protein with Coomassie Brilliant Blue.
Figure 10.1.1. Lane a cytochrome C (12,384 MW) and dimer; lane b 
mouse IgG (150,000 MW); lane c F(ab')2 (120,000 MW).
Figure 10.1.2. Lane a cytochrome C (12,384 MW) and dimer; lane b 
mouse IgG (150,000 MW); lane c sample before purification on 
protein A column after treatment with pepsin containing IgG, 
F(ab')2 and Fc fragments; lane d Fab' (50,000).
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with pepsin (Sigma) at a ratio of 1:25 (w/w). The IgG pepsin
mixture was incubated at 37°C in 70 mM acetate buffer (pH4.1) 
for 16h, after which time the mixture was neutralized with 2 M 
sodium hydroxide. The resultant mixture of F(ab' ) 2  and Fc 
fragments was applied to a protein A-Sepharose CL-4B (Sigma) 
column (section 10.7). The F(ab' ) 2  fragments did not bind to the 
column and were collected in the eluate. From 1.2 mg IgG in 1 ml, 
0.67 mg of F(ab')2 fragments was obtained. Fab' fragments were 
obtained from F(ab' ) 2  by partial reduction with 10 mM cysteine 
(Sigma) for 2h at 37 °C. Cysteine was removed by dialysis for 18h 
against 3 changes of PBS. F(ab' ) 2  and Fab' fragments were 
characterized biochemically by SDS-PAGE (Figures 10.1.1; 10.1.2 )
and stored at * 70°C with 0.1 mg/ml cytochrome C (Sigma) as a 
protein carrier. The strong bands seen on the gels demonstrated 
that F(ab' ) 2  fragments (approx. MW 120,000) and Fab' fragments 
(approx. MW 50,000) were obtained with high purity.
10.9. Isolation of Immunoglobulin M
To produce IgM rabbits (2kg half-lops, Hylyne Rabbits Ltd., 
Northwich, U.K.) were injected with 105 HAD of purified V31 
intravenously and serum was obtained daily between days 2 and 9 
post-inoculation. IgM was purified either by affinity
chromatography or gel filtration. Affinity chromatography was 
most suitable for small amounts of IgM, but gel filtration 
yeilded greater quantities (Table 10.1)
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10.9.1. Affinity chromatography purification of IgM.
An affinity column was constructed by coupling goat 
anti-rabbit IgM (Fc) (Nordic Immunological Laboratories Ltd., 
Maidenhead, U.K.) to cyanogen bromide-activated Sepharose (Sigma) 
(Hudson and Hay, 1980). 4ml serum was passed through the column 
seven times with 0.01 M Tris-HCl, 0.15 mM sodium chloride (pH8). 
The column was then extensively washed with the same buffer and 
IgM eluted with 0.6% sodium acetate in 150 mM sodium chloride 
(pH3). Eluted samples were dialyzed overnight against 1 mM 
Tris-HCl, 0.05 M sodium chloride, pH7.4, and then lyophilyzed. 
IgM was characterized biochemically by SDS-PAGE (Figure 10.2) and 
immunologically by immunodiffusion (Ouchterlony ) against 
anti-rabbit IgM (Fc) antibody (Figure 10.6.1), the 
immunoprecipitin line between anti-IgM and the sample well 
confirming the identity of IgM.
IgM purified by affinity chromatography subjected to 
SDS-PAGE through a 5-30% w/v acrylamide gel under non-reducing 
conditions gave a strong band of about 900,000 MW at the expected 
position of the IgM pentamer (Figure 10.2). There was some 
contamination with smaller proteins (possibly breakdown 
products), but immunodiffusion (Figure 10.6.1) demonstrated that 
IgM was the only immunoglobulin present. Serum obtained from 
bleeds 5,6 and 7 produced maximum yields of H7 specific IgM as 
measured by HI. Neutralizing IgM reduced the infactivity of 1.5 x
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Figure 10.2. SDS-PAGE analysis of affinity purified IgM (section 
10.9.1) (45 i^g) Lane a IgM (900,000 MW), smaller MW protein 
contaminants can also be seen; lane b slgA (400,000 MW); and lane 
c rabbit IgG (150,000 MW); The samples were run on the gel (5-30* 
polyacrylamide) in non-reducing solubilizer buffer (section
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
a b c
Figure 10.2. SDS-PAGE analysis of affinity purified IgM (section
10.9.1) (45 fig) Lane a IgM (900,000 MW), smaller MW protein
contaminants can also be seen; lane b slgA (400,000 MW); and lane 
c rabbit IgG (150,000 MW); The samples were run on the gel (5-30% 
polyacrylamide) in non-reducing solubilizer buffer (section
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
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Table 10.1. Purification of immunoglobulins obtained by affinity chromatography* (sections 10.7; 10.9.1; 10.10.1) or gelfiltration 9 (sections 10.9.2; 10.10.2).
» All are from polyclonal sources unless stated. 
b Monomeric IgA was obtained from 0.094 mg purified slgA. 
c Quantities are mean values.
Purified 
antibody *
Origin Cone, per ml 
peak fraction e
Volume
(ml)
Recovery/ml of 
original sample
IgM * rabbit serum 0.037 mg 1.5 M •ft X M 0 1 to mg
slgA * rat bile 0.153 mg 1.5 1.15 X  10-2 mg
monomeric 
IgA *b
slgA 0.077 mg 1 . 0 58%
IgG * rabbit serum 1.42 mg 1.5 1.42 mg
monoclonal 
IgG *
mouse
ascites
1.75 mg 1.5 1.75 mg
IgM @ rabbit serum 0.165 mg 5.5 1.14 x 10-1 mg
slgA ® rat bile 0.388 mg 4.5 8.75 x 10-1 mg
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107 PFU FPV/R by 99%. IgG purified from the identical serum 
source had negligible specific neutralization (less than 30%).
The microimmunodiffusion technique was carried out in 1% 
(w/v) Noble agar in 10 mM Tris 150 mM sodium chloride (pH7.5) on
7.5 x 2.5 cm glass microscope slides. A template defined the 
wells into which 25 ul of 10"1 dilutions of goat anti-rabbit IgM 
and IgG (Nordic Labs.) were placed. A 10_l dilution of sample in 
buffer was placed in the centre well. Antigen and antibody 
preparations diffused in a moist atmosphere for 3 days at room 
temperature. The slides were soaked for 48 h in PBS which removed 
soluble protein. The remaining precipitin bands were stained with 
0.5% Coomassie Brilliant Blue R250 in 50% methanol containing 1% 
acetic acid. Excess stain was removed in the same solvent.
10.9.2. Isolation of IgM by gel filtration.
IgM could also be obtained from serum by gel filtration 
using a Sephacryl S-300 (Sigma) column. A polyethylene glycol 
precipitation step was a useful preliminary procedure. 8 ml 
rabbit serum were dialyzed against 3 changes of 10 volumes of 2 
mM phosphate buffer (pH6) at 4°C. The pH of the serum was brought 
to pH8 with 2 M Tris and the solution was made 6% (w/v) in 
polyethylene glycol 6000 (PEG) (BDH Labs. Ltd. ). After 30 min at 
4°C the sample was centrifuged at 2000g for 10 min at 4°C. The 
precipitate was resuspended using 6% PEG in 10 mM Tris-HCl
Figure 10.3. Isola-tion of IgM from rabbit serum on a Sephacyrl 
S-300 column in TBS, following polyethylene glycol precipitation 
as determined by Aa*o (section 10.9.2). The first peak contained 
IgM, the shoulder of the second peak contained marker (ferritin) 
and smaller contaminants including IgG were eluted after this. 
The bar graph shows the HI titres of all fractions, as determined 
by the assay described in section 10.12. fractions 10, 11 and 12 
were used.
(pH8.0) and recentrifuged. This procedure was repeated once 
again. The final precipitate was dissolved in TBS at room 
temperature. This in turn was centrifuged at 2000g for 10 min at 
4°C and the supernatant retained. This was applied to a 30 cm3 
column of Sephacryl S-300 and eluted with TBS at 4°C. 2 ml 
fractions were collected and the absorbance monitored at 280nm. 
The first major peak was found to contain pentameric IgM. IgG was 
eluted after the peak produced by the marker protein ferritin 
(Sigma). (Figure 10.3). Gel filtration yielded 8 times as much 
IgM as affinity chromatography (Table 10.1).
IgM was stored at 4°C in 0.05% sodium azide. Bovine serum 
albumin (Sigma) (BSA) (to 0.5mg/ml) was added to solutions of low 
IgM concentration (less than 0.1 mg/ml). Pre-immune IgM (plgM) 
was prepared from pre-immunization serum. An E l%/280 of 13.5 was 
used to calculate the concentration of IgM (Metzger, 1970). The 
number of IgM molecules was determined using a MW for rabbit IgM 
of 900,000 (Nisonoff et al., 1975). IgM purified by gel 
filtration was fully classified immunologically by 
immunodiffusion (giving similar results to those with affinity 
purified IgM, Figure 10.6.1) and biochemically by SDS-PAGE (Figure
10.7).
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Gel filtration produced a greater yield of uncontaminated 
IgM than affinity chromatography (Table 10.1). The 
characterization of IgM by SDS-PAGE under reducing conditions 
showed Hmu chain (75,000 MW) and L chain only (Figure 10.7). IgM
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purified by gel filtration was used for enumeration studies.
10.10. Secretory Immunoglobulin A (slgA) from bile.
3 x 105 purified FPV/D suspended in PBS was inactivated with 
0.0025% beta propiolactone (BPL) (Sigma) for 8h at 4°C, after 
which BPL was renewed and the mixture left for a further 24h. The 
virus suspensions were then dialyzed against PBS, and when tested 
in 11 day embryonated eggs, were found to contain no residual 
activity (zero haemagglutination titre). Inactivated virus was 
kept at 4°C until use. 7 x 10s HAU of inactivated FPV/D was 
injected into the Peyer’s patches (PP) of anaesthetized inbred 
male Wistar rats (Wistar/PC61), 10 weeks old and weighing about 
200g each (Hall et al., 1979). The best strategy is to inject the
largest PP carefully just underneath the membrane, being careful 
not to inject into the gut. In this manner approximately 15ul was 
injected into each PP. 7 days after inoculation the bile ducts of 
the rats were cannulated with a nylon catheter (0.94mm external 
diameter; Portland Plastics, Hythe, Kent, U.K.) and the rats 
were confined in Bollman restraining cages (Bollman, 1948). Bile 
was collected over days 7-9 postinoculation and stored at - 20°C. 
The inoculation proceedure was carried out with the practical 
assistance of L. Gyure and J.G. Hall (Institute of Cancer 
Research, Sutton, Surrey, U.K.).
Bile salts were removed by exhaustive dialysis against 0.01M
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tris-HCl buffer and 0.15M sodium chloride (pH7.4), bile was 
concentrated 10-25 fold either on an Amicon B15 filter (Amicon 
Corp., Danvers MA, USA) or in centricon 10 microconcentrators 
(Amioon) by centrifugation at 5000g at 4°C for 70 min. IgG could 
be removed by passing the bile concentrate seven times down a 
protein A-Sepharose CL-4B column to which slgA does not bind 
(Kronvall et al., 1970).
Secretory IgA was purified either using affinity 
chromatography or gel filtration. As with IgM purification, gel 
filtration provided a greater quantity of purified immunoglobulin 
(Table 10.1).
10.10.1. Affinity chromatography purification of slgA.
An affinity column was constructed by coupling goat 
anti-rat alpha chain antibody (Nordic) to cyanogen 
bromide-activated Sepharose (Sigma) (Hudson and Hay, 1980). 2ml 
of bile concentrate was passed through the column in 0.01 M 
Tris-HCl, 0.15 M sodium chloride (pH8). Secretory IgA was then 
eluted from the column with 0.1M ammonium hydroxide and 0.05 M 
diethylamine (pH11.5). Eluted samples were neutralized with HC1, 
dialyzed for 18h against 1 mM Tris-HCl, 0.05 M sodium chloride 
(pH7.4), and lyophilyzed. Purity of slgA was monitored by 
SDS-PAGE (Figure 10.4) and immunologically by immunodiffusion 
(Ouchterlony) against anti alpha-chain antibody (Figure 10.6.2),
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Figure 10.4. SDS-PAGE analysis of purified slgA (section 10.10.1) 
(94 ug) before and after partial reduction with 0.01 M BMK 
(section 10.10.3): Lane b slgA; lane c slgA after treatment with 
BME, monomeric IgA at 160,000 MW and secretory component (Sc) at 
70,000 MW; lane a monomeric IgA obtained after passing the sample 
shown in lane c through an affinity column of anti-alpha chain 
IgG. MW markers are: Lane d rabbit IgG (150,000 MW); and lane e 
transferrin (Trfn) at 80,000 MW. The samples were run on the gel 
(5% acrylamide) in non-reducing solubilizer buffer (section 
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
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Figure 10.4. SDS-PAGE analysis of purified slgA (section 10.10.1) 
(94 ug) before and after partial reduction with 0.01 M BME 
(section 10.10.3): Lane b slgA; lane c slgA after treatment with 
BME, monomeric IgA at 160,000 MW and secretory component (Sc) at 
70,000 MW; lane a monomeric IgA obtained after passing the sample 
shown in lane c through an affinity column of anti-alpha chain 
IgG. MW markers are: Lane d rabbit IgG (150,000 MW); and lane e 
transferrin (Trfn) at 80,000 MW. The samples were run on the gel 
(5% acrylamide) in non-reducing solubilizer buffer (section 
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
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Figure 10.5. Isolation of slgA from rat bile on a Sephadex G-200 
column in 0.1M sodium phosphate (pH 6.8) following removal of 
lipid and concentration of bile (section 10.10.2.). the first 
peak contained slgA and the second and third peaks contained IgG 
and free secretory component (Sc). The bar chart shows the HI 
titres of all fractions as determined by the assay described in 
section 10.12. Fractions 11, 12 and 13 were used.
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Figures 10.6.1 and 10.6.2. Immunodiffusion of affinity purified 
IgM (section 10.9.1) and slgA (section 10.10.1). The 
microdiffusion technique was performed as described in section
10.9.1. Identical results were acheived with IgM and slgA 
purified by gel filtration (section 10.9.2; 10.10.2).
Figure 10.6.1. Goat anti-rabbit IgM and anti-rabbit IgG were 
placed at 10"1 dilutions in TBS in wells a and b respectively. A 
sample of putively purified IgM was placed in the central well, 
c. A precipitin line can be seen between the centre well and well
Figure 10.6.2. Goat anti-rat IgA, goat anti-rat IgG and sheep 
anti-rat IgM were placed at 10-1 dilutions in TBS in wells a, b 
and c respectively. A sample of putively purified slgA was placed 
in the central well, d. A precipitin line can be seen between the 
centre well and well a.
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Figures 10.6.1 and 10.6.2. Immunodiffusion of affinity purified 
IgM (section 10.9.1) and slgA (section 10.10.1). The 
microdiffusion technique was performed as described in section
10.9.1. Identical results were acheived with IgM and slgA 
purified by gel filtration (section 10.9.2; 10.10.2).
Figure 10.6.1. Goat anti-rabbit IgM and anti-rabbit IgG were 
placed at 10"1 dilutions in TBS in wells a and b respectively. A 
sample of putively purified IgM was placed in the central well, 
c. A precipitin line can be seen between the centre well and well
Figure 10.6.2. Goat anti-rat IgA, goat anti-rat IgG and sheep 
anti-rat IgM were placed at 10-i dilutions in TBS in wells a, b 
and c respectively. A sample of putively purified 3lgA was placed 
in the central well, d. A precipitin line can be seen between the 
centre well and well a.
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Purified slgA obtained using an anti-alpha chain affinity 
chromatography retained antiviral activity without loss. By 
non-reducing SDS-PAGE (Figure 10.4), slgA was shown to consist of 
a single protein species (Figure 10.6.2) of MW of approximately 
400,000, as expected (Koshland, 1975; Tomasi, 1976).
10.10.2. Isolation of slgA by gel filtration.
"the immunoprecipitin line between anti-rat IgA and the sample
well confirming the immunological identity of slgA.
Alternatively slgA was purified on a G-200 Sephadex 
(Pharmacia, Uppsala, Sweden) column. Firstly, 16ml of crude bile 
was mixed with 8ml isotonic saline (0.9% w/v NaCl) and 
centrifuged for 1 h at 95,000g at 4°C. The pale green supernatant 
was removed and the pellet discarded. The bile/saline mixture was 
then concentrated ten-fold using centricon microconcentrators. 
2ml of the concentrate was applied to the column and eluted with 
0.1M sodium phosphate buffer pH6.8 at 4°C. 3ml fractions were 
collected and monitored by absorbance at 280 nm. Secretory IgA 
was eluted in the first major peak (Figure 10.5) after a small 
amount of excluded material. Gel filtration yielded 76 times as 
much slgA as affinity chromatography.
An E l%/280 of 13.4 was used to calculate the concentration 
of IgA (Schultz and Heremans, 1966). Secretory IgA produced by
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'this method was characterized by SDS-PAGE (5% acrylamide) under 
non-reducing conditions gave a strong band at 400,000 MW (data 
not shown) in a similar manner to that achieved with affinity 
purified slgA (Figure 10.4). Under reducing conditions (Figure
10.7) slgA purified by gel filtration was separated into Sc, 
Hal pha chain and L chain polypetides. The number of slgA 
molecules was calculated using an estimated MW for rat slgA of 
405,000 (Tomasi, 1976). Secretory IgA purified by gel filtration 
was characterized immunologically by immunodiffusion (giving 
similar results to those with affinity purified slgA, Figure 
10.6 .2 )
Purified slgA was stored at - 70°C. Pre-immune slgA (psIgA) 
was prepared from bile from non-immunized rats.
10.10.3. Preparation of monomeric IgA from slgA.
Monomeric IgA was prepared from purified slgA (obtained by 
affinity chromatography) by differential reduction with 0.01M 
beta-mercaptoethanol (BME) (Sigma) in 0.3M Tris-HCl (pH8) for lh 
at 25°C. After dialyzing for 18h against ImM Tris-HCl, 0.015 M 
sodium chloride (pH7.4), IgA was separated from the secretory 
component (Sc) and J chain by affinity chromatography on a anti 
alpha-chain column (section 10.10.1). The J chain and Sc emerged 
in the void volume and IgA monomers were eluted as before and 
lyophilyzed. IgA (160,000 MW) was characterized by PAGE (Figure
10.4) and by immunodiffusion against anti alpha-chain antibody.
Figure 10.7. SDS-PAGE analysis of sIgA and IgM purified by gel 
filtration (section 10.10.2; 10.9.2). The samples were run on the 
gel (10-30% acrylamide) in reducing solubilzer buffer (section 
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
Lane a BSA (68,000 MW); lane b IgG, gamma H chain (50,000 MW) and 
L chain (25,000 MW); lane c slgA, Sc (72,000 MW), alpha H chain 
(55,000 MW) and L chain (25,000 MW); lane d IgM, mu H chain 
(75,000 MW) and L chain (25,000). The J chains from both slgA and 
IgM were not resolved in this gel system.
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Figure 10.7. SDS-PAGE analysis of slgA and IgM purified by gel 
filtration (section 10.10.2; 10.9.2). The samples were run on the 
gel (10-30% acrylamide) in reducing solubilzer buffer (section 
10.6). The gel was stained for protein with Coomassie Brilliant 
Blue.
Lane a BSA (68,000 MW); lane b IgG, gamma H chain (50,000 MW) and 
L chain (25,000 MW); lane c slgA, Sc (72,000 MW), alpha H chain 
(55,000 MW) and L chain (25,000 MW); lane d IgM, mu H chain 
(75,000 MW) and L chain (25,000). The J chains from both slgA and 
IgM were not resolved in this gel system.
a b e d
BSA
O C
Lch's
titre of theThe HI titre per mg of IgA was never <80% of the 
slgA from which it was derived. J chain (Koshland, 1975) (15,000 
MW) was not detected on the gels.
Purified IgA was stored at - 70°C, with BSA (to 0.5mg/ml) if 
the concentration of IgA was less than 0.1 mg/ml. The 
neutralization activities of bile concentrate (x 20 fold), 
affinity purified slgA, and IgA are shown in Table 10.2. All 
failed to neutralize influenza A/WSN.
Table 10.2. Neutralization of FPV/R influenza virus by bile 
concentrate, purified slgA, and ■onomeric IgA. Percentage 
neutralization (section 10.11) was determined relative to virus 
incubated with the appropriate control (bile concentrate, 
purified slgA and monomeric IgA) obtained from non-immunized 
rats. These gave negligible neutralization.
Percentage neutralization of:
Immune sample : 1 x IO’ PFU 
FPV/R
1 x 107 PFU 
WSN
Bile concentrate 98.5 0
Purified slgA 96.5 0
Purified monomeric IgA 98.5 0
10.11. Neutralization Assays
Influenza virus was incubated with purified immunoglobulins 
or IgG fragments for lh at 25°C in a water bath before assaying 
for residual infectivity on CEF cell monolayers. F(ab ' ) 2  and Fab' 
fragments neutralized FPV/R with about the same efficiency as the 
IgG from which they were derived (Table 10.3). However the Fab' 
underwent dilution dissociation with resulting restoration of 
virus infectivity. When it was necessary to employ a dilution 
step to measure the extent of neutralization (i.e. after 
neutralization of a high titre virus preparation) the virus-Fab' 
complex was incubated with rabbit anti-mouse IgG (Fab' specific) 
(Nordic) This stabilized neutralization before inoculation and 
subsequent assay on cell monolayers.
A neutralization assay was performed in parallel to each 
attachment and penetration assay with each immunoglobulin 
investigated (sections 11.1; 11.2) and the results of the 
neutralization assay is given where pertinent.
In a series of experiments to investigate the importance of 
polyvalency virus neutralized with IgG was reacted with rabbit 
anti-mouse IgG (Fc region specific) (RAM) (Nordic). Neutralizing 
mouse monoclonal IgG (HC2) was incubated with [*2P]-labelled 
FPV/R virus for lh at 25°C and subsequently RAM was added to 5% 
protein w/v in PBS for a further lh at 25°C.
Neutralization was also measured by 50% endpoint titration. 
In this manner the dilution of antibody that reduced a 50-60 PFU 
FPV/R by 50* was determined. This method was used in the
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Table 10.3. Comparison of "the efficiency of neutralisation1» by monoclonal anti-haemagglutinin IgG (HC2) and fragments derived thereof.»
Antibody/
antibody
fragment
Approx. MW
(K)
No. of molecules 
reacted with 
virus'1
Total No. of 
binding sites 
available
% Neutral 
ization
IgG 150 1 x 1013 2 x 1013 99.5
F(ab' )2 120 1 X  IO1 3 2 x IO1 3 98.5
Fab' 50 1 X  10!3 1 X  1013 98.0
• Section 10.8.
b 9 x 107 PFU (which contains 200 HAU).
e Neutralization by incubation with Fab* followed by 5% RAM in 
PBS; equally efficient neutralization is obtained in conventional 
neutralization test (section 10.11) providing there is no 
dilution of the virus-Fab* mixture.
d The number of molecules of antibody or antibody fragments was 
determined using an E l%/280 nm of 13.5, L= 6.02 x 1023 /mol and 
the respective MWs.
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investigation of the kinetics of neutralization. Purified 
monoclonal IgG was incubated with 50-60 PFU at 4 or 25°C for time 
intervals from 0-45 min before inoculation on to CEF cell 
monolayers held at 4°C. Incubation on cell monolayers was for 45 
min before overlaying with 0.9% agar in 199 medium/5% NCS 
followed by incubation for 3 days.
10.12. HA-inhibition (HI) assay.
The titres of anti-HA serum, or purified immunoglobulin were 
determined by making doubling dilutions in 0.25ml volumes of PBS, 
adding 4 HAU virus to each dilution and incubating for lh at room 
temperature. The chicken erythrocytes were added to 0.5% 
(equivalent to 7.3 x 10® erythrocytes per well) and the 50% 
end-point estimated after 30 min as for the HA assay.
10.13.Iodination of Immunoglobulins.
Antibody was iodinated by a modification of the chloramine T 
method (Hunter and Greenwood, 1962). Firstly 15 }il 100 mM 
sulphuric acid and 15 jil 1.5 mM chloramine T (BDH) were mixed 
with 15 i^l potassium iodide and 250 )iCi of sodium [i 25 I ]-iodide 
(Amersham) and left for 30 seconds. After this time 15 jil sodium 
phosphate buffer (pH 7.5) was added, and the mixture was then 
combined with 500 ul antisera containing polyclonal IgG or 500 ul
ascites containing monoclonal IgG. This was left for 2 min before 
being applied to and purified on a protein A sepharose CL-4B 
column (Sigma) as described in section 10.7. The radioactivity in 
the IgG peak was measured and the protein concentration 
determined by absorbance at 280 nm (E l%/280 = 13.5). Purified 
slgA and IgM were also iodinated using the chloramine T method as 
described above except that the sodium phosphate buffer contained 
0.5mg/ml BSA as a protein carrier for the labelled protein. 
Radiolabelled slgA or IgM was separated from unreacted 
[l 25i]-iodide on a 0.5 x 10 cm column of Sephadex G-25 
(Pharmacia) equilibrated in 0.25M sodium phosphate buffer (pH 
7.5) containing 0.5 mg/ml BSA. The column was run until the 
immunoglobulin and the [l 25j]-iodide peaks had been eluted. The 
specific activity of the iodinated antibodies was determined and 
the biological activities of the radiolabelled immunoglobulins 
were assayed by HI and neutralization ability.
10.14. Mapping of monoclonal antibodies to FPV/R to 
non-overlapping epitopes on the FPV/R haemagglutinin 
by the isolation of antibody resistant mutants.
10® PFU FPV/R were incubated in turn with each of the 
monoclonal antibodies (HC2, HC10, HC58 and HC61) for lh at 25°C. 
All monoclonal antibodies were at concentrations that would give 
99.99% neutralization. Aliquots were injected into 11 day old 
fertile hens eggs and incubated for 22h at 37°C. Allantoic fluid
was harvested and examined for the presence of putative resistant 
variants (escape mutants) resistant by HI to the selecting 
monoclonal antibody. Consistent lack of HI indicated that 
particular escape mutant was no longer susceptible to that 
particular antibody. The treated virus was plaque purified then 
incubated again with the selecting antibody (as above) and 
passaged through eggs. This was repeated twice in order to obtain 
stable escape mutants. The resultant HI pattern provided evidence 
of non-overlapping epitopes to which the monoclonal antibodies 
bound.
The ability of polyclonal IgG (WR6, WR45 and WR69) to select 
escape mutants was also investigated in a similar manner. This 
was necessary to determine if the populations of specific IgG in 
the sera were recognizing single epitopes (i.e
"pseudo-monoclonal" in nature) or a 
genuinely polyclonal).
(i.e.range of epitopes
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10.15. Production and characterization of influenza A/V31/83.
Influenza A/V31/83 (V31) (H7N2) is a reassortant 
non-pathogenic fowl plague strain derived from a double infection 
of CEF monolayers with FPV/R and A/X49 (H3N2) conducted according 
to the method described by Rott et al. (1976). CEF cell 
monolayers (1 x 107 ) were co-infected with 3 x 10® PFU of each 
virus in 200 ul PBS for 1 h at 25°C. The inoculum was then 
removed and monolayers were incubated for 15 h at 37°C under 3 ml 
buffered 199 medium. The virus yield was diluted and plated onto 
confluent CEF cell monolayers and incubated for 3 days under an 
agar overlay (section 9.1) containing anti-Nl (FPV/R NA) serum at 
5% v/v. This concentration of anti-Nl serum suppressed the plaque 
formation of virus that contained the homologous neuraminidase. 
Thus the agar selects for virus carrying the H7 HA, against FPV/R 
NA and against H3 influenza viruses which require trypsin for 
infectivity (Klenk et al., 1975).
Dishes with not more than 25 plaques were selected as a 
source of virus clones. The agar and the underlying cells over 
the area of well-isolated plaques were picked with sterile 
Pasteur pipettes, added to tubes containing 1ml 5% BSA in PBS and 
transferred to 11 day old embryonated eggs for the production of 
virus. Before serological tests and further characterization 
virus isolates were purified by a further 3 serial plaque 
passages in the selection media.
The reassortants were then screened for H7 HA with H7 
specific monoclonal and polyclonal IgG and for H3 HA with H3 
specific monoclonal IgG by HI assay (section 10.12).
173
Table 10.4. Biological properties of influenza viruses A/FPV/R and reassortant A/V31.
Strain HA» NAb Plaque
diameter
HAU/ml= PFU/mlc Embryo 
deathd 
at 24h pi
Pathogen
icity«
FPV/R H7 Nl > 2 mm 1024 2 x 109 + N/A
V31 H7 N2 < 1mm 630 3.9 x 108 Alive
» As determined by HI assay (section 10.12). 
b As determined by NI assay (section 10.11).
c Virus activity in allantoic fluids 22h after inoculation of 2 x 10* 
PFU virus.
d Embryos examined after inoculation with 2 x 10* PFU.
• Condition of embryos six days post-inoculation.
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The neuraminidase was examined by neuraminidase inhibition 
(NI) assay. NA and NI assays were carried out using fetuin as a 
substrate. The NA activity of each virus was assayed by 
incubation of 0.lml virus with 0.1 ml fetuin (12.5 mg/ml) in 
sodium phosphate buffer for 1 h at 37®C. Neuraminidase releases 
N-acetylneuraminic acid from the fetuin which was measured using 
the colorimetric assay developed by Aminoff (1961). The NI assay 
measured residual NA activity in virus-antiserum mixtures after 
incubation at 25 ®C for 1 h. Before use in the NI assay 
non-specific inhibitors were inactivated by the incubation of 1 
ml serum with 4 ml 0.1% (w/v) trypsin in sodium phosphate buffer 
(pH 7.5) for 30 min at 56°C. To this mixture 3 ml (2.6 mg/ml) 
potassium iodate was added at 4°C for 15 min. After this time 3 
ml glycerol was added. The mixture was dialysed for 18 h against 
PBS at 4°C before being used in the assay.
To test for virulence and pathogenicity 11 day old 
embryonated hens eggs were inoculated with 2 x 104 PFU virus. At 
24 and 48 h post-inoculation the condition of the embryos and the 
allantoic fluid were examined. Embryos were also examined 6 days 
post inoculation for development. The pathogenic effect produced 
by V31 was minimal; embryos inoculated with V31 were comparable 
to appearence to control embryos. Those inoculated with FPV/R 
were dead after six days.
On the isolation of the desired reassortment after the above
assays a further 3 plaque purification cycles were performed. 
Table 10.4 classifies the biological properties of V31 compared 
to parental strains.
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11.1. Assay for attachment of neutralized and non-neutralized 
[32p]-labelled FPV/R to avian and mammalian cells.
Virus was first incubated for 1 h at 25°C with neutralizing 
immunoglobulin, bile concentrate, IgG fragments or the equivalent 
from preimmune sources. lOOul volumes of virus-Ig mixtures were 
inoculated onto monolayers of BHK-21 cells in plastic Petri 
dishes, held on ice to give a temperature at the monolayer 
surface of 4°C, unless otherwise stated. This temperature 
prevents virus directed macromolecular synthesis (Stephenson and 
Dimmock, 1975). At the required times monolayers were rinsed 
three times with cold PBS and removed by scraping into 0.5 ml 
cold PBS. Radioactivity associated with cells and washes was 
determined by binding to Whatman DE81 filter discs (Whatman Ltd., 
Maidstone U.K.), which were washed successively with sodium 
dihydrogen orthophosphate (three times), water, and ethanol. 
Filter papers were inserted into scintillation vials containing a 
pre-mixed liquid scintillation cocktail, Ready Solv EP (Beckman 
Instruments, Galway, Ireland). The amount of radioactivity 
associated with the cells was determined using a Packard Tri-carb 
(model 3385) Liquid scintillation spectrometer. The radioactivity 
determined represented [*2P]-labelled virion RNA. Lipids and
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proteins do not bind to Whatman DE81 filter paper (Whatman Ltd. 
Technical Enquiry Service). This was confirmed by the evidence 
that C125 I]-labelled antibody does not bind. Results were 
expressed as a percentage of the [®2P]-labelled virion RNA 
originally inoculated.
The majority of experiments were carried out on BHK-21 
cells, but the ability of neutralizing IgG to interfere with the 
binding of FPV/R to La29 , HFF-4, and CEF cells was also 
investigated.
11.2. Assay for the uptake of virion RNA into the nuclei (using 
a nuclear monolayer fractionation technique).
BHK-21 cells were fractionated by removing cytoplasm from 
cell monolayers by an adaptation of the technique described by 
Hudson and Dimmock (1977). BHK-21 cells were incubated for two 
successive periods of 5 min, in 0.5% Nonidet P-40 (NP-40) (BOH 
Pharmaceuticals Ltd. London, U.K.) in 0.25 M sucrose, 0.01 M 
Tris-HCl (pH 7.4), 1 mM MgCl2 on ice. Nuclei remained attached to
the Petri dish and were scraped into the same buffer without 
NP-40, rinsed vigorously on a vortex mixer for 60 sec, and then 
pelleted at 150 g for 5 min at 4°C. This last step is crucial to 
remove all remaining cytoplasmic tags. The supernatant was pooled 
with the cytoplasmic fraction. This method gives a high yield of 
nuclei that have a cytoplasmic contamination of approximately 5%
(section 11.2.1). Uptake of [32P]-labelled virion RNA was 
measured by inoculating monolayers with neutralized or 
non-neutralized virus and fractionating the cells at intervals. 
Radioactivity was collected as before (section 11.1) using 
Whatman DE81 filters. This procedure provides a measure of the 
early stages of infection up to the transport of virion RNA to 
the nucleus. (Hudson and Dimmock, 1977). The same technique was 
performed for the fractionation of CEF cells except that 2% NP-40 
was used (Hudson and Dimmock, 1977).
11.2.1.Validation of the nuclear monolayer 
fractionation methodology.
To test the possibility that there was plasma or other 
membrane contamination of nuclei, BHK-21 cell monolayers were 
inoculated with 6 x 10« PFU [32P]-labelled SFV (6 x 104 CPM). 
SFV multiplies exclusively in the cytoplasm (Grimley et al., 
1968) and therefore no RNA should be detected in the nuclear 
fractions of BHK-21 cells. The nuclear fractionation assay was 
carried out with SFV as described in section 11.2. Fig 11.1.1 
shows the rate of attachment at 4, 25 and 37°C and Fig 11.1.2 
shows that irrespective of temperature 95% of SFV remains in the 
cytoplasm.
The assay was also validated by assay for HA production in 
the cytoplasm of infected cells, uptake of [* H]-thymidine in the
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Figure 11.1.1 and Figure 11.1.2. Validation of the nuclear 
monolayer fractionation method using BHK-21 cell monolayers (1 x 
107 cells) inoculated with purified [32 P]-labelled Semliki 
Forest virus (SFV). Monolayers were inoculated with 6 x 105 PFU 
containing 6 x 10* cpm with replicates at 4, 25 and 37°C. 
Radiolabelled virion RNA binding to Whatman DE 81 filter discs 
(section 11.1) is presented here. After incubation monolayers 
were washed extensively with PBS and all placed at 4°C. Nuclei 
were isolated using the method described in section 11.2. Figure 
11.1.1 represents virus attached to cells and Figure 11.1.2 
represents the distribution of virion RNA between the cytoplasmic 
and nuclear fractions.
Figure 11.1.1 Figure 11.1.2.
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nuclei, uptake of [3 H]-uridine in "the cytoplasm and monitored by 
phase contrast microscopy. The HA of influenza in infected cells 
remains cytoplasmic. Therefore removal of HA from the periphery 
of the nucleus would provide a stringent test of purity. To assay 
for HA production in BHK-21 cells, monolayers were inoculated 
with 100 i^l PBS containing 107 PFU FPV/R for lh at room 
temperature, the inoculum washed away before incubation for a 
further 5h at 37°C in 3 ml GMEM/5% NCS. Cells were then 
fractionated as previously described or scraped into 0.5 ml PBS. 
The nuclei and whole cell fractions were assayed for HA. BHK-21 
cell monolayers were incubated for 24h at 37°C with 3 ml 
GMEM/5%NCS containing either 4 jiCi [3H] thymidine (Amersham) to 
label DNA in the nuclei or 4 i^Ci [3 H] uridine (Amersham) to label 
RNA in the cytoplasm. Cells were chased for 24h with medium 
without radioisotope then fractionated as previously described. 
Radioactivity in the cytoplasmic and nuclear fractions was 
determined. Parallel experiments were performed on CEF cells.
Table 11.1 summarizes the results obtained using the 
fractionation method on BHK-21 cell monolayers showing that 
little newly synthesized HA was associated with the nuclei 
(2.2%), labelled DNA was mostly nuclear (7.7%) and labelled RNA 
was cytoplasmic (92%). On the basis of the results obtained with 
SFV it is assumed that the 5% of virus RNA in the nucleus of 
BHK-21 cells represents the level of contamination by cytoplasmic
17$
constituents.
Table 11.1. Summary of the assessment of the nuclear monolayer 
fractionation method for obtaining nuclei from BHK-21 cell
monolayers. Duplicate monolayers were: (a) Inoculated with 107 
PFU FPV/R for 1 h at 25°C followed by 5 h at 37°C in 3ml 199 
medium. Cells were then fractionated as described (section 11.2) 
or scraped into 0.5 ml PBS. Cells were then assayed for HA. (b)
Incubated for 24 h with 4 uCi [3 H]-thymidine or (c) 4 uCi [3
H]-uridine in 3ml 199 medium at 37°C then chased with medium
without radiolabel for 24 h. Cells were then fractionated as 
described (section 11.2). (d) Inoculated with 6 x 10® PFU [3i 
P]-labelled SFV containing 6 x 10< cpm (section 10.3.1) at 25°C 
for 120 min (Figure 11.1.2). Cells were then fractionated as 
described (section 11.2) and radioactivity determined by binding 
to Whatman DE81 filter discs. The corresponding percentage value 
obtained in the nuclei of CEF cell monolayers (107 cells) treated 
in a similar manner i3 shown. The nuclear monolayer fractionation 
of CEF cell monolayers requires 2% NP40 (Hudson and Dimmock,
1977).
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Assay Cell 
assoc.
Cytoplasm (%) 
(cpm)
Nucleus (%) 
(cpm)
% in c:
nuc
(a) HA (HAU) 3548 HAU - 3
(b) DNA [3 H] - 10436 (9) 105270 (91) 94
(c) RNA C»H] - 160620 (92.3) 13329 (7.7) 10
(d) SFV [32P] - 34570 (95) 1820 (5) 6
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Phase contrast microscopy showed that BHK-21 nuclei were 
discrete refractile bodies without any cytoplasmic "tags" after 
fractionation. Possee (1981) had previously shown that the 
nuclear monolayer technique produces nuclei comparable to those 
produced by Dounce homogenization. The nuclear monolayer 
fractionation technique has the advantages of minimizing damage 
to nuclei and of allowing several monolayers to be fractionated 
simultaneously and speedily.
11.3. Proteinase K removal of [*2P]-labelled FPV/R attached to 
the surface of BHK-21 cells.
To determine the percentage of virus attached to BHK-21 
cells, [3 2 P]-labelled FPV/R-antibody mixtures were incubated with 
monolayers for 2h, and cells were then rinsed three times with 
cold PBS and incubated at 4°C with 2 ug/ml proteinase K (sp. 
act., 20 Anson units/g; BDH) in 500pl. After 60 min, the enzyme 
solution was removed and pooled with two subsequent washes of 250 
pi PBS. The cells were then fractionated and radioactivity 
determined as before. The proteinase K was auto-digested before 
use by incubation of 0.5 pg/ml in PBS for 1 h at 37°C.
11.3.1. Validation of the proteinase K 
removal technique.
0.1 mg concanavalin A (Sigma) in 400 pi PBS was iodinated
with [125]-iodine using the chloramine T method (section 10.13.). 
100 ul PBS containing 5 ug [l 25 I]-labelled concanavalin A (38410 
CPM) was inoculated onto BHK-21 cell monolayers. After 30 mins 
cells were washed three times with cold PBS. The cell monolayers 
were then incubated with 2 jug/ml proteinase K for 60 min at 4°C. 
This was found to remove 85% of the [!25 I]-labelled concanavalin 
A associated with an untreated BHK-21 cell monolayer.
11.4.Attachment of radiolabelled antibody 
to FPV/R particles.
Antibody-virus mixtures were initially used at the same 
ratio as previously used in virus-cellular association studies; 
that is the amount of polyclonal IgG that gave 99.95% 
neutralization of l x  107 PFU or 3.75 haemagglutination 
inhibition units (HIU) of purified antibody to 1 HAU virus. The 
standard assay conditions were as follows: iodinated
immunoglobulin was incubated with 20 HAU FPV/R plus 20 pg 
cytochrome C for 1 h at 25°C. The mixtures were made up to 300 pi 
total volume with PBS. At the end of this time the mixtures were 
incubated for 18h at 4°C to allow equilibration. 
Virus-C1 25 I]-labelled antibody complexes were sedimented through 
a 5 ml cushion of 5% (w/v) sucrose in PBS by ultracentrifugation 
at 75,000g for 90 min in BSA coated 5.5ml polycarbonate tubes. 
This separated complexes from free antibody. The supernatants 
were discarded and the amount of radioactivity associated with
the pellet determined. Iodinated IgG binding to FPV/R was 
determined with respect to nonspecific binding to influenza 
B/Lee.
11.4.1. Two step competition binding assay.
This assay consisted of incubating 20 HAU FPV/R particles 
with two different antibodies sequentially. Firstly unlabelled 
immunoglobulin was incubated with 20 HAU virus lh at 25°C then 
for 18h at 4°C then the radiolabelled second antibody was added, 
incubated as before, and the virus and any associated antibody 
was pelleted. Ratios of unlabelled and C1 25 I]-labelled antibody 
were varied in order to investigate the amount of binding that 
could be achieved by the labelled antibody.
11.4.2. Solid phase radioimmunoassay (RIA)
A solid phase radioimmunoassay system was developed to check 
the results obtained from the competitive binding of virus and 
antibody in solution. Competitive binding RIAs were performed on 
viral antigens adsorbed onto the wells of polyvinyl flat bottomed 
48 well tissue culture plates (Linbro Scientific, subsidary of 
Flow Laboratories). 5 HAU of purified FPV/R in lOOul PBS (0.1% 
BSA) were adsorbed onto each well of the microtitre plate by 
incubating for 18h at 4°C. Wells were washed 3 times with PBS
before use in the assay.
Haemagglutinin was cleaved from FPV/R by treatment with 
bromelain (Grade II) (Sigma Chemical Co.) as detailed by Brand 
and Skehel (1972). 3 x 10* HAU FPV/R (approx. 80 jag) was 
incubated for 16 h at 37°C with 40 tig bromelain in 0.1 M Tris/HCl 
(pH 8) and 0.05 M beta mercaptoethanol (total volume equalled 
200pl). After digestion the virus "cores" and undigested virions 
were sedimented through a 5 ml cushion of 5% (w/v) sucrose in TBS 
by ultracentrifugation at 75,000g for 90 min at 4°C. Cleaved 
haemagglutinin (BrHA) did not enter the sucrose cushion to any 
extent and the top 1 ml was dialyzed against 3 changes of PBS 
over 10 h. BrHA was passively adsorbed onto the wells of titre 
plates for 6h at 25°C, then for 12h at 4°C (Gerhard et al., 1981) 
before assay for HA activity.
The assay consisted of incubating mixtures of antibody and 
iodinated antibody with viral antigen coated wells for lh at 25°C 
and 18h at 4°C. Then wells were throughly washed with cold PBS 
and the radioactivity associated with the wells determined.

SECTION 12:
MECHANISMS OF NEUTRALIZATION OF
INFLUENZA VIRUS A/FOWL PLAGUE/ROSTOCK/34 (H7N1)
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The neutralizing activity of various immunoglobulins and IgG 
fragments with specificity for the haemagglutinin of type A 
influenza virus (A/Fowl plague virus/Rostock/34; H7N1) (FPV/R) 
were investigated. When neutralized by either IgG or monomeric 
IgA, FPV/R attached to and penetrated into BHK-21 cells, at a 
rate indistinguishable from that of non-neutralized virus. This 
behaviour was independent of temperature from 4 to 37°C. Thus IgG 
and monomeric IgA neutralized infectivity at a stage subsequent 
to penetration. Virus was efficiently neutralized by F(ab’)2 and 
Fab’ fragments of monoclonal anti-HA IgG. Neither prevented the 
attachment, penetration, or the accumulation of viral genomes in 
the nucleus.
In contrast the polymeric immunoglobulins secretory IgA 
(slgA) and IgM completely blocked attachment at 4°C. The large 
molecular structure of these antibodies suggests that steric 
hindrance may be the mechanism by which attachment is impaired. 
However at 25 and 37® C neutralizing slgA and IgM inhibited 
attachment of only 50% of the neutralized virus but none of this 
attached virus was internalized. Therefore it seems likely that 
IgM and slgA interfere with the endocytotic event responsible for 
internalization of virus.
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Introduction.
Infection is initiated by attachment of virus to cells and 
it has been assumed that neutralizing antibody acts by combining 
with the virus attachment protein and preventing this process. 
This generalization, however, is not always true (section 9.2.1; 
section 9.2.2; Joklik, 1964; Mandel, 1967; Yoden et al,, 1982; 
Possee et al., 1981; Emini et al., 1983a; Schlegel and Wade, 
1983; Kingsford and Ishizawa, 1984; Fuller and Spear, 1985), and 
it is emerging through studies such as these that there are 
mechanisms other than preventing attachment by which virus is 
neutralized (Dimmock, 1984).
It has been found previously (Possee et al., 1981; Possee, 
1981) that FPV/R neutralized by polyclonal or monoclonal IgG 
attached to chick embryo fibroblast (CEF) cells at the same rate 
as non-neutralized virus. Using a fractionation technique to 
isolate nuclei from CEF cells, it was found that neutralization 
of influenza by IgG did not effect the penetration or transport 
of virion RNA into the nuclei. In fact the rate of nuclear 
accumulation of [32P]-labelled RNA from neutralized virus was 
similar to that of non-neutralized virus.
In this section these earlier studies have been extended to 
include observations on the neutralization of FPV/R by IgG in 
BHK-21 cells and other mammalian cells, and investigations on the 
interactions of FPV/R neutralized by IgM, slgA, monomeric IgA and 
IgG fragments with BHK-21 cells. A comparison of the manner in 
which these antibodies neutralize can now be made.
12.1. Mechanisms of neutralization by IgG.
Figure 12.1.1 confirmed previous studies (Possee and Dimmock, 
1981; Possee, 1981) that the kinetics of attachment of FPV/R 
neutralized by IgG to CEF cell monolayers is similar to that of 
non-neutralized virus. Further to these observations the ability 
of neutralizing IgG to interfere with the binding of FPV/R to 
mammalian cells was examined (Figures 12.1.2 - 12.1.4). Serum 
containing neutralizing IgG did not significantly alter the rate 
of attachment of virus to mouse (L929), human (HFF-4) and hamster 
(BHK-21) cells at 4°C. FPV/R, neutralized by purified monoclonal 
IgG also attached to BHK-21 cells at 4°C a at rate 
indistinguishable from that of non-neutralized virus (Figure 
12.2 ).
After attachment to the cell, virus is internalized and 
uncoated; the virus envelope components remain in the cytoplasm 
while the transcriptase complex of virion RNA and associated 
proteins enter the nucleus (Stephenson and Dimmock, 1975).
The nuclear monolayer fractionation method (sections 11.2;
11.2.1) was used to determine the proportion of cell-associated 
virion RNA that enters the nuclei. Validation of this method 
(section 11.2.1) demonstrated that irrespective of temperature 95% 
of SFV RNA remains cytoplasmic. It is assumed that the 5% of 
virion RNA in the nuclear fraction represents the level of 
contamination by cytoplasmic constituents (Figure 11.1.2).
Figures 12.3 and 12.4 show that the accumulation of RNA from 
FPV/R neutralized by either polyclonal IgG or monoclonal IgG is
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Figures 12.1.1 -to 12.1.3 Attachment of neutralized (^  ) and non-neutralized (+ ) [3*P]-labelled FPV/R to CEF cell monolayers (Figure 12.1.1), to L929 cell monolayers (Figure 12.1.2) and to HFF 4 cell monolayers (Figure 12.1.3).
2 x 107 PFU (containing 200 HAU and 1.7 x 10s cpm) were incubated 
with a 1:10 dilution of polyclonal anti HA ( #  ) (rabbit anti 
A/FPV/D; WR45) or the equivalent pre-immunization serum (pig) (+ 
) for lh at 25°C. Mixtures were then cooled to 4°C and inoculated 
onto monolayers* held at 4°C. At each time interval monolayers 
were rinsed (x3) with cold PBS and the radioactivity associated 
with cells and in washes was determined by binding to Whatman BE 
81 filter discs (section 11.1). This is virion RNA. 
Neutralization was > 99.9%. Pre-immune serum did not neutralize.
* CEF and Lsr:9 cell monolayers at 9 x 10* cells per dish and HFF 
4 cell monolayers at 1 x 107 cells per dish.
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Figure 12.1.4. Attachment of neutralized C #  ) ( 
non-neutralized ( ♦ ) (treated with pre-immune IgG, 
[32p]-labelled FPV/R on BHK-21 cell monolayers at 4°C ( 
cells per plate). Conditions as detailed in Figure 12.1.1.
) and 
pig) x 106
mrs
Figure 12.2. Attachment of neutralized ( •) and non-neutralized ( ♦) [32P]-labelled FPV/R on BHK-21 cell monolayers at 4°C (6 x 106 
cells per plate). Conditions as detailed in Figure 12.1.1 except 
that purified monoclonal anti-H7 IgG (HC2) (section 10.7) was 
used. Neutralizing IgG reduced the infectivity of 1.4 x 107 PFU 
(630 HAU and 1.7 x 105 cpra) by 99.9 %.
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Figure 12.3. Association of non-neutralized (treated with pig) and neutralized (N) [3 aP]-labelled FPV/R with cytoplasmic and nuclear fractions of BHK-21 cells at 4“C. Virus was treated and 
inoculated as described in Figure 12.1.1. At the intervals 
indicated nuclear and cytoplasmic fractions were prepared 
(section 11.2; Figure 11.1.2).
Figure 12.4. Association of non-neutralized and neutralized [3*P]-labelled FPV/R with cytoplasmic and nuclear fractions of 
BHK-21 cells at 4°C. Virus was neutralized with purified 
monoclonal anti H7 IgG (HC2) (section 10.7) and inoculated as 
described in Figure 12.1.1. Neutralizing monoclonal IgG reduced 
the infectivity of 1.4 x 10? PFU (630 HA(J and 1.7 x 10® cpm) by > 
99.9%. At the intervals indicated nuclear and cytoplasmic 
fractions were prepared (section 11.2; Figure 11.1.2).
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Table 12.1. Summary of the attachment to BHK-21 cells, and 
association with the nuclear compartments of such cells by 
[32 p]-labelled RNA from neutralized or non-neutralized FPV/K. Virus 
was either neutralized by one of a panel of four purified monoclonal 
IgGs (HC2: HC10; HC58: HC61) or polyclonal IgG (WR69; WR45). 
Virus-immunoglobulin mixtures total volume = 100 ul) were incubated 
for 120 min on BHK-21 cell monolayers at 4°C before the assays were 
carried out. 825 HI units (HIU) of each neutralizing IgG was present 
in each volume giving a HAU:HIU ratio of 3.75.
% Neutraliz- 
Purified ation of
IgG 1.5 x 10? PFU
(220 HAU).
Attachment %) Accumulation
in nucleus(%)
HC2 99.99 27 69
HC10 99.9 31 72
HC58 99.5 25 76
HC61 ' 99.99 21 68
77/1 - 30 75
WR69 99.8 26 72
WR45 99.5 32 71
plgG 28 68
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similar to that of infectious virus. The loss of infactivity due 
to neutralization by IgG must result from the inhibition of a 
stage subsequent to penetration.
A summary of several experiments concerning the attachment 
and association of FPV/R neutralized by IgG with BHK-21 cells 
compared to that of infectious virus is presented in Table 12.1. 
The effect of each of four neutralizing monoclonal IgGs was 
examined; HC2, HC10, HC53 and HC61. All, despite substantial 
neutralization titres (from 99.5 - 99.99%), failed to inhibit 
attachment to BHK-21 cells or penetration of the virion RNA into 
the nuclei of these cells. Attachment and nuclear accumulation of 
neutralized virion RNA was consistently similar to that of 
non-neutralized virus. Interaction by FPV/R neutralized by either 
of the two polyclonal IgGs tested (WR45 and WR69) also confirmed 
that neutralizing IgG has no effect on attachment or on the stages 
of infection leading to the accumulation of virion RNA in the 
nucleus.
Initial experiments used monolayers held at 4°C, as this 
temperature allows the genome of influenza to enter the nuclei but 
prevents any virus-directed macromolecular synthesis from taking 
place (Stephenson and Dimmock. 1975). Subsequent experiments using 
cells held at 25 and 37°C (data not presented in full, but see 
Table 12.2) produced results similar to those observed at 4,JC.
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12.2. Mechanisms of neutralization by secretory IgA 
and monomeric IgA.
FPV/R that had been neutralized with immune bile concentrate 
(section 10.10) did not attach in significant amounts to BHK-21 
cells (Figure 12.5). Secretory IgA was purified from the bile 
concentrate (section 10.10.1). The attachment to BHK-21 cells at 
4°C of virus neutralized by slgA was compared with virus 
neutralized by IgG (Figure 12.6). Pre-immune slgA did not restrict 
the attachment of virus to the BHK-21 cell monolayers, but 
attachment of virus neutralized by slgA (to 96.5%) remained at a 
low level. In contrast virus neutralized by IgG attached to the 
cells (section 12.1).
To determine if the ability of neutralized virus to attach to 
cells is related to the structure of the neutralizing 
immunoglobulin, the attachment to BHK-21 cells of virus 
neutralized with monomeric IgA (prepared from slgA; section 
10.10.3) was investigated. Figure 12.7 shows that monomeric IgA, 
like IgG, did not inhibit attachment. Thus, inhibition of 
attachment by slgA appears to be related to its dimeric structure, 
or this structure plus Sc, and not to any intrinsic property of 
the immunoglobulin alpha heavy chain itself.
To investigate if virus neutralized with slgA was able to 
undergo any of the stages of infection subsequent to attachment 
(as it does when neutralized with IgG), the levels of virion RNA
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similar to that of infectious virus. The loss of infectivity due 
to neutralization by IgG must result from the inhibition of a 
stage subsequent to penetration.
A summary of several experiments concerning the attachment 
and association of FPV/R neutralized by IgG with BHK-21 cells 
compared to that of infectious virus is presented in Table 12.1. 
The effect of each of four neutralizing monoclonal IgGs was 
examined; HC2, HC10, HC58 and HC61. All, despite substantial 
neutralization titres (from 99.5 - 99.99%), failed to inhibit 
attachment to BHK-21 cells or penetration of the virion RNA into 
the nuclei of these cells. Attachment and nuclear accumulation of 
neutralized virion RNA was consistently similar to that of 
non-neutralized virus. Interaction by FPV/R neutralized by either 
of the two polyclonal IgGs tested (WR45 and WR69) also confirmed 
that neutralizing IgG has no effect on attachment or on the stages 
of infection leading to the accumulation of virion RNA in the 
nucleus.
Initial experiments used monolayers held at 4°C, as this 
temperature allows the genome of influenza to enter the nuclei but 
prevents any virus-directed macromolecular synthesis from taking 
place (Stephenson and Dimmock, 1975). Subsequent experiments using 
cells held at 25 and 37°C (data not presented in full, but see 
Table 12.2) produced results similar to those observed at 4°C.
12.2. Mechanisms of neutralization by secretory IgA 
and monomeric IgA.
FPV/R that, had been neutralized with immune bile concentrate 
(section 10.10) did not attach in significant amounts to BHK-21 
cells (Figure 12.5). Secretory IgA was purified from the bile 
concentrate (section 10.10.1). The attachment to BHK-21 cells at 
4°C of virus neutralized by slgA was compared with virus 
neutralized by IgG (Figure 12.6). Pre-immune slgA did not restrict 
the attachment of virus to the BHK-21 cell monolayers, but 
attachment of virus neutralized by slgA (to 96.5%) remained at a 
low level. In contrast virus neutralized by IgG attached to the 
cells (section 12.1).
To determine if the ability of neutralized virus to attach to 
cells is related to the structure of the neutralizing 
immunoglobulin, the attachment to BHK-21 cells of virus 
neutralized with monomeric IgA (prepared from slgA; section 
10.10.3) was investigated. Figure 12.7 shows that monomeric IgA, 
like IgG, did not inhibit attachment. Thus, inhibition of 
attachment by slgA appears to be related to its dimeric structure, 
or this structure plus Sc, and not to any intrinsic property of 
the immunoglobulin alpha heavy chain itself.
To investigate if virus neutralized with slgA was able to 
undergo any of the stages of infection subsequent to attachment 
(as it does when neutralized with IgG), the levels of virion RNA
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Figure 12.5. Attachment of non-neutralized L32P]-labelled FPV/R and virus neutralized with immune bile concentrate to BHK-21 cell monolayers at 4<>C. Virus was first incubated for 1 h at 25°C with 
immune bile concentrate (A  ) or the equivalent from non-immunised 
rats ( • ). Infectivity was neutralized only by the former to 
97.5%. The subsequent procedure is described in Figure 12.1.1. 
except that each 100 ul chilled virus-bile mixture inoculated onto 
the monolayers of BHK-21 cells (6 x 106 cells/dish) contained 1.1 
x 107 PFU, 320 HAU and 1.98 x 10S cpm.
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Figure 12.6. Attachment of non-neutralized [3 2 P]-labelled FPV/R 
and virus neutralized with purified slgA to BHK-21 cell monolayers at 4°C. Virus was first incubated for 1 h at 25°C with 
neutralizing slgA (nsIgA), neutralizing (polyclonal) IgG (nlgG), 
pre-immune slgA (psIgA), or pre-immune IgG (plgG). Immune slgA and 
IgG neutralized virus by 96.5% and 99.5% respectively. the 
subsequent procedure is described in Figure 12.1.1, except that 
each 100 ul inoculated onto the cell sheet contained initially 1.2 
x 107 PFU, 36 HAU and 1.2 x 10* cpm.
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which accumulated in the nuclei were measured.
Experiments on the small fraction of virus neutralized by 
slgA that attaches to cells at 4°C (Figure 12.8) showed that 
virion RNA remained in the cytoplasmic fraction whereas that from 
virus neutralized by IgG entered the nucleus as previously seen 
(Figures 12.3; 12.4). It was therefore of particular interest to 
determine if monomeric IgA, which had no effect on attachment of 
neutralized virus (Figure 12.7), prevented internalization like 
slgA or behaved like IgG. Figure 12.9 shows that RNA from virus 
neutralized by monomeric IgA accumulates in the nucleus at the 
same rate as RNA from non-neutralized virus.
Although it is experimentally convenient to examine the early 
stages of infection at 4°C (since this temperature prevents virus 
macromolecular synthesis) it is possible that virus may behave 
differently at physiological temperatures. Fig 12.10 shows that, 
although slgA almost completely prevented attachment of 
neutralized virus at 4°C, attachment at 25 and 37°C was only 
reduced by 50%. However, in contrast to FPV/R neutralized by IgA 
or IgG, the majority of virion RNA that associated with the cells 
at 25 and 37»C remained in the cytoplasmic fraction (Figure 12.11) 
and less than 5% was taken up into the nuclei.
The cytoplasmic fraction obtained by fractionation includes 
the plasma membrane and as such it was not possible to determine 
if virus was attached to the outside of the cell or had been
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Figure 12.7. Attachment of non-neutralized [3 2 P]-labelled FPV/R and virus neutralized with monomeric IgA to BHK-21 ceil monolayers at 4°C. Virus was first incubated for 1 h at 25 °C with 
neutralizing IgA (nlgA), neutralizing IgG (nlgG), pre-immune IgA 
(plgA) or pre-immune (plgG). Immune IgA and IgG neutralized virus 
by 98.5% and 99.5% respectively. The subsequent procedure is 
described in Figure 12.1.1, except that each 100 ul inoculated 
onto the cell monolayers contained initially 1.3 x 107 PFU, 47 HAU 
and 2 x 105 cpm.
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Figure 12.8. Association of non—neutralized and neutralized [32p]-labelled FPV/R with cytoplasmic and nuclear fractions of 
BHK-21 cells at 4°C. Virus was neutralized with neutralizing slgA 
(nsIgA) or neutralizing IgG (nlgG) and inoculated as previously 
described in Figure 12.1.1. nsIgA and nlgG neutralized virus by 
96.5% and 99.5% respectively. Each 100 ul inoculated contained 
initially 1.2 x 107 PFU, 36 HAU and 1.2 x 10s cpm. at the 
intervals indicated nuclear and cytoplasmic fractions were 
prepared (section 11.2; Figure 11.1.2).
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Figure 12.9. Kinetics of Migration of virion RNA from cytoplasm to nucleus in cells inoculated with virus neutralized by monomeric 
IgA and non-neutralized virus at 4°C. Virus was neutralized and 
inoculated as previously described in Figure 12.1.1. Immune IgA 
(nlgA) neutralized virus by 98.5%. Each 100 ul inoculated 
initially contained 1.3 x 107 PFU, 47 HAU and 1.2 x 105 cpm. At 
the intervals indicated nuclear and cytoplasmic fractions were 
prepared (section 11.2; Figure 11.1.2).
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Figure 12.10. Attachment, of non-neutralized and neutralized 
[32p]-labelled FPV/R to BHK-21 cell monolayers at 4, 25, and 37°C. 
Virus was first incubated for 1 h at 25°C with neutralizing slgA 
(solid symbols) or pre-immune slgA (open symbols). The 
neutralizing slgA reduced infectivity by 98%. Virus antibody 
mixtures (100 ul) were then inoculated onto BHK-21 cells at 4, 25 
and 37°C. Each 100 ul initially contained 1.3 x 107 PFU, 316 HA(J 
and 1.9 x 10s cpm. The percentage attachment was determined as 
previously described.
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Figure 12.11. Kinetics of migration of [32P]-labelled virion RNA from cytoplasm to nucleus in BHK-21 cells inoculated with virus neutralized by slgA. Virus was neutralized and inoculated at 4, 25 
and 37oC as described in Figure 12.10. The immune slgA neutralized 
virus by 98%. Each 100 ul initially contained 1.3 x 107 PFU, 316 
HAU and 1.9 x 10* cpm. Neutralizing slgA at 4°C (A), 25°C (■) and 
37°C (♦); pre-immune 3lgA at 4°C (A), 25°C (□) and 37°C (0).
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Figure 12.12. Release of [32P]-labelled virus neutralized by slgA and attached -to BHK-21 cells by incubation with proteinase K.
BHK-21 cell monolayers were inoculated with virus that had been 
incubated with psIgA or nsIgA for lh at 25°C. 100 ul of 
virus-antibody mixtures were incubated with the cells at the 
temperatures shown for 2h before being washed twice with PBS and 
incubated with 500 ul proteinase K (2 ug/ml) in PBS or 500 ul PBS 
for 60 min at 4°C. The percentage [32P]-labelled FPV/R released by 
proteinase K or by PBS was calculated relative to the total 
[32p]-labelled FPV/R associated with cells before digestion was 
carried out. Each lOOul inoculated contained initially 1.4 x 107 
PFU, 700 HAU, and 1.4 x 10s cpm.
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internalized. The question was resolved by treating cells 
Inoculated with virus neutralized by slgA with proteinase K 
(sections 11.3; 11.3.1). This released the majority of virus 
attaching at 25° and 37»C (58 and 68.2% respectively), 
demonstrating that the majority of virus had not been internalized 
but remained attached to the outside of the cell. Treatment of 
cells that were inoculated with virus treated with pre-immune slgA 
released no more than 8% cell-associated virus (Figure 12.12).
12.3. Mechanisms of neutralization by IgM.
The attachment of FPV/R neutralized by IgM and of
non-neutralized virus to BHK-21 cells was measured as described 
previously. At 4°C, neutralizing IgM prevented the attachment of 
neutralized virus (Figure 12.13) whereas over 25% infectious virus 
that had been incubated with preimmune IgM had attached to BHK-21 
cells after 120 min. At 25°C and 37°C similar amounts of 
non-neutralized virus attached as at 4°C but attachment of 
neutralized virus rose at 25°C to 38% and at 37®C to 47% of their 
respective control values after 120 minutes (Figure 12.14). This 
was very similar to the temperature dependence of the attachment 
of virus neutralized by slgA (section 12.2). To investigate 
whether virus neutralized with IgM was able to undergo any of the 
subsequent stages of infection as it does when neutralized with 
IgG, the levels of virion RNA which accumulated in the nuclei were 
measured. Figure 12.15 shows that even though a substantial
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Figure 12.13. Kinetics of attachment of non-neutralized [3 2P] —labelled FPV/R and virus neutralized with IgM to BHK-21 cells at 4<>C. Virus was first incubated for 1 h at 25°C with 
neutralizing IgM (0 ) or pre-immune IgM ( O )■ Infectivity was 
neutralized (by 99%) only by the former. The subsequent procedure 
is described in Figure 12.1.1, except that each 100 ul inoculated 
initially contained 1.5 x 107 PFU, 630 HAU and 1.34 x 10s cpm.
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Figure 12.14. Kinetics of attachment of neutralized and 
non-neutralized [3*P]-labelled FPV/R to BHK-21 cell monolayers at 4, 25 and 37°C. Virus was first incubated for 1 h at 25° with 
neutralizing IgM (solid symbols) or pre-immune IgM (open symbols). 
The immune IgM neutralized virus by 99%. Each 100 ul initially 
contained 1.5 x 107 PFU, 631 HAU and 1.34 x 10s cpm. Neutralizing 
IgM at 4° C (#) , 25° C (A) and 37° C (■) ; pre-immune IgM at 4° C ( O), 
25°C (A) and 37°C (□) .
2 1 0
Figure 12.15. Kinetics of migration of [*aP]-labelled virion BNA from cytoplasm -bo nucleus in BHK-21 cells inoculated with virus 
neutralized by IgM. Virus was neutralized and inoculated at 4, 25 
and 37°C as described in Figure 12.14. The immune IgM neutralized 
virus by 99%. Neutralizing IgM at 4°C (#) , 25°C (A) and 37°C (■) ; 
pre-immune IgM at 4°C (O)• 25°C (A) and 37°C (□).
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Figure 12.16. Release of attached SSP-labelled virus neutralized 
by IgM. Performed as described in Figure 12.14, except that virus 
was incubated with either neutralizing IgM or pre-immune IgM. The 
neutralizing IgM reduced infectivity by 99%. Each lOOul of 
inoculum initially contained 1.5 x 10? PFU, 6.31 x 10* HAU and 
1.34 x 10* cpm
o
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proportion of virus neutralized with IgM attached to the cells at 
25 and 37oC, virion RNA did not travel to the nucleus. However, as 
previously indicated (section 12.2) this procedure does not 
discriminate between virus attached to the outside of the cell and 
virus which has been fully internalized into the cytoplasm. To 
remove virus putatively attached to the outside, cells were 
treated with proteinase K (sections 11.3; 11.3.1). Figure 12.16 
shows that 80% or more virion RNA was released from those cells 
which had been inoculated with virus neutralized by IgM compared 
to less than 20% released from cells receiving non-neutralized 
virus. This clearly demonstrated that the majority of attached 
neutralized virus is remaining on the outer surface of the cell.
Table 12.2 presents a summary of the interactions of FPV/R 
neutralized with different classes of immunoglobulin with BHK-21 
cells at 37°C. When neutralized by either IgG or monomeric IgA, 
FPV/R attached to and penetrated BHK-21 cells at a rate 
indistinguishable from that of non-neutralized virus. In contrast 
the polymeric immunoglobulins slgA and IgM blocked attachment of 
50 and 47% of the neutralized virus respectively. None of the 
attached virus was internalized.
12.4. Mechanisms of neutralization by a "manufactured
IgG dimer.
In another series of experiments virus neutralized with IgG
Table 12.2. Summary of interaction of FPV/R with BHK-21 cells after being neutralized with different classes of neutralizing immunoglobulin.
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Purified
antibody®
Attachment. Internal­
ization
Penetration %
Neutral
ization
slgA ++ - - 98.5
IgM ++ - - 99.0
IgG +++ + ++ + + ++++ 99.5
I gA*> ++++ ++++ ++++ 99.5
monoclonal
IgG
++++ +++ + ++++ 99.99
All mixtures of virus and neutralizing (n) antibody were held at 
25°G for lh before inoculation onto BHK-21 cell monolayers and 
each parameter was measured after 120 min incubation at 37°C. The 
value obtained was compared to that observed with non-neutralized 
virus (treated with purified antibody from pre-immune sources), 
++++. At 4°C IgM and slgA blocked attachment by about 50%. ++.
Internalization was determined by evidence of penetration and by 
the ability of proteinase K treatment (section 11.3) to remove 
virus from the cells (-). Penetration is defined by the presence 
of virion RNA in nuclear fractions (section 11.2).
* All from polyclonal sources unless stated.
» Derived from purified slgA by differential reduction.
/
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Figure 12.17.1. Attachment of [32P]-labelled FPV/R neutralized by a polymeric IgG complex to BHK-21 cells at 37°C. Virus was 
first incubated for lh at 25°C neutralizing monoclonal IgG then 
incubated for a further hour with rabbit anti-mouse IgG (Fc 
specific; RAM) ( 0  ) or incubated with neutralizing monoclonal
IgG followed by non-specific rabbit IgG ( O  )- The neutralizing 
IgG plus RAM (polymeric IgG complex) reduced infectivity by 98%. 
Virus-antibody mixtures were then inoculated (100 ul) onto BHK-21 
cells at 37 »C. The subsequent procedure is described in Figure
12.1.1, except that each 100 ul initially contained 1.4 x 107PFU, 
700 HAU, and 1.4 x 105cpm.
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Figure 12.17.2. Kinetics of migration of [32P]-virion RNA from 
the cytoplasm to nucleus in cells inoculated as described in 
Figure 12.17.1. Fractionation was performed as previously 
described (section 11.2; Figure 11.1.2). Symbols as in Figure
12.17.1.
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was reacted with rabbit anti-mouse IgG (Fc region specific) (RAM) 
(Nordic Immunological Laboratories) to investigate if this would 
cause IgG to behave like a polymeric antibody. Neutralizing mouse 
monoclonal IgG (HC2) was incubated with [32P]-labelled FPV/R for 
lh at 25°C and subsequently RAM was added for a further lh at 
25°C. Figure 12.17.1 shows the kinetics of attachment of 
[32p]-labelled virus to BHK-21 cells at 37°C. Neutralizing IgG 
plus RAM reduced attachment of virus to BHK-21 cells to 40% of 
that of virus treated with neutralizing IgG and control rabbit IgG 
(purified from normal rabbit sera). At 4°C there was very little 
attachment. A non-specific monoclonal IgG (171/1) plus RAM had no 
effect on attachment. Thus neutralization by this manufactured 
"mock polymeric antibody" proceeded in the manner observed with 
slgA (section 12.2) and IgM (section 12.3). It was further found 
(Figure 12.17.2) that the RNA of neutralized virus that did attach 
at 37° C in the above experiment remained in the cytoplasmic 
fraction which is consistent with the view that neutralized virus 
is remaining on the surface of the cells, as seen with virus 
neutralized by either slgA or IgM.
12.5. Mechanisms of neutralization by antibody fragments 
derived from monoclonal IgG
To determine if the Fc region and the bivalent character of 
IgG is necessary for neutralization, virus was reacted with 
F(ab')2 and Fab' fragments (section 10.8). F(ab')s fragments 
neutralised FPV/R with about the same efficiency as the IgG from
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which it. was derived. Table 12.3 shows that neutralizing F(ab')2 
fragments failed to inhibit the attachment of neutralized virus to 
BHK-21 cell monolayers and migration of the virion RNA to the 
nucleus after incubation for 90 and 120 min at 37°C. Thus neither 
neutralization nor attachment of neutralized virus to BHK-21 cells 
is dependent on the Fc region.
Neutralization by Fab' had about the same efficiency as that 
of IgG even though the Fab' was standardized with IgG and F(ab')2 
on a molar basis which meant that the Fab’ preparation had half 
the number of antigen binding sites (Table 12.3). In general this 
agrees with earlier work with polyclonal antibody (Lafferty, 1963a) 
and it is concluded that bivalency is not necessary for 
neutralization. However this particular Fab' undergoes dilution 
dissociation with restoration of virus infectivity (section 10.11; 
A.S. Carver, personal communication) which underlies the 
importance of antibody bivalency under normal physiological 
conditions. When it was necessary to employ a dilution step to 
measure the extent of neutralisation by (i.e. after neutralization 
of high titre radiolabelled virus) the neutralized virus was first 
reacted with rabbit anti-mouse IgG (Fab/specific). This stabilised 
neutralization, presumably by restoring bivalency and resurrected 
infectivity was no longer apparent upon dilution.
Figure 12.18.1 shows that attachment of virus neutralized with 
Fab' was slightly reduced compared to that of virus treated with 
non-specific Fab' (obtained from digestion of a non-specific
218
Table 12.3. Percentage attachment of FPV/R and nuclear accumulation of FPV/R genomes from such virus neutralized by F(ab’ )2 fragments to BHK-21 cell monolayers.
Attachment(%) Accumulation in nucleus
Time on
BHK-21
cells
pF(ab’)2 nF(ab’)2 pF(ab’)2 nF(ab ’ )2
90 min 32 33 71 73
120 min 35 34 74 69
[32p]-labelled FPV/R was incubated for lh at 25°C with equivalent 
amounts (20 ug/ml) of either neutralizing, (n) or non-neutralizing 
(p) F(ab’)2 fragments. Percentage nuclear accumulation 
(penetration) in parentheses. Conditions were as described in Fig. 
12.18.1 and 12.18.2. Neutralizing F(ab’)2 fragments reduced 
infectivity by 98.534.
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Figure 12.18.1. Attachment of non-neutralized [32P]-labelled A/FPV/Ros-tock/34 (H7N1) incubated with non-neutralizing Fab* ( Q) and virus incubated with neutralizing Fab' fragments ( 0  ) to BHK-21 cell monolayers. Virus was incubated at 25°C for lh with 
equivalent amounts (8.5 ug/ml) of Fab* fragments then 100 ul was 
inoculated onto monolayers of BHK-21 cells in Petri dishes (6 x 
10s/dish) at 37°C. Each inoculum contained initially 9 x 107 PFU, 
200 HAU, and 1.6 x 105 cpm. The subsequent procedure is described 
in Figure 12.1.1. Neutralizing Fab* fragments reduced infectivity 
by 98%.
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Figure 12.18.2. Kinetics of migration of [32P]-virion RNA from 
the cytoplasm to nucleus in cells inoculated with virus 
neutralized by Fab' fragments ( 9  ) or virus treated with 
non-neutralizing Fab' fragments ( O  ) as described in Figure12.18.1. Fractionation was performed as previously described 
(section 11.2; Figure 11.1.2).
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monoclonal antibody, 171/1. The nuclear accumulation of 
[32P]-labelled RNA from FPV/R neutralized by Fab' fragments 
proceeded at a rate similar to that of RNA from non-neutralized 
virus (Figure 12.18.2). This confirmed that the penetration, and 
transport of the influenza virus genome to the nucleus was 
unimpaired by neutralizing Fab' fragments and that none of these 
processes in neutralized virus depends upon the Fc region or the 
bivalent character of IgG.
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12.6. DISCUSSION
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These studies suggest that the mechanism of neutralization 
of FPV/R is dependent on the class of the neutralizing 
immunoglobulin as represented by the different physical
properties of each of these classes.
FPV/R neutralized by polyclonal IgG attached to a variety of 
different cell types (CEF, L9 2 9 , HFF 4, and BHK-21 cells) with 
kinetics indistinguishable from those of non-neutralized virus. 
Further studies demonstrated that FPV/R neutralized by monoclonal 
IgG or polyclonal monomeric IgA (derived from slgA by 
differential reduction, section 10.10.3) attached to BHK-21 cells 
at the same rate as non-neutralized virus. Using a fractionation 
technique to isolate nuclei from BHK-21 cells, it was found that 
neutralization of influenza virus by IgG or monomeric IgA did not 
affect penetration or transport of viral RNA to the nucleus. In 
fact, the rate of nuclear accumulation of [33 P]-labelled RNA from 
neutralized virus was indistinguishable from that of
non-neutralized virus, therefore loss of infectivity must result 
from the inhibition of a subsequent stage of infection (Possee et 
al., 1982). As there was no difference in the early stages of 
infection between virus neutralized by IgG or by monomeric IgA it 
may be that IgA and IgG have the same mechanism of
neutralization.
12.6.1. Why both neutralizing IgG and monomeric 
IgA fail to inhibit attachment.
The HA spike on the surface of an influenza virus is
composed of three monomers each with a virus attachment site
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(VAS) in a pocket, surrounded by antigenic determinants to which 
neutralizing antibody must bind (section 2.2; Wilson et al., 
1981; Rogers et al. , 1983). Neutralizing IgG antibodies do not 
bind to the HA VAS itself. Studies with [!25 I]-labelled IgG and 
intact viruses (section 13) show that at saturation only one 
molecule is bound per HA trimer. This could leave the VASs on the 
two adjacent monomers freely available for binding to CRUs and 
explain why neutralizing IgG or monomeric IgA does not prevent 
attachment. In contrast to the studies with cultured cells as 
described above, neutralized FPV/R does not bind to chicken 
erythrocytes (Possee, 1981). The influence of host cell on the 
neutralization of virus is well documented (section 9.1) and the 
binding of neutralized influenza virus to cultured cells could 
highlight the difference in the topography of the CRUs of 
erythrocytes and the CRUs on other cells (section 3.1; section
9.2.1). Glycophorin A sialoglycoproteins, the main molecules 
carrying CRUs for influenza viruses on erythrocytes (section 3.1; 
Jackson et al., 1973) are short (5 nm) molecules that lie amongst 
a dense web of carbohydrate and larger molecules on the 
erythrocyte cell surface (section 3.1; Viitala and Jarnefelt,
1985). The phenomenon of HI could therefore be a reflection of 
the nature of the erythrocyte surface topography. The barrier of 
IgG molecules on an influenza virus is successful in blocking 
attachment to erythrocytes. However, this "fringe" of IgG or IgA 
molecules may be penetrated by longer and less impeded receptors 
(as yet uncharacterized) on cultured cells.
Yoden et al. (1982) found "that haemagglutination by 
influenza A/duck/Hokkaido/5/77 (H3N2) was not inhibited by 
neutralizing polyclonal IgG. Also Kida et al. (1982) found that 
some groups of monoclonal antibodies to influenza 
A/seal/Mass./1/80 failed to inhibit haemagglutination of intact 
virus yet effectively neutralized virus infectivity. The physical 
presence of the IgG molecules in these examples cannot be 
sufficient to prevent CRU-VAS interaction, a reflection of the 
situation with BHK-21 cells and other cultured cells, suggesting 
that neutralization is at a later step than adsorption.
Burton (1986), challenges the traditional view that IgG 
molecules bound to antigen remain in a undistorted Y-shape. He 
proposes that IgG molecules in interaction with antigen can be 
dislocated so that the Fc portion of the molecule moves with 
respect to the two Fab arms bound to the antigen. This 
distortion also occurs with IgM and is important in the 
interaction of antibody with complement and Fc receptors. The 
occurrence of an IgG or IgA in a dislocated Y-shape rather than 
the conventional Y-shape or T-shape (section 7.1) may be a 
crucial feature in the interaction of antibody-virus complexes 
with CRUs. The distortions of IgG or IgA molecules could result 
in an inconsistent barrier allowing CRUs on BHK-21 cells and 
other cultured cells to gain access to VASs on the HA spikes.
12.6.2. How does IgG neutralize FPV/R?
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Possee et al. (1982) showed that FPV/R neutralized by IgG
has reduced transcriptase activity both in vivo and in vitro. 
There is considerable evidence that antibodies can mediate 
conformational changes in antigens and that these may be 
transmitted through and along molecules (section 9.2.2). Since 
the transcriptase function, situated internally in the virus, is 
modified by antibody on the other side of the viral envelope it 
has been proposed that the effect is mediated by conformational 
change. The binding of neutralizing immunoglobulin could trigger 
changes in the tertiary structure of the HA which are transmitted 
across the envelope via the transmembrane segment of HA2 to the 
transcriptase.
However, the reduction in transcriptase activity by 
neutralizing IgG is only three to ten fold; which does not 
correlate with the neutralization titre of 99.99% (Possee et al.,
1982). Recent work (R.Rigg, unpublished data) has shown that 
neutralizing monoclonal IgG has little effect on the in vitro 
messenger RNA primed transcription of FPV/R RNA. Further 
investigation of the molecular mechanism of influenza 
neutralization (R.Rigg, unpublished data) suggests that a 
secondary uncoating step (Bukrinskaya et al., 1982) could be 
inhibited by neutralizing antibody and that this results in the 
delivery of non-infectious sub-viral particles to the nucleus. It 
may become apparent that an accumulative affect of neutralizing 
antibody on these post attachment phases (uncoating and 
transcription) is responsible for loss of infectivity.
Competitive binding radioimmunoassays on isolated influenza 
virus HA have demonstrated that binding of certain monoclonal 
antibodies increases the binding of other monoclonal antibodies 
to different epitopes due to conformational changes within the HA 
(Lubeck and Gerhard, 1962). Studies with [! 25J]-labelled
neutralizing IgG and intact influenza virus have shown that at 
saturation only one IgG molecule is bound per HA spike (section 
13). This prevents the further binding of not only monoclonal 
antibodies to different epitopes but polyclonal IgG (section
13.5) and polyclonal slgA (section 13.7.1). These results mean 
that studies indirectly demonstrating conformational change on 
FPV/R HA by neutralizing antibody by its effect on subsequent 
antibody binding on intact FPV/R particles would be unlikely to 
succeed. Susceptibility of HA to proteolytic enzymes provided 
evidence that HA had undergone a conformational change at low pH 
(Skehel et al., 1982). However, studies with a range of
proteolytic enzymes (trypsin, chymotrypsin, subtilisin, and 
elastase) on neutralized and non-neutralized virus failed to 
demonstrate any evidence of differing susceptibility to enzyme 
digestion (G. Ward and N.J. Dimmock, unpublished data). The 
physical presence of the neutralizing IgG bound to the HA may 
inhibit the action of enzymes, therefore preventing this
technique from being definitive. Chemical cross-linking studies 
failed to detect conformational changes in the HA1, HA2, NP or M 
proteins of neutralized FPV/R. Circular dichromism studies of 
neutralizing IgG-virus complexes could prove as useful to the 
study of influenza virus neutralization as they did in studies of
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pH induced conformational changes in BrHA (Skehel et al., 1982). 
Small angle X-ray or neutron scattering investigations (Review: 
Cusack, 1982) could be used to investigate the effect of 
neutralizing immunoglobulins on gross influenza virus structure. 
The scans obtained from small angle X-ray scattering studies of 
neutralized influenza virus would not only provide insight into 
the possibility of conformational changes in the HA spikes, but 
also within the virus particle itself.
One problem of the studies with neutralizing immunoglobulin 
is in estimating the extent to which aggregation contributes to 
neutralization. However, it is known that under similar 
experimental conditions used in this thesis, virus neutralized 
with IgG has the same sedimentation velocity as non-neutralized 
virus (A.S. Carver and N.J. Dimmock, unpublished data). This 
indicates that aggregates, if there are any, are not large. 
Electron microscope studies on neutralization by IgG and 
polymerization (aggregation) also indicated that at high IgG 
concentration to virus particle ratios similar to those used in 
my studies there is minimal aggregation (S.J. Armstrong and N.J. 
Dimmock, unpublished observations). In fact most (> 95%) virus 
particles are monomeric and are completely coated with IgG. 
Aggregation only occurs at lower IgG to virus ratios. High 
concentrations of slgA also resulted in virus monomers coated 
with slgA. However, IgM caused significant polymerization in 
conditions similar to my studies.
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Bo-th F(ab )2 and Fab neutralized virus efficiently 
indicating that neither the Fc region or bivalency respectively 
are necessary prerequisites. Virus neutralized by Fab attached 
to cells and was internalized, showing that neither the Fc region 
or bivalency is responsible for the behaviour of neutralized 
virus (Lafferty 1963b). However experience with poliovirus 
suggests that under some circumstances Fab fragments from 
certain monoclonal IgGs are not neutralizing (section 9.2.2) so 
no generalization is yet possible.
Interestingly the amount of virus neutralized by Fab which 
attached to the BHK-21 cells was consistently slightly lower than 
that of non-neutralized virus or virus neutralized by IgG. It may 
be that because of its smaller size, more Fab can bind per HA 
spike than IgG and thus impede attachment by steric hindrance.
12.6.3. Neutralization by slgA and IgM.
Influenza virus neutralized by slgA and IgM behaved in the 
same way, perhaps indicating a common mechanism of 
neutralization. At 4°C neutralizing slgA and IgM effectively 
prevented attachment of influenza. Steric hindrance of the 
attachment of virus neutralized by IgM and slgA is probably the 
mechanism of neutralization at 4°C but it is possible that virus 
has already been rendered non-infectious by the same mechanism 
that operates with IgG and slgA. The extent to which aggregation 
by these antibodies contribute to neutralization has yet to be
229
determined. At 25 and 37°C half the virus neutralized by either 
IgM or slgA attaches to cells presumably through increased 
thermal agitation bringing VASs and CRUs into the correct 
juxtaposition. Very little of this attached virus was 
internalized and it is apparent that IgM and slgA interfere with 
the endocytotic event responsible for internalization. It is not 
known why such virus is not endocytosed into vesicles (section
3.2) but the physical presence of these polymeric immunoglobulins 
may jam the circumferential adherence or "zipper" mechanism of 
endocytosis (Griffin et al., 1975; Marsh, 1984). The curtailment 
of endocytosis by neutralizing slgA and IgM at 25 and 37°C is so 
substantial that the majority of neutralized virus particles can 
be removed from the surface of BHK-21 cells by proteinase K 
treatment. Virus neutralized by an IgG + anti-(IgG Fc) complex 
interacted with cells in the same manner as virus neutralized 
with slgA or IgM supporting the idea that the physical size of a 
polymeric antibody, unlike IgG and IgA, impedes attachment 
(especially at 4°C ) and prevents successful endocytosis. The 
effective agglutination characteristics associated with the 
pentameric and dimeric structures of IgM and slgA respectively 
could also be relevant.
Attachment to cells without internalization at physiological 
temperatures by neutralizing IgM may be relevant in vivo, it 
could lead to complement-mediated cell lysis early in the disease 
(section 5.4; Lachmann,1985). slgA does not fix complement 
(Tomasi, 1976) but can mediate ADCC (section 5.4; Tagliabue et
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al., 1983), -therefore the presence of slgA-virus complexes on 
cells in vivo could be important in the elimination of infection. 
Neutralizing slgA obtained from the milk of pigs did not inhibit 
the attachment of transmissible gastroenteritis virus (TGEV) to 
porcine derived cell lines (Nguyen et al., 1986). However, the
neutralized TGEV was unable to enter cells as demonstrated by the 
action of proteinase K which removed it from the cell surface. 
These are similar results to those reported in this thesis for 
the neutralization of influenza virus by slgA at 25 and 37°C.
12.6.4. In what way could IgM and slgA physically block
attachment?
Since IgM is pentaraeric (i.e. composed of 5 four chain 
immunoglobulin units; section 6.2.2) as well as binding in a 
spider-like conformation (section 7.1; Figure 7.1.3) with all 
Fab’mu arms to the influenza HAs, it is possible that it could 
bind with only a few Fab’mu with the rest of the molecule 
providing a physical wedge between virus and CRUs (Figure 7.1.3). 
Since slgA is composed of 2 four chain immunoglobulin units 
linked by the Sc and J chain (section 6.2.3), slgA may bind in a 
"hair-pin" conformation (evidence suggests that slgA is flexible 
enough to have this conformation; section 7.1; Figure 7.1.3), 
with both four chain units attached to the virus, or through only 
one unit so that the slgA molecule would be orientated in the 
double Y extended conformation perpendicular to the virus surface 
(Figure 7.1.3). This latter docking orientation would
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approximately double the distance between VAS and CRU achieved 
when IgG or monomeric IgA binds. This measure of steric hindrance 
may be crucial and could account for the failure of IgG and 
monomeric IgA to prevent attachment (see above).
The determination of the mechanism of neutralization of 
influenza virus by slgA is of particular interest, since in the 
respiratory tract of man neutralizing slgA is a major determinant 
of resistance to re-infection with influenza virus (section 5.5). 
For example, local slgA memory for influenza HA has been 
demonstrated in the upper respiratory tract of humans challenged 
with an inactivated vaccine (Wright et al., 1983). IgG and IgM 
can also contribute to human local immunity but are present in 
low concentrations compared to that of slgA. The problem of 
obtaining sufficient amounts of immune slgA for the studies in 
this thesis was overcome by using bile from appropriately 
immunized rats (section 10.10). This method could be adapted to 
investigate neutralization by slgA of other viruses. slgA 
comprises approximately 70% of the total immunoglobulin in bile 
(Andrew and Hall, 1982) and immunochemical analysis has 
established (Andrew and Hall, 1982; Tomasi and Bienenstock, 1968; 
Nagura et al., 1981) that slgA from bile and respiratory 
secretions is identical. Stimulation of the gastrointestinal 
tract of human volunteers established neutralizing slgA in the 
respiratory secretions (Waldman et al., 1981). Monomeric IgA is 
present in the serum of mammals, comprising 20% of normal serum 
immunoglobulins in man (Nisonoff et al., 1975; Tomasi, 1976), but
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definitive studies of its role in resistance to influenza 
infections have not been carried out. Systemically the 
neutralization of influenza virus is a function primarily of IgG 
(section 5.5).
In conclusion, the mechanism of neutralization of influenza 
virus A/fowl plague virus/Rostock/34 (H7N1) is clearly dependent 
on the class of neutralizing immunoglobulin. Only at 4°C does 
neutralizing slgA and IgM effectively prevent attachment of 
influenza virus. At physiological temperatures IgM and slgA 
permit the attachment of approximately half the neutralized virus 
but this is not internalized. In contrast, neither neutralizing 
IgG or IgA has any effect on attachment at temperatures of 4 to 
37° C, or on the subsequent stages of infection up to the 
accumulation of virion RNA in the nucleus. Functional Fab 
fragments from monoclonal IgG reduced only slightly the
penetration of neutralized FPV/R to BHK-21 cells, whereas FPV/R 
neutralized by F(ab )2 fragments attached and penetrated BHK-21 
cells to the same extent as infectious FPV/R.
It is emerging that virus neutralization is a tripartite 
system inter-dependent on cell, virus and immunoglobulin. Studies 
on the mechanisms of influenza neutralization in the natural 
target tissues of the virus in the mammalian host (i.e. those of 
the upper respiratory tract) using homologous immunoglobulin need 
to be done to yield information on the relevant mechanisms which
operate in vivo.
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SECTION 13:
THE NUMBER OF IMMUNOGLOBULIN MOLECULES BINDING TO FPV/R 
HAEMAGGLUTININ ON INTACT FPV/R PARTICLES.
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Summary
Radiochemical data in this investigation on the binding of 
immunoglobulins to the HA of FPV/R in suspension suggest that the 
virus is saturated at approximately one IgG molecule per HA 
spike. slgA saturates at a level of 0.4 (the equivalent of 0.8 
four chain immunoglobulin units) per spike and IgM at a level of 
0.1 (the equivalent of 0.5 four chain units) per spike. Two-step 
competition assays show that the binding of one molecule of 
monoclonal IgG to a HA spike prevented the binding of monoclonal 
antibodies to two other epitopes on that spike and also the 
binding of polyclonal antibody to the HA.
Kinetics of neutralization of FPV/R with monoclonal IgG 
under all conditions, except low temperature or minimal 
neutralizing concentrations of antibody, were single-hit. However 
at 4°C with a low concentration of antibody kinetics were 
multi-hit and extrapolation suggested that about 3 IgG molecules 
were required to neutralize an infectious virus particle. This is 
at variance with radiochemical data showing that at least 50 
antibodies per virus particle are required for neutralization. 
The apparent conflict can be reconciled by a theory that 
neutralization only occurs when antibody binds to certain 
"neutralization relevant" HA spikes which are in the minority. 
Binding to the majority of HA spikes is irrelevant to 
neutralization. The neutralization relevant and irrelevant spikes 
would differ only in their interaction with the virion core
structure.
Introduction
Studies on the mechanisms of neutralization of FPV/R
(section 12; Possee 1981; Possee et al. , 1981) have demonstrated
that FPV/R neutralized to greater than 99.9% by polyclonal or 
monoclonal IgG attaches to mammalian and avian cells at the same 
rate as non-neutralized virus. In order to understand the 
quantitative aspects of the neutralization reaction more fully an 
estimate of the number of IgG molecules binding to FPV/R
particles is required.
Kinetic data (section 8.1.1) show that neutralization 
follows either single-hit or multi-hit kinetics with at most 3 
hits required to inactivate one infectious virus particle. The 
aim of this investigation was to obtain direct biochemical 
evidence, using radiolabelled antibody, of the minimum number of 
antibody molecules per particle which are required to achieve 
neutralization and to correlate this with kinetic data.
The kinetic data also suggest that as one or a few 
neutralizing IgG molecules are bound to the surface of an 
influenza virus particle the vast majority of potential VASs 
would be free of antibody. If this is the case, then one would 
expect the unencumbered HA to be able to attach virus to a cell. 
Firstly, to examine this problem and to address in part how 
neutralized virus attaches to cells (section 12), the number of 
HA spikes on an influenza particle was determined. Then, using 
radiolabelled antibody molecules, the maximum number of 
immunoglobulin molecules binding to each HA spike was calculated.
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It was determinad that one bound immunoglobulin molecule had the 
ability to interfere with the binding of antibodies to vacant 
identical, or even different epitopes, on the same HA spike.
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13.1. Estimation of the number of surface projections.
The number of surface projections was estimated using the 
method of Tiffany and Blough (1970b). The mean overall diameter 
(Do) of a FPV/R particle was 119.5nm (+/- 23.2; n=100) (Figure
13.0. 1). The diameter of non-spherical (quasispherical) particles 
was estimated as an average of three axes; the longest axis, the 
shortest axis and an intermediate axis. The diameter of the virus 
particle at the enveloped surface (De) was calculated by 
119.5nm-2x external length of a spike (24 nm) ; De =95.5nm. The 
mean area of a FPV/R particle (De2 Tf ) was 28652 nm2 . The spacing 
between the spikes was 5.1 nm (+ /- 1.9; n=50) (Figures 13.0.2 to
13.0. 5). For spikes spaced that distance (a) apart, the mean area 
per spike surrounded by six others is 0.5 x a2/3 which for FPV/R 
was found to be 22.52 nm (+/-2.08). The mean number of spikes per 
particle was found to be 1273 spikes (2 De2J3^ /a2^ 31 .
13.1.1. Estimation of the number of virus particles 
per HAD FPV/R.
The number of FPV/R particles per HAU was determined by 
diluting latex spheres of pre-determined concentration with a 
known HAU of FPV/R. Using an electron microscope each particle 
was scored. The latex particles were scored for the initial 
dilution and the conversion factor used is also the factor 
required to convert the FPV/R count to total particles. In this 
ten separate determinations were made. The mean value wasmanner
Figure 13.0.1. Electromniorograph of influenza virus particles visualized by negative stain with IX sodium silicotungstate. 109
nm (SD +/- 2.7 nm) diameter latex beads (B) were used to
calibrate size. The mean overall diameter (Do ) of a FPV/R 
particle was 119.5 nm (SD +/- 23.2; n= 100). Virus particles were 
approximately spherical and closely covered with projecting 
haemagglutinin and neuraminidase spikes. Some can be seen end on 
and around the periphery of the particle (x 312,000).
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Figure 13.0.1. Electronmlcrograph of influenza virus particles 
visualized by negative stain with IX sodium silicotungstate. 109
nm (SD +/- 2.7 nm) diameter latex beads (B) were used to
calibrate size. The mean overall diameter (Do ) of a FPV/R 
particle was 119.5 nm (SD +/- 23.2; n= 100). Virus particles were 
approximately spherical and closely covered with projecting 
haemagglutinin and neuraminidase spikes. Some can be seen end on 
and around the periphery of the particle (x 312,000).
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Figure 13.0.2 "to 13.0.5. Negatively stained preparations of FPV/R particles. The surface spike distribution when sufficiently 
distinct (circled regions) permitted calculation of a mean spike 
spacing of 5.1 nm (SD +/- 1.9; 50 measurements from 20 different 
particles).
Figure 13.0.2
(x 360,000) Figure 13.0.3(x 560,000)
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Figure 13.0.2 to 13.0.5. Negatively stained preparations of FPV/R 
particles. The surface spike distribution when sufficiently 
distinct (circled regions) permitted calculation of a mean spike 
spacing of 5.1 nm (SD +/- 1.9; 50 measurements from 20 different 
particles).
Figure 13.0.2
(x 360,000) Figure 13.0.3(x 560,000)
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1 HAU = 3.981 x 107 particles (SD +/- £.4.? x 10®).
13.2. Estimation of the proportion of haemagglutinin (HA) and 
neuraminidase (NA) spikes.
Coomassie blue BSA-complexes on polyacrylamide gels gave 
linear plots of area under peak against ug protein and were shown 
to follow Beers law. This demonstrated that as well as being a 
suitable method for studying relative concentrations of 
polypeptides in a mixture this method is satisfactory for 
quantifying protein concentration iFasekas de St. Groth et al.. 
1963; Ske’nel and Schiid, 1971). By scanning the polypeptide bands 
stained by Coomassie brilliant blue (Figure 13.0.6) on a 
polyacrylamide gel with a Joyce-Loebi densitometer and measuring 
the areas (mm2 ) under the peaks of the scan (Figure 13.0.7) it 
was estimated that the ratio of HA to NA was 4.6/1 (mean of 5 
measurements). This would suggest that out of an estimated 1273 
spikes approximately 1000 were haemagglutinin.
13.3.1. HI antibody resistant patterns defined 3 HI epitopes
Information on the antigenic properties of monoclonal 
antibodies was required in order to plan and interpret 
investigations concerning the quantification of binding of 
competing monoclonal IgGs.
An antigenic site of a protein i3 defined here as a region
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Figure 13.0.6. The polypeptide 
components of influenza A/FPV/R. 
10,000 HAÜ of purified FPV/R were 
loaded onto and separated by SDS-PAGE 
as described in section 10.6. The 
protein bands were stained by 
Coomassie Brilliant Blue and then 
scanned in a Joyce-Loebl densitometer.
Figure 13.0.7. Densitometer tracing of the stained Dolypeptiae 
components of FPV/R separated on an SDS-PAGE gel (Figure 13.0.6). 
Gels were scanned at 620 nm in a Joyce-Loebl densitometer. The 
percentage of total stain bound for NA and HA (HA1 + HA2) protein 
was calculated and from the results of 5 measurements the average 
HA:NA ratio was taken to be 4.6:1 (SD +/- 0.6).
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Figure 13.0.6. The polypeptide 
components of influenza A/FPV/R. 
10,000 HAU of purified FPV/R were 
loaded onto and separated by SDS-PAGE 
as described in section 10.6. The 
protein bands were stained by 
Coomassie Brilliant Blue and then 
scanned in a Joyce-Loebl densitometer.
Figure 13.0.7. Densitometer tracing of the 3tained Dolypeptiae 
components of FPV/R separated on an SDS-PAGE gel (Figure 13.0.6). 
Gels were scanned at 620 nm in a Joyce-Loebl densitometer. The 
percentage of total stain bound for NA and HA (HA1 + HA2) protein 
was calculated and from the results of 5 measurements the average 
HA:NA ratio was taken to be 4.6:1 i SD +/- 0.6).
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composed of contiguous (or non-contiguous) amino acids that 
induces and binds antibodies. An epitope is the molecular 
conformation of a sequence of amino acids (contiguous or 
non-contiguous) on the antigenic site that a monoclonal antibody 
will recognize and bind to. Therefore a single antigenic site may 
be capable of expressing many epitopes. The epitopes within an 
antigenic site may or may not overlap functionally, that is an 
escape mutant resistant to the action of one monoclonal antibody 
may or may not escape the action (i.e. HI) by other monoclonal 
antibodies belonging to the same cluster.
Each monoclonal immunoglobulin in mouse ascites fluid was 
used to select escape mutants resistant to HI by that antibody. 
Of 21 mutants, 12 behaved reproducibly in HI assays. Unstable 
mutants were not studied further. Each one of the 12 escape 
mutants was classified by its sensitivity to HI by each of the 
monoclonal IgGs. This defined a series of epitopes. The escape 
mutants resistant to HC61 defined epitope X; those resistant to 
HC10 defined epitope Y, and those resistant to HC58 and HC2 
defined epitope Z (Table 13.1).
13.3.2. Selection of escape mutants by polyclonal sera.
Sera WR45, WR6 (both containing IgG to FPV/D HA; H7) and 
WR69 (serum containing IgG to FPV/R HA; H7) were used to select 
escape mutants from parental virus stocks. However it was found 
that only WR45 could be used to select such mutants. The ability
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Table 13.1. HI analysis of influenza A/FPV/R antigenic mutant 
viruses selected by anti-H7 monoclonal antibody.
Virus Monoclonal IgG
HC61 HC10 HC58 HC2
[X] [Y] [Z] [Z]
Mutant 61B _ +++ +++ +++
61D ++ +++ +++
10B + + + - +++ ++
IOC + + + - +++ +++
10E + + - +++ +++
10F + + + - +++ +++
• 58A + + + +++ _ _
58C + + + +++ - -
58D + + + +++ - -
2C + + + +++ _ _
2G + + + +++ - -
• 2H + + + +++ - -
FPV/R(p) + + + +++ +++ +++
FPV/R(a) + + + +++ +++ +++
Monoclonal antibodies HC2, HC10, HC58 and HC61 were used
select escape mutants from parental stocks (section 10.14). Epi
in parentheses.
+++ > 3.3 logio HI*
++ >2.2 logio , <3.3 logio HI.
<1.45 logio HI.
FPV/R(p) = parental FPV/R 
FPV/R(c) = control passage FPV/R
* HI titre expressed as logio reciprocal of dilution causing 50% 
inhibition of 4 HAU FPV/R.
n.b. Additional anti-H7 ascites fluids HC1, HC3 and Ml (gifts 
from J.J. Skehel) were also mapped in this study. HC1 mapped to 
antigenic site Z, and HC3 and Ml mapped to X. These monoclonal 
antibodies were not used in any other experiments.
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Table 13.2. Antigenic relationship between escape mutant virusesselected by anti-H7 polyclonal antibody (WR45) and escape mutantviruses selected by monoclonal antibody as measured by HI.
Virus Mono- or poly- clonal IgG
WR45 HC61 HC10 HC58 HC2 WR69
[X] [Y] [Z] [Z]
Mutant R< 5 A 2.8 4.7 - 2.7 4.7 3.4
R4 5 B 2.8 4.7 1.9 3.1 4.7 3.4
R4 5 C 2.5 4.7 - 2.9 4.7 3.6
• R4 5 D 2.8 4.7 1.6 3.0 4.7 3.1
6 IB 3.4 - 4.4 to CD NT 3.4
10C 3. 1 4.7 _ 2 . 8 NT 3.6
58D 3.6 4.7 4.4 - NT 3.6
FPV/R(a) 3.4 4.7 4.1 3 . 1 4.7 3.4
FPV/R(b ) 3.4 4.4 4.4 3.8 4.1 3.4
FPV/R(p ) 3.4 4.7 4.4 3.8 4.7 3.4
Polyclonal WR45 was used to select escape mutants from parental FPV/R 
(p) (section 10.14). Escape mutants selected by WR45 are mutants 
R4 5A-D. Designation of antibodies as text.
HI titre expressed as the logi 0 reciprocal of the dilution inhibiting 
heamagglutination (section 10.12). All are corrected for homologous 
interaction.
<1.45 logi 0
FPV/R (a) and (b) are control FPV/R passages.
NT = not tested.
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Table 13.3. Neutralization assays as determined by plaque reduction 
of mutant viruses by polyclonal and monoclonal IgG.
% Neutralization * by
Virus poly- or mono- clonal IgG
WR4 5 HC61 HC10 HC58 HC2
[X] [Y] [Z] [Z]
Mutant R< 5 A 99.99 >99.99 - 86.0 >99.99
R4 5 B 99.98 99.96 - 90.0 >99.99
6IB (X) 99.99 - >99.99 98.2 >99.99' IOC (Y) 99.96 99.95 - 98.0 >99.99" 58D iZ) 99.99 99.98 >99.99 - -
2C ( Z) 99.96 99.99 >99.99 - -
FPv/R(a) 99.99 99.96 >99.99 98.2 >99.99FPV/R(p) 99.99 >99.99 >99.99 98.0 >99.99
* Neutralization of 5 x 107 PFU. 
< 25% neutralization
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of the mutants to react with antibody was assayed by HI (Table
13.2). The escape mutant viruses (R45 A-D) selected by WR45 
consistently failed to react with ascites fluid containing HC10, 
but essentially gave a complete pattern reactivity against the 
other monoclonal antibodies. An exception was the slightly 
lowered HI reactivity of HC58 towards the escape mutants. This is 
surprising since HC10 and HC58 map to different antigenic sites 
(Y and Z respectively) and since reactivity to HC2 (Z) was 
unaffected. The mutants also showed a lowered HI reactivity with 
WR45. WR45 significantly inhibited the haemagglutination activity 
of mutant IOC, a variant resistant to HC10. The reactivity of the 
R45 escape mutants against another polyclonal IgG, WR69, was not 
diminished.
The escape mutants selected by WR45 on three separate 
occasions were re-passaged in the presence of WR45 antibody or 
HC10 antibody and each remained mutant in character. No further 
selection occurred when these escape mutants were incubated with 
polyclonal sera WR6 and WR69.
An HI assay with FPV/D revealed that all monoclonal and 
polyclonal IgG sources reacted precisely as they did with FPV/R. 
This demonstrated exact serological relatedness between the FPV/D 
H7 and FPV/R H7, with respect to the reagents used.
Disparity between HI tests and neutralization assays have 
been described (Lu et al., 1982; Kida et al., 1982), therefore,
REPRODUCED 
FROM THE 
BEST
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neutralisation assays were carried out on escape mutants iTable
13.3). This study revealed that the slightly reduced HI activity 
of WR45 towards escape mutants R4 5A and B was not reflected by a 
comparable resistance of the mutants to neutralization by WR45. 
The neutralization of the mutants by WR45 was, in fact, slightly 
more efficient than the neutralization of control passage 
FPV/R(a) and parental FrV/Rip). Apart from this deviation the
results observed in the HI assay were refleczed in th
neutrali zatior. tests. WR4 5 neutralised the escape mutant
selected by monoclonal antipodies. including the mutant seieetc1
by HC10. HC10 failed to neutralize the P.4 s escape mutants 
reflecting its inability to inhibit haemagglutination. HC58 
showed a lowered capability to neutralize F;4 5 A/B that mirrored 
the reduced HI activity of HC58 against these escape mutants. The 
correlation between the neutralization of escape mutants selectee 
by the monoclonal immunoglobulins and the HI pattern was strong.
The results suggest that WR45 can indeed select variants, 
but that this capacity is limited to mutations in one epitope, Y, 
the epitope also recognized by HC10. However WR45 is a polyclonal 
serum as it retains the ability to neutralize and inhibit the 
haemagglutination ability of the mutant viruses it has selected. 
It must contain populations of IgG that bind to other epitopes 
apart from epitope Y. These undefined populations of IgG ensure 
complete neutralization of site Y mutants as further variants do 
not arise upon re * incubation of escape mutants with WR45.
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These observations or tne properties of WR45 IgG became 
important in investigations concerning the inhibition of binding 
of antibody to virus by pre-bound antibody.
The levels of neutralisation of FPV/R achieved with 
polyclonal slgA or polyclonal Ig’d although significant were not 
high enough to select escape mutants.
13.4.1. Estimation of the number of radiolabelled 
polyclonal IgG molecules binding to FPV/R particles.
Table 13.4 shows that when FPV/R and purified polyclonal IgG 
were mixed together in a ratio giving ¿9.95% neutralisation of 
the virus there were from 0.41 to 0.69 (mean = 0.53) IgG 
molecules binding to each haemagglutinin spike (see sample 
calculation, Table 13.4). The reproducibility of these results 
encouraged further investigation. When the ratio of IgG in terms 
of HIU to HAU of virus was varied (Figure 13.1.1) it was found 
that the maximum amount of IgG that could bind to each 
haemagglutinin spike was approximately 0.9 (i.e. in the order of 
1). At this level neutralisation was in excess of 99.5%. This 
pattern was similar with neutralising IgG obtained from two 
different rabbits, WR26 and WR45. which had been inoculated 
(section 10.7) with FFV/D (H7N7) and one rabbit WR69 that had 
been inoculated with V31 which has an H7 derived from FPV/R
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Table 13.4. Estimation of -the amount of specific polyclonal IgGbinding to each HA HIU/HAU ratio of 3.spike on an intact 75:1*. FPV/R
particle at an 1
IgG designation cpm due to 
specific binding
No. of IgG 1 
molecules/HA spike 1
WR4 5 8452 0.56 I
• 8960 0.58 I
• 10559 CT)CDO
• 6298 0.41
WR26 10521 0.42
* 20 HAU FPV/R (7.962 x 10s virus particles) were incubated with 
75 HIU purified IgG derived from WR45 or WR26 as described in 
section 11.4. This gave an HIU/HAU ratio of 3.75:1 and would 
ensure the neutralization of 1 x 107 PFU FPV/R by >99.5%.
Virus-[l25x]-labelled IgG complexes were sedimented through 
a 5 ml cushion of 5% sucrose in PBS by ultracentrifugation. The 
amount of radioactivity associated with the pellet was 
determined. Iodinated IgG binding to FPV/R was determined with 
respect to non-specific binding to influenza B/Lee. The number of 
IgG molecules binding was calculated from using a MW of IgG of 
150,000; that 1 HAU FPV/R equals 3.981 x 107 virus particles 
(v.p); there are an average of 1000 HA spikes per FPV/R particle 
and L= 6.02 x 1022/mol. Sp. act. of [i25 I]-labelled WR45 = 7.68 x 
10® cpm/ug; sp act. of [1 25j]-labelled WR26= 1.25 x 105 cpm/ug.
Sample calculation: Number of WR45 IgGs binding to each HA spike 
on FPV/R.
___8452 com__
7.6 x 10®cpm/pg = 0.11 jig IgG.
0.11 x 10-7 g 
1.5 X 105
7.33 x 10*13 x L
= 7.33 X 10-13
= 4.42 x 1011 molecules IgG.
4.42 x ion
7.962 x 10« v.p. = 555 IgG molecules per virus particle. 
= 0,56 molecules per HA spike.
251
Figure 13.1.1 and Figure 13.1.2 Number of specific polyclonal IgG 
molecules binding to each haemagglutinin spike on an intact FPV/R 
particle.
Figure 13.1.1 20 HAU FPV/R (7.962 x 10* particles) were incubated 
with increasing HIU of purified IgG (section 11.4) derived from 
WR45 or WR26 ( . WR45 and WR26 were antisera produced 
from the inoculation of rabbits with FPV/D (H7N7) (section 10.7).
_L
2
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Figure 13.1.2.20 HACJ FPV/R (7.962 x 10* particles) were incubated 
with increasing HIU of purified IgG (section 11.4) derived from 
WR69. WR69 was antiserum produced from the inoculation of rabbits 
(section 10.7) with V31 (H7N2) (section 10.15). The specific
activity of [!25j]-labelled WR69 IgG was 4.2 x 104 cpm/ug.
The number of IgG molecules was calculated as described in Table
13.4.
R a t i o  H I U / H A u
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(H7N1) (Figure 13.1.2).
The activity of IgG was expressed in terms of HIU because 
protein concentration and neutralization capability could not be 
reconciled with the variable degrees of iodination and 
inactivation inherent in producing [1 25 I]-labelled antibody.
13.4.2. Estimation of the number of radiolabelled 
monoclonal IgG molecules binding to FPV/R particles.
Binding curves for monoclonal antibodies HC2, HC10, HC58 and 
HC61 were also obtained (Figures 13.2.1 to 13.2.4). All showed 
that the maximum number of IgG molecules that would attach per 
spike was in the order of 1 (or 1000 IgG molecules per 
particle).
13.4.3. The relationship between the number of antibodies 
binding to a FPV/R particle and neutralization.
Figure 13.3. shows the relationship between percentage 
neutralization of 1.3 x 10* PFU and the number of HC2 IgG 
molecules bound per FPV/R particle. At 50% neutralization it was 
calculated that there were an average of 45 IgG molecules bound 
per particle (the "neutralization dose 50" or Nso ). To achieve 
more than 90% neutralization the virus population has to bind 
more than 150 IgG molecules/particle. Figure 13.4 demonstrates 
the number of HC10 IgG molecules that are required for
25 4
Figures 13.2.1-13.2.4. Number of monoclonal IgG molecules binding 
-to HA spikes on FPV/R particles at increasing HIO/HAO ratios.
Monoclonal IgG (derived from HC2, HC10, HC58 AND HC61) were 
incubated with 20 HAU FPV/R as described in section 11.4. and 
Table 13.4. The profiles of the binding of HC2 IgG (Fig. 13.2.1), 
HC10 IgG (Fig 13.2.2), HC58 IgG (Fig 13.2.3) and HC61 IgG (Fig. 
13.2.4) indicate that the level of saturation is in the order of 
1 IgG molecule per HA spike. The specific activities of
[125l]-labelled HC2, HC10, HC58 and HC61 were 5.6 x 10«, 8.44 x
10«, 9.8 x 10« and 5.14 x 10« cpm/ug respectively.
Figure 13.2.1. Number of HC2 
IgG molecules binding
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Figure 13.2.2. Humber of HC10
IgG molecules binding
R a t i o  H I U / H A U
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Figure 13.2.3. Number of HC58IgG molecules binding
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Figure 13.2.4. Number of HC61IgG molecules binding
R a t i o  H I U / H A U
neutralization of 2 x 107 PFU FPV/R. The Nso for HC10 was 50 IgG 
molecules per particle which compares favourably with the Nso of 
HC2 of 45. The relationship between the number of IgG molecules 
binding and neutralization is linear up to 99.98% neutralization.
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Figure 13.3. Graph showing the percentage neutralization against 
the number of monoclonal (HC2) IgG molecules binding to a FPV/R 
particle. The Nso is the amount of IgG binding that will 
neutralize 50% of the virus, i.e. 45 IgG molecules/particle. The 
number of IgG molecules was calculated as described in Table
13.4.
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Figure 13.4. Reduction in the infectivity of 2 x 107 PFO FPV/R by 
HC10 IgG correlated with the number of IgG molecules binding per 
HA spike or FPV/R particle. Increasing amounts of C1 25 I]-labelled 
HC10 were incubated with 2 x 107 PFU and the % neutralization 
measured by plaque reduction (section 10.11). Parallel binding 
assays (section 11.4) were carried out in order to estimate the 
number of IgG molecules bound/particle ( ■  ).
Significant neutralization titres are denoted:
50% : A
99% O
99.9% : 0
99.98% • □
N o .  o f  H C  1 0  I g G  m o l e c u l e s  p e r  F P V / R  p a r t i c l e  
2 0 0  4 0 0  6 0 0  3 0 0  1 0 0 0
No. of HC to IgG molec
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13.5. Two step competition assay of binding IgG 
to influenza virus.
These experiments were carried out using two different 
populations of purified immunoglobulins incubated separately with 
20 HAU FPV/R. These investigations would determine if the feature 
of not more than one antibody binding to a HA spike was a 
functional or an intrinsic phenomenon. The monoclonal IgGs used 
in each assay mapped to different epitopes, therefore direct 
competition should not be a factor in the inhibition of binding. 
Prior to each experiment in these studies binding curves for each 
[l25 I]-labelled IgG were obtained and saturating levels (in terms 
of HIU) were determined. Using this information two step 
incubation assays of 20 HAU FPV/R with unlabelled and labelled 
immunoglobulins were performed. The maximum number of IgG
molecules binding per spike was consistently in the order of 1 
(mean value for all IgGs at 175 HIU = 1.1, +/- 0.28). All 
antibodies exhibited homologous inhibition, i.e. unlabelled IgG 
inhibited the binding of labelled IgG from the same source.
13.5.1. HC58 (mapping to epitope Z) 
and HC10 (mapping to epitope Y) IgG.
Firstly, FPV/R was incubated with increasing amounts of 
unlabelled HC58 at 2.5, 3.75, 5 and 8.75 HIU/HAU ratios for lh at 
25°C, and then for 18h at 4°C. After this time a saturating
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Figure 13.5. Increasing amounts of unlabelled HC58 (mapping to 
epitope Z) IgG (from 50-180 HIU) restrict the binding of a 
constant amount (175 HID) of [*■251]-labelled BC10 (mapping to 
epitope Y) IgG. 20 HAU FPV/R was incubated with increasing HIU of 
unlabelled HC58 before a second incubation with 175 HIU 
[l 2sI]-labelled HC10 IgG (section 13.5.1). Specific activity of 
[l 25x]-labelled HC10 IgG = 9.07 x 10« cpm/ug, specific activity 
of [i 25I]-labelled HC58 IgG = 9.8 x 10</ug. The binding of
[l 251]-labelled HC10 IgG (# # ) was reduced from 1.1 IgG
molecules per spike (iodinated HC10 IgG alone with virus,#.....) to 
0.03 per spike.
( # 1 st«p)
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Figure 13.6. Increasing amounts of unlabelled HC10 IgG (from 
50-175 HIU) restrict the binding of a constant amount (175 HIU) 
of [l25I]-labelled HC58 IgG. Experiment performed as described in 
Figure 13.5, except that incubation of unlabelled HG10 IgG was 
followed by incubation with C125 I]-labelled HC58 IgG. The binding 
of [l 2 5 I ]-labelled HC58 IgG (A— A ) was reduced from 1.05 IgG 
molecules per spike (iodinated HC58 IgG alone with virus to 
0.09 per spike.
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amount (8.75 HIU/HAU) of [i25 I]-labelled HC10 IgG was added to 
each virus:antibody mixture. The radioactivity associated with 
the virus pellet was determined (section 11.4) and Figure 13.5. 
shows that increasing the concentration of unlabelled HC58 
restricted the attachment of [l25X]-labelled HC10 IgG from 1.1 
antibody per HA spike to less than 0.03 per spike.
Figure 13.6 illustrates that this pattern was essentially 
repeated when the incubations were reversed using increasing 
amounts of unlabelled HC10 IgG against a second incubation of a 
constant amount of [*25 I]-labelled HC58 IgG that would without 
the HC10 incubation achieve saturation. The binding of 
[i25 I]-labelled HC58 IgG was reduced from 1.05 IgG molecules per 
spike to 0.09 per spike. Thus, despite these antibodies being 
directed to different epitopes they prevented the binding of the 
second antibody, indicating that inhibition could be steric 
hindrance and is intrinsic to the binding of antibody to HA 
spikes.
13.5.2. HC2 (mapping to epitope Z) 
and HC10 (mapping to epitope Y) IgG.
This experiment was performed as described in section
13.5.1. except that HC2 was used instead of HC58. Both HC58 and 
HC2 map to antigenic site Z (section 13.3.1; Table 13.2). Figure 
13.7 shows that increasing the concentration of unlabelled HC2 
restricted the attachment of [l25 I]-labelled HC10 IgG from 0.94 
antibody per HA spike to less than 0.09 per spike. A reciprocal
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Figure 13.7. Increasing amounts of unlabelled HC2 (mapping to 
epitope Z) IgG (from 50-175 HIU) restrict the binding of a 
constant amount (175 HIU) of [l 25 I]-labelled HC10 (mapping to 
epitope Y) IgG. Experiment performed as described in Figure 13.5, 
except that incubation of unlabelled HC2 IgG was followed by 
incubation with [l 2SI]-labelled HC10 IgG. The binding of 
[l 25 I]-labelled HC10 IgG (# ' < ) was reduced from 0.94 IgG
molecules per spike (iodinated HC58 IgG alone with virus,®.. ) to
0.09 per spike. The specific activity of [125 I]-labelled HC10 IgG 
= 8.44 x 10* cpm/ug.
experiment with unlabelled HC10 and labelled HC2 produced a 
similar result.
These studies indicate that the initial incubation of 
increasing concentrations of unlabelled monoclonal antibody 
restricts, almost completely the binding of the other antibodies 
tested. This consistently occurs despite the fact that the two 
monoclonal IgGs used in each assay map to different epitopes.
In the next series of experiments the ability of monoclonal 
antibodies to prevent binding of polyclonal IgG (WR45 or WR69) 
was investigated.
13.5.3. HC10 (mapping to epitope Y) and WR45 (polyclonal) IgG.
WR45 is a polyclonal IgG and would be expected to contain a 
mixed population of IgG molecules binding to a range of
neutralizing epitopes. In the two step incubation assay it was 
found that preliminary incubation of unlabelled HC10 in
increasing amounts (2-8.75 HIU/HAU) with 20HAU FPV/R restricted 
the attachment of a constant amount (8.75 HIU/HAU) of
[l25I]-labelled WR45 IgG in the second incubation (Figure 13.8). 
This amount of WR45 would be expected to bind in the order of 1 
IgG per spike, but in fact was restricted from 1.3 to an
undetectable number of molecules per spike by increasing amounts
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of HC10.
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Figure 13.8. Increasing amounts of unlabelled HC10 (mapping to epitope Y) IgG (from 40-175 HIU) restrict the binding of a constant amount (175 HIU) of C12sI]-labelled WR45 IgG. Experiment 
performed as described in Figure 13.5, except that incubation of 
unlabelled HC10 IgG was followed by incubation with 
[l251]-labelled polyclonal WR45 IgG. The binding of
[l25i]-iabelled WR45 IgG (# # ) was reduced from 1.3 IgG
molecules per spike (iodinated WR45 IgG alone with virus,#..) to
<0.01 per spike. The specific activity of C125 I]-labelled WR45 
IgG = 2.84 x 10* cpm/ug.
R a t i o  H I U / M A U  u n l a o a l l a d  H C 1 0  l o O
( # 1  s t o p )
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13.5.4. HC2 (mapping to epitope Z) and WR45 (polyclonal) IgG.
Figure 13.9 shows that if unlabelled HC2 IgG is incubated 
first with 20 HAU FPV/R at increasing levels (from 40-175 HIU) 
then it restricts the binding of [i2 * I]-labelled WR45 IgG 
molecules down to 0.06 per HA spike. At the concentration of WR45 
used and without the preliminary incubation with HC2 IgG it would 
be expected that WR45 IgG would bind at a level of 1.15 IgG 
molecules per HA spike.
The inhibition of binding by HC2 is especially significant 
when the properties of WR4 5 are considered. Antigenic variant 
studies demonstrated (section 13.3.2) that WR45 on incubation 
with FPV/R can select mutants that are resistant to HI by HC10. 
Thus antigenic site Y would seem to be a crucial site as far as 
WR45 is concerned and direct competition could have been the 
reason for the inhibition of binding. However, HI and
neutralization studies have shown that WR45 also contains other 
populations of IgG (Tables 13.2; 13.3) that interact with FPV/R 
HA at epitopes X and Z whose binding is inhibited by HC2.
13.5.5. HC2 (mapping to epitope Z) 
and WR69 (polyclonal) IgG.
WR69 IgG is polyclonal and its anti H7 response is directed 
against the H7 of V31 (section 10.15) which was donated by FPV/R. 
Figure 13.10 shows that if unlabelled HC2 IgG is incubated first
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Figure 13.9. Increasing amounts of unlabelled HC2 (mapping -to epitope Z) IgG (from 40-175 HIU) restrict the binding of a constant amount (175 HIO) of C125I]-labelled WR45 IgG. Experiment 
performed as described in Figure 13.5, except that incubation of 
unlabelled HC2 IgG was followed by incubation with 
[l25 I]-labelled WR45 polyclonal IgG. The binding of 
[l 2 5 i ]-labelled WR45 IgG (•— #  ) was reduced from 1.15 IgG 
molecules per spike ( iodinated WR45 IgG alone with v i r u s t o  
0.06 per spike. The specific activity of [) 25j]-labelled WR45 IgG 
= 2.94 x 10« cpm/ug.
R a t i o  H I U / H A U  u n l a b e l l o d  H C 2  I g G
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Figure 13.10. Increasing amounts of unlabelled HC2 (mapping to epitope Z) IgG (from 40-175 HIU) restrict the binding of a constant amount (175 HIU) of C125I]-labelled WR69 IgG. Experiment 
performed as described in Figure 13.5, except that incubation of 
unlabelled HC2 IgG was followed by incubation with 
[l 25l]-labelled WR69 polyclonal IgG. The binding of 
[i 2 5 I ]-labelled WR69 IgG (•— #  ) was reduced from 1.11 IgG 
molecules per spike (iodinated WR69 IgG alone with virus,®,....) to 
0.04 per spike. The specific activity of [t25I]-labelled WR69 IgG 
= 4.22 x 10* cpm/ug.
R a t i o  H I U / H A U  u n l a b e l l e d  H C 2  I g O
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with 20 HAU FPV/R at increasing levels (from 40-175 HIU) then it 
restricts the binding of [l25 I]-labelled WR69 IgG molecules down 
to 0.04 IgG molecules per HA spike. At the concentration of WR69 
used and without the preliminary incubation with HC2 IgG it would
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be expected that WR69 IgG would bind at a level of 1.11 IgG
molecules per HA spike. This experiment shows that the
restriction of binding by monoclonal antibody is not limited to
one source of polyclonal IgG.
13.6. Competition assay with HC2 (mapping to epitope Z) 
and HC10 (mapping to epitope Y) IgG.
This series of experiments, performed with HC2 and HC10 IgG, 
was designed to find out how the simultaneous incubation of two 
monoclonal IgG populations affected the amount of binding. In 
earlier experimentsboth HC2 and HC10 bound to a maximum of 
approximately one IgG per HA spike. Also in two step incubation 
experiments each reciprocally inhibited the binding of the other.
Different results were achieved in a direct competition 
assay with simultaneous incubation of antibody and virus. In 
Figure 13.11 increasing the concentration of unlabelled HC2 
restricted the attachment of [l *sI]-labelled HC10 IgG to only 
0.56-0.59 IgG molecule per spike in contrast to the results in a 
two step incubation assay where binding was restricted to less 
than 0.1 (Figure 13.7).
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Figure 13.11. Competition assay to show how the presence of increasing amounts of HC2 (mapping to epitope Z) IgG (50-200 BIO) affects the binding of [l2sI]-labelled BC10 (mapping to epitope Y) IgG in simultaneous incubation. Increasing amounts of 
unlabelled HC2 IgG (from 40-175 HIU) were added simultaneously 
with a constant amount of [l25X]-labelled HC10(175 HIU) to 20 HACJ 
FPV/R (section 13.6). In this manner the binding of HC10 IgG was 
only restricted to 0.56-0.59 IgG molecules per spike. The 
specific activity of [l 25j]-labelled HC10 IgG = 8.44 x 104 
cpm/ug.
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These levels of approximately 0.5 IgG molecules per spike 
would be expected in an assay that allowed two IgG antibodies 
with similar affinities to bind with equal opportunity. It could 
be pictured from these data that at the end of the incubation 
period the haemagglutinin spikes would have an average of 1 IgG 
molecule per spike with one in two spikes having a
[125I]-labelled HC10 IgG bound.
13.7. Number of polyclonal slgA molecules able to 
bind to an HA spike of FPV/R.
The binding curve obtained for polyclonal slgA performed as 
described in section 11.4 showed that the maximum number able to 
bind was in the order of 0.4 molecules per HA spike (Figure 
13.12). An slgA molecule consists of two four chain
immunoglobulin units (section 6.2.3), therefore 0.4 slgA is
approximately equivalent to 0.8 immunoglobulin units. At the
concentration of 100 HIU slgA to 20 HAU FPV/R the level of 
neutralization of 1 x 10 7 PFU was 97.5%.
13.7.1. Two step binding assay with polyclonal slgA 
and HC61 IgG (mapping to epitope X).
In a two step assay a constant saturating amount of 
unlabelled slgA (3.75 HIU/HAU) was first incubated with 20 HAU
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Figure 13.12. Number of polyclonal slgA molecules binding to HA spikes on FPV/R particles at increasing HIU/HAO. Polyclonal slgA 
(purified by gel filtration) was incubated with 20 HAD (as 
described in section 11.4 and Table 13.4). The profiles of the 
binding of slgA indicates that the level of saturation is in the 
order of 0.4 HA per spike. The number of slgA molecules binding 
was calculated from using a MW of slgA of 400,000. The specific 
activity of [l 25I]-labelled slgA was 1.463 x 10 < cpm/ug.
R a t i o  H I U / H A U
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Figure 13.13. Dnlabelled polyclonal slgA (75 HIU) restricts the 
binding of increasing amounts of [l*5I]-labelled HC61 IgG. 20 HAU 
FPV/R was incubated with a constant amount (giving an HIU/HAU 
ratio of 3.75) of slgA before a second incubation with 100-175 
HIU of [i251]-labelled HC61 IgG (mapping to antigenic site X) . 
The binding of HC61 was restricted to below 0.18 IgG molecules 
per HA spike (+ + ) when incubation of HC61 IgG alone with virus 
at such levels achieved >0.8 IgG molecules per HA spike ( <^ — 0)- 
The specific activity of [l25 I]-labelled HC61 IgG = 5.14 x 10* 
cpm/ug.
R a t i o  H I U / H A U  l a b e l l e d  H C 6 t  I q G
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Figure 13.14. Number of polyclonal IgM molecules binding to HA spikes on FPV/R particles at increasing HltJ/HAD. Polyclonal IgM 
(purified by gel filtration) was incubated with 20 HAU (as 
described in section 11.4 and Table 13.4). The profiles of the 
binding of IgM indicates that the level of saturation is in the 
order of <0.1 HA per spike. The number of IgM molecules binding 
was calculated from using a MW of IgM of 900,000. The specific 
activity of [i25 I]-labelled IgM was 9.7 x 10 3 cpm/ug. 100 HIU 
per 20 HAU achieved 98.5% neutralisation.
1 2 3 4  5
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before incubating with increasing amounts of [1 25 I]-labelled HC61 
IgG was added (at 5, 7.5 and 8.75 HIU/HAU). Figure 13.13 shows 
that the binding of HC61 was restricted to below 0.2 IgG 
molecules per spike by the previous incubation with slgA.
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13.8. Number of polyclonal IgM molecules able 
to bind to the HA spikes of FPV/R.
The binding curve obtained for polyclonal IgM showed that 
the maximum number able to bind was in the order of 0.1 per 
haemagglutinin spike (Figure 13.14). At the concentration of 100 
HIU IgM to 20 HAU FPV/R the level of neutralization of 1 x 107 
PFU was 98.5%.
13.9. Binding of IgG in solid-phase radioimmunoassay.
These assays differed from the previous assays in that the 
antigen, FPV/R particles (5 HAU) and BrHA (HA enzymatically 
removed from FPV/R particles), were adsorbed to the wells of 
plastic microtitre plates.
Binding curves obtained with HC2 and HC10 in solid-phase RIA 
(Figures 13.15.1; 13.15.2) showed that in the order of 3 IgG 
molecules bind per HA spike. Essentially the same curves for HC2 
and HC10 was seen whether FPV/R particles or BrHA molecules were 
used as the solid-phase binding substrate.
278
Figure 13.15.1. and Figure 13.15.2. Number of HC2 IgG and HC10 IgG molecules binding bo FPV/R particles (5 HAD/well) ( 0  ) or bo the equivalent HA of isolated BrHA spikes ( |  ) in solid phase RIA. 5 HAD intact FPV/R or isolated BrHA were absorbed onto 
the surfaces of microtitre plate wells (section 11.4.2?).Figure 13.15.1. Increasing amounts of [l 25 I]-labelled HC2 IgG 
(5-90 HIU) were added to prepared microtitre wells for 1 h at 
25°C and then 18 h at 4°C. The wells were then washed throughly 
with cold PBS and the radioactivity associated with the wells 
determined allowing the number of IgG molecules binding to be 
calculated. The specific activity of C1 25 I]-labelled HC2 IgG = 
4.95 x 104 cpm/ug.Figure 13.15.2. Increasing amounts of C1 25 I]-labelled HC10 IgG 
(5-90 HIU) was added to prepared microtitre wells as described in 
Figure 13.15.1. The specific activity of [l 25 I]-labelled HC10 IgG 
= 4.28 x 104 cpm/ug.
Figure 13.15.1.
R a n o  H I U / H A U
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Figure 13.15.2.
R a t i o  H I U / H A U
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Figure 13.16. Increasing amounts of unlabelled HC10 IgG (10-75 HIU) restrict the binding of constant amount (75 HIU) of [12 5I]-labelled HC2 IgG . Experiment performed as described
in Figure 13.15.1 except that incubation of increasing amounts 
(10-75 HIU) of unlabelled HC10 IgG was followed by incubation 
with 75 HIU [l25X]-labelled HC2 IgG in microtitre wells coated 
with intact FPV/R particles at 5 HAU per well. The binding of a 
constant amount of [! 25 I]-labelled HC2 IgG was reduced from 3.85 
IgG molecules per HA spike (iodinated HC2 IgG alone with virus,1 
.) to 0.05 per spike.
R a t i o  H i U / H A U  u n l a b e l l e d  H C 1 0  I g G  
( *  1 s t e p )
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Figure 13.17. Increasing amounts of unlabelled HC2 IgG (10-75 
HIU) restrict the binding of a constant amount (75 HIO) of [12 5 I]-labelled HC10 IgG (#— #  ). Experiment performed as 
described in Figure 13.15.1 except that incubation of increasing 
amounts (10-75 HIU) of unlabelled HC2 IgG was followed by 
incubation with 75 HIU [i25X]-labelled HC10 IgG in microtitre 
wells coated with intact FPV/R particles at 5 HAU per well. The 
binding of a constant amount of [l25 I]-labelled HC10 IgG was 
reduced from 3.1 IgG molecules per HA spike (iodinated HC10 IgG 
alone with virus,#..) to <0.05 per spike.
R a t i o
( • I  s t e o )
H I U / H A U  u n l a b e l l e d  H C  2 I g G
In two step incubation assays it was found (Figures 13.16; 
13.17) that increasing amounts of unlabelled antibody (either HC2 
or HC10 IgG) in the first incubation with 5 HAU FPV/R restricted 
the binding of a constant amount of [1251]-labelled IgG (either 
HC10 or HC2) from 3 IgG molecules per spike to an almost 
undetectable level.
Thus the use of a solid-phase RIA results in an increase in 
the number of IgG molecules able to bind from 1 per HA spike 
observed with FPV/R particles free in solution to approximately 
three. In the solid-phase RIA restriction of binding of a second 
antibody occurs in much the same way as that when virus is free 
in suspension, i.e. three IgGs binding per HA spike are able to 
inhibit the binding of further antibody to theoretically 
available antigenic regions.
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13.10. Kinetic studies on the interaction 
between FPV/R and monoclonal IgG.
Figure 13.18 is a plot of the course of inactivation of 
influenza virus by purified monoclonal HC2 IgG as a function of 
time. At this temperature (25°C) and concentration (0.01 /ag IgG), 
there is an immediate loss of virus infectivity which could be 
taken as evidence for the inactivation of one influenza virus 
particle by one antibody molecule (section 8.1.1; Figure 8.1). 
Figure 13.19 shows that the slope of the curve is dependent on
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Figure 13.18. Kinetics of inactivation of 60 PFO FPV/R by purified monoclonal HC2 IgG (0.Olug).Virus and IgG were mixed at t=0 and incubated at 25»C. At subsequent times samples were 
inoculated onto CEF monolayers in duplicate and assayed for 
residual infectivity (section 10.1).
min
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Figure 13.19. Kinetics of inactivation of 60 PFO FPV/R by 
purified monoclonal HC2 IgG (O.lpg) at 4, 25, or 37<>C. Virus and 
IgG were mixed at t=0 and incubated at either 4°G ( A ), 25°C ( 
■  ) , or 37°C ( #  ). At subsequent times samples were inoculated 
onto CEF monolayers in duplicate and assayed for residual 
infactivity (section 10.1). The intercept of the lines of best 
fit calculated by linear regression analysis are shown 
(correlation coefficents for 37, 25, and 4°C were 0.99, 0.99, and 
0.97 respectively).
the temperature; decreasing the temperature whilst keeping the 
antibody concentration constant (0.1 jig) decreased the rate of 
virus inactivation. Decreasing the IgG concentration to 0.01 jig 
IgG per 60 PFU at 4°C produced a slight lag in the loss of FPV/R 
survival with both HC2 and HC58 IgG (Figures 13.20; 13.21 
respectively). Linear regression analysis and extrapolation of 
the slope obtained with O.Ol^ig HC2 indicated that 3 HC2 IgG 
molecules were required for neutralization. Similar analysis of 
the slope achieved with 0.01 jjlg HC58 IgG indicated that 3.4 (or 
between 3 and 4) IgG molecules were required. An indication of a 
lag phase was seen with 0.03 pg HC58 IgG, linear regression 
analysis and extrapolation of the slope predicted that 2.8 (i.e 
3) IgG molecules were required. At these concentrations shoulders 
were not produced when virus and antibody were incubated at 25 
and 37°C. Reducing the concentration of both antibodies below 
0.01 ug in this system produced variable results.
The lag phase observed at 4°C with low concentrations of IgG 
is compatible with the hypothesis that the neutralization of 
FPV/R required the binding of more than one IgG molecule with a 
virus particle to bring about neutralization (Lafferty, 1963a) 
and is thus a multi-hit phenomenon.
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Figure 13.20. Kinetics of inactivation of 60 PFU FPV/R by 0.1, 0.03, and 0.01 ug purified monoclonal HC2 IgG at 4°C. Virus and 
either 0.1 ;ug ( 9 ), 0.03 ug ( ▲ ), or 0.01 pg ( ■ ) IgG were 
mixed at t=0 and incubated at 4°C. At subsequent times samples 
were inoculated onto CEF monolayers in duplicate and assayed for 
residual infectivity (section 10.1). The intercept of the lines 
of best fit calculated by linear regression analysis are shown 
(correlation coefficents for 0.1, 0.03, and 0.01)jg were 0.99, 
0.99, and 0.96 respectively).
Figura 13.21. Kinetics of inact.ivat.ion of 60 PFU FPV/R by 0.1, 0.03, and 0.01 ug purified monoclonal HC58 IgG at 4°C. Virus and 
either 0.1 jug ( •  ), 0.03 }ig ( 4 ), or 0.01 pg ( ■  ) IgG were 
mixed at t=0 and incubated at 4°C. At subsequent times samples 
were inoculated onto CEF monolayers in duplicate and assayed for 
residual infactivity (section 10.1). The intercept of the lines 
of best fit calculated by linear regression analysis are shown 
(correlation coefficents for 0.1, 0.03, and 0.0lug were 0.99,
0.93, and 0.95 respectively).
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13.11. DISCUSSION
13.11.1. The average number of HA spikes on 
a FPV/R particle is 1000.
The investigations in this section rely on an accurate 
determination of the average number of HA spikes on an FPV/R 
particle. Electron microscopy was employed to estimate the number 
of surface projections, following the method employed by Tiffany 
and Blough (1970b) for myxo- and paramyxoviruses. The number of 
surface projections is calculated from the moan surface area of 
virus particles (calculated from the diameter) and the mean area 
occupied by each spike (calculation given in section 13.4.1). The 
average diameter of quasispherical FPV/R virus particles was 
determined to be 120 nm, which compares favourably with the 
average diameter of 118 nm determined for the reassortant 
influenza A virus V31 (section 10.15) by small angle X-ray 
scattering (M.T. Stubbs and H.P. Taylor, unpublished data) and 
the range of diameters estimated in EM studies for influenza A 
virus of 80-150 nm (Wrigley, 1979). By neutron scattering the 
average diameter of laboratory passaged strains of influenza A 
viruses was determined to be 120 nm (Cusack, 1982). The mean 
distance separating spikes of 5.1 nm used in my calculation is at 
the narrow end of the range of 5-8 nm reported for influenza A 
viruses (Tiffany and Blough, 1970b). The calculated mean number 
of spikes per FPV/R particle was 1273 (section 13.1), which is at 
the top of the reported range for a number of (mostly) human 
influenza A viruses. The proportion of HA to NA was determined 
(section 13.2) to be 4.6/1, which is within the reported range of
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4/1 to 5/1 (Wrigley, 1979). Therefore the average number of HA 
spikes on a FPV/R particle was taken to be approximately 1000.
13.11.2. FPV/R in suspension is saturated with 
approximately one IgG per HA spike.
Knowing the specific activity of radiolabelled 
immunoglobulins and knowing the total radioactivity bound per 
particle means that it is possible to estimate the number of 
immunoglobulin molecules bound to each HA spike on intact FPV/R 
particles. Errors inherent to such measurements mean that the 
estimates of the number of immunoglobulin molecules binding 
should not be taken as precise values, rather as a indication of 
the order of magnitude.
Saturation of FPV/R with HC2, HC10, HC58 and HC61
[l 25 I]-labelled IgG showed consistently that only one IgG 
molecule could bind to each FPV/R HA spike. Polyclonal IgG (WR26 
and WR45) also bound up to a maximum of 1 IgG molecule per HA 
spike. It appears that the binding of one IgG molecule to a HA 
spike precludes any further immunoglobulin molecules from 
binding. Therefore we have the situation that a monoclonal 
antibody bound to a HA spike prevents the binding of any more
monoclonal antibody to the other 2 identical epitopes on that
spike. Secretory IgA bound up to a maximum of 0.4 slgA molecules 
per spike. Considering the dimeric structure and mass of slgA
(section 6.2.3) compared to IgG this is equivalent to 0.8 four
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chain immunoglobulin units per spike. With reference to the 
possible conformations of slgA when bound to antigen (section 
7.1; Figure 7.1.3; section 12.6.4) this would provide a 
formidable barrier to contact between VASs and CRUs. This contact 
is also likely to depend on the length and mobility of the CRU 
molecules, but these are unknown. The binding of polyclonal IgM 
was approximately 0.1 molecules per HA spike, which in terms of 
mass and structure is equivalent to 0.5 four chain immunoglobulin 
units per spike. The extra bulk and orientation of binding 
(section 7.1; Figure 7.1.3) could be responsible for this 
two-fold decrease in four chain immunoglobulin unit binding.
13.11.3. Radiochemical determination of the number of IgG 
molecules required to achieve neutralization.
"Efficient" neutralization (i.e >90%) by HC2 IgG was 
achieved only when there were over 150 antibody molecules per 
particle (approx. 1 IgG molecule per 7 HA spikes). 50% 
neutralization was achieved with 50 IgG molecules per virus 
particle or 1 IgG molecule per 20 HA spikes. Investigation of the 
number of HC10 IgG molecules binding showed that at the "high" 
levels of neutralization of 99.9% and 99.98%, 0.8 and 1.1 IgG
molecules respectively were binding per spike. This was the
maximum "saturation" value. As the data in section 12
demonstrate, FPV/R neutralized to greater than 99.95% by IgG
attached to cells at the same rate as non-neutralized virus, thus 
even when saturated with IgG virus is still able to attach to
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cells unimpaired.
13.11.4. Two step competition assays show 
that pre-bound IgG prevents the binding of any further 
IgG to the HAspike.
Escape mutant mapping of the monoclonal IgGs used in this 
study defined three epitopes; HC61 mapped to epitope X, HC10 to 
epitope Y, and HC2 and HC58 mapped to epitope Z. Exhaustive 
studies demonstrated that the binding of one monoclonal IgG to 
one epitope (e.g. Z) at saturation prevented the binding of 
[l25l]-labelled monoclonal IgG to a different epitope (e.g. Y). 
It can be infered from this that once an IgG molecule is bound to 
an HA spike it sterically or allosterically prevents the binding 
of another antibody. Also, the binding of monoclonal antibody 
(from a limited panel, however) to an HA spike prevents the 
binding of IgG molecules from a polyclonal anti-HA population. 
The one monoclonal antibody tested (HC61) at saturation inhibited 
the binding of slgA.
The possibility of "positional" (or pseudo) competition 
occurring between the monoclonal IgGs cannot be ruled out despite 
work which shows that each one of the pairs of monoclonal 
antibodies used map to different epitopes. The problem is that 
the information judging whether or not these epitopes may be in 
close enough proximity on the HA to lead to "positional 
competition is not available. In an attempt to assess this
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possibility the ability of monoclonal antibody to inhibit the 
attachment of polyclonal IgG was investigated. Polyclonal 
populations of immunoglobulins should by definition contain 
antibodies that bind to many different epitopes and one 
particular monoclonal IgG would not be expected to interfere with 
the binding of antibody with the diverse range of specificities 
found in a polyclonal serum. An immune animal would be expected 
to produce antibodies against the four antigenic sites on the HA 
molecule, although there is little information on their relative 
immunogenicity.
HC10 (mapping to epitope Y) blocked attachment of all 
specificities of IgG that are contained in polyclonal WR45 IgG. 
HC2 IgG (mapping to epitope Z) bound at 1 IgG molecule per spike 
also inhibited the binding of [l 25 I]-labelled WR45 IgG and 
another polyclonal antiserum WR69. Thus no matter what 
specificity of paratope, an incoming antibody was always blocked 
by the immunoglobulin already resident on the HA spike. Thus the 
conclusion was that the majority of the antibodies in the 
polyclonal population were not prevented from binding to HA by 
positional competition. However an alternative explanation was 
also considered - that the polyclonal sera contained a majority 
of antibodies directed towards an antigenic site which happens to 
include epitopes Y and Z. This was investigated by asking if WR45 
could generate escape mutants like a monoclonal antibody (a 
property not thought to be associated with a normally avid 
polyclonal antibody population). Results revealed the surprising
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fact that WR45 could select variants, resistant to neutralization 
by monoclonal antibody directed to epitope Y iHCIO). This argued 
that WR45 contained largely antibodies to or which overlapped 
with epitope Y. Such a hypothesis was easily tested by asking if 
WR45 could react with escape mutants generated by HC10. This it 
did by both neutralization and HI assays at titres near to tnose 
achieved with non-selected virus iTables 13.2;13.3). However in 
the reciprocal experiments HC10 failed to neutralize escape 
mutants selected by WR45. Matai i et si. (1961) demonstrated a 
similar phenomenon. HI mapping with murine monoclonal antibodies 
and convalescent childrens’ sera showed that seme of the latter 
possessed HA-antibody repertoire that was restricted to only one 
or two non-overlapping epitopes. Thus in summary WE45 appears to 
have a limited repertoire of the possible specificities of 
antibody to FFV/R HA. However unlike the sera used by Natali et 
al. (1931) WR45 was a hyperimmune rabbit serum (section 10.7). 
Another polyclonal IgG, WR69. failed to select any escape mutants 
that could be characterized with the monoclonal IgGs available. 
WR45 and WR69 antisera were both obtained by intravenous 
inoculation of virus and bleeding at day 6 post-boost (section
10.7). However, the immunogen for WR45 was FPV/D (H7N7) and for 
WR69 was V31 (a reassortant with H7 directly derived from FFV/R; 
section 10.15). This difference may be significant. for despite 
demonstration of very similar serological relatedness between the 
FPV/R H7 and FPV/D H7 with respect to the polyclonal reagents and 
the limited monoclonal antibodies available, it could be that 
these viruses share minimal but immunodominant antigenicity.
The HA spike is a trimer (Wilson et al.,1981) and as such 
will have 3 identical epitopes available for a given monoclonal 
immunoglobulin to bind to. The data above suggest that in 
practice only one epitope can engage an antibody and that 
subsequently all other available neutralizing epitopes on that 
spike are then unavailable. It can be envisaged that one antibody 
per spike would create a fringe of antibodies around the FPV/R 
particle and that this would prevent the binding of any other 
immunoglobulin. However this has to be reconciled with the 
observations that this fringe is successful in preventing 
attachment to cultured mammalian and avian cells (section 12; 
Possee and Dimmock, 1981). One possible explanation is that the 
CRU is a much less bulky molecule than an IgG molecule and can 
thus be inserted where there is no room for antibody. 
Alternatively binding of one antibody might allosterically mask 
other epitopes although there is no evidence for this. Almost 
total interference by pre-bound antibody was demonstrated with 
intact virus in suspension, intact virus in solid-phase, and BrHA 
in solid-phase. Therefore the restrictive abilities of pre-bound 
antibodies were not dependent on the assay system.
Therefore in summary, the competition studies argue against 
direct epitope-epitope competition and for a steric or allosteric 
block on the binding of further IgG to the HA spike of influenza 
virus by pre-bound IgG.
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13.11.5. Op -to 3 IgG molecules bind per- HA 
spike in solid-phase RIA.
Kida e-t al. (1982) found that monoclonal IgG to influenza A/
seal/Mass./1/10 failed to inhibit haemagglutination activity of 
the intact virus but inhibited HA activity of purified isolated 
rosettes of HA. Their explanation was that the monoclonal 
antibodies may be able to combine bivalently with sites on the 
trimeric HA molecule of the opened rosette form which are 
sterically blocked when the HA is present on the intact virus 
particle. Kida et al. (1982) reported that electron microscopy 
showed "much more" antibody attached to rosettes than to intact 
particles. My finding that in solid phase RIA with purified BrHA 
all three antigenic sites are occupied by antibody, instead of 
just one in the virus particle, is in accord with Kida et al. 
(1982). It is suggested that this results from the increase in 
inter-spike distance when BrHA is adsorbed to a plastic matrix 
compared to that on the intact virus in solution with a resulting 
increase in access for IgG molecules. BrHA spikes on the surface 
of the microtitre wells are far enough apart to allow the maximum 
expected immunoglobulin binding of 3 molecules per spike (Wiley 
et al. 1981). The fact that adsorption of intact virus to plastic
increases IgG binding must result from changes in the structure 
of the virus particle allowing greater IgG access, but what these 
might be are difficult to envisage. Such observations emphasize 
the caution that should be applied to the use of bound antigens
296
in solid phase RIA (Nestorowicz et al., 1985), although in their 
study binding to plastic created a new epitope.
13.11.6. Kinetic data indicate that about 3 IgG molecules 
per particle are required for neutralization.
The kinetic data of the neutralization of FPV/R by 
monoclonal IgG support the view that influenza virus 
neutralization is mediated by about 3 IgG molecules per particle 
(section 8.1.1). This is not in agreement with the physical 
evidence obtained using [l 25X]-labelled IgG, i.e. 50 IgG 
molecules per virus particle are required to cause 50% 
neutralization. However, supporting the radiochemical results are 
EM data on virus-antibody complex formation showing that antibody 
can still be detected on virus surface at around a 100-fold 
dilution of the minimum amount of HC2 antibody needed to cause 
neutralization (S.J. Armstrong and N.J. Dimmock, unpublished 
data).
13.11.7. Reconciliation of kinetic and 
radiochemical data.
How can the difference between the kinetic data and 
radiochemical data of around an order of magnitude in the number 
of antibody molecules required to neutralize virus be explained? 
One possibility is that although all HA spikes are identical in 
structure virus is only neutralized when antibody binds to a
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"neutralization relevant" HA spike, defined as one which has a 
critical interaction with the internal core structure. Binding to 
other HA spikes is irrelevant to neutralization (N.J. Dimmock, 
personal communication). Thus this extends the modified 
conclusion of Possee et al. (1981) that neutralization leads to a 
failure of secondary uncoating.
Inactivation kinetics of between 1 and 3 hits means that 
antibody must bind up to 3 of the neutralization relevant HA-core 
interacting spikes. When approximately 50 IgG molecules are 
detected radiochemically per particle, 50% of the infectious 
virus is neutralized. This represents the majority of IgG binding 
to "neutralization irrelevant" spikes. As more antibody binds the 
level of neutralization increases as the statistical chance of an 
IgG molecule binding to a neutralization relevant HA spike 
increases. If it is assumed that neutralization is single-hit 
then at 50% neutralization only 1 in 50 antibody molecules are 
binding to a neutralization relevant HA spike. Thus since there 
are 1000 HA spikes then there are 1000/50 = 20 neutralization 
relevant spikes. Testing the hypothesis in reverse by probability 
theory (with the kind assistance of Professor P.J. Harrison, 
Department of Statistics, University of Warwick) confirms that 
indeed with 980 neutralization irrelevant spikes and 20 
neutralization relevant spikes with independent binding of 
antibody at 50% neutralization you would expect 50 antibody 
molecules per particle. Extending the theory to two-hit or 
three-hit kinetics, calculations show that at 50% neutralisation
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you would expect about 100 or 150 antibody molecules per particle 
respectively. It is impossible from the radiochemical data to 
decide whether an experimental figure of 50 antibody molecules 
per particle indicates single or multi-hit kinetics. The 
neutralization kinetics affect the calculation of the number of 
neutralization relevant sites. For example, with 50 antibody 
molecules per particle and three-hit kinetics there would be 60 
neutralization relevant sites per particle, still involving only 
a minority of the HA spikes.
13.11.8. In what way would the "neutralization-relevant" 
spikes be different from their 
"neutralization-irrelevant" neighbours.
It is postulated that antibody induces a signal which is 
transmitted through the HA across the envelope and which then 
affects a crucial molecular function. Hay et al. (1985) examined
the genetics of sensitivity of influenza virus to amantadine, 
which has an inhibitory function acting at an early stage in 
influenza virus infection. They found that M2 protein (section
2.5) was the primary determinant of amantadine sensitivity 
implicating M 2 in the infectious process and by inference, its 
presence in the virion. Zebedee et al. (1985) were not able to
detect M2 in virus particles at a limit of detection of 20 
molecules/virion. If indeed there are some M2 molecules present 
in the virus particle they could provide the vital "bridge" 
between the neutralization relevant HA spikes and a critical
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function. The binding of an antibody to such a HA linked to M2 
could then lead to inhibition of secondary uncoating observed by 
R-Rigg and N.J. Dimmock (unpublished observations). 
Quantitatively this argument is reasonable since if there are 1 
to 3 hits required for neutralization and yet 50 antibody 
molecules bound per total of 1000 HA spikes there will be between 
1/50 and 3/50 neutralization relevant spikes per 1000 HA spikes 
which calculates to a total of between 20 and 60 neutralization 
relevant spikes in total.
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